

(19)



(11)

EP 2 937 697 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:

28.10.2015 Bulletin 2015/44

(21) Application number: **13864465.3**

(22) Date of filing: **24.12.2013**

(51) Int Cl.:

G01N 33/574 ^(2006.01) **A61K 39/395** ^(2006.01)
A61K 45/00 ^(2006.01) **A61P 1/16** ^(2006.01)
A61P 35/00 ^(2006.01) **G01N 33/48** ^(2006.01)
G01N 33/53 ^(2006.01) **C07K 16/30** ^(2006.01)

(86) International application number:

PCT/JP2013/007529

(87) International publication number:

WO 2014/097648 (26.06.2014 Gazette 2014/26)

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

(30) Priority: **21.12.2012 JP 2012280304**

(71) Applicant: **Chugai Seiyaku Kabushiki Kaisha**

Kita-ku

Tokyo 115-9543 (JP)

(72) Inventors:

- **OHTOMO, Toshihiko**
Tokyo 103-8324 (JP)
- **AMANO, Jun**
Gotemba-shi
Shizuoka 412-8513 (JP)
- **NAKAMURA, Mikiko**
Tokyo 103-8324 (JP)

(74) Representative: **Power, David**

J A Kemp

14 South Square

Gray's Inn

London WC1R 5JJ (GB)

(54) **GPC3-TARGETED THERAPEUTIC AGENT FOR ADMINISTRATION TO PATIENTS FOR WHOM GPC3-TARGETED THERAPEUTIC AGENT THERAPY IS EFFECTIVE**

(57) The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concen-

tration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

EP 2 937 697 A1

Description

[Technical Field]

5 **[0001]** The present invention provides a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient or determining the continuation of GPC3-targeting drug therapy for a patient. The present invention also provides a GPC3-targeting drug or a preparation which is to be further administered to a patient for the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

10 [Background Art]

15 **[0002]** Hepatocellular cancer is reportedly the fifth leading cause of cancer deaths worldwide, accounting for approximately 600,000 deaths each year (Non Patent Literature 1). Most patients with hepatocellular cancer die within 1 year after being diagnosed with the disease. Unfortunately, hepatocellular cancer cases are frequently diagnosed at a late stage which rarely responds to curative therapies. Still, medical treatments including chemotherapy, chemoembolization, ablation, and proton beam therapy are insufficiently effective for such patients. Many patients exhibit recurrence of the disease with vascular invasion and multiple intrahepatic metastases, which rapidly progresses to the advanced stage. Their 5-year survival rates are only 7% (Non Patent Literature 2). Patients with hepatocellular cancer amenable to the resection of local foci have relatively good prognosis, though their 5-year survival rates still remain at a level of 15% and 39% (Non Patent Literature 3). Thus, there has been a demand in the art for novel therapy for such a malignant disease hepatocellular cancer.

20 **[0003]** Hepatocellular cancer is reportedly responsible for more than 90% of primary liver cancer cases in Japan. Medical methods for treating such hepatocellular cancer include, for example, chemotherapy-based transcatheter arterial embolization (TAE) therapy, which involves inducing the selective necrosis of the hepatocellular cancer by the injection of a mixture of an oil-based contrast medium (Lipiodol), an anticancer agent, and an obstructing substance (Gelfoam) into the hepatic artery (which serves as a nutrient supply pathway to the tumor) resulting in the obstruction of the nutrient artery. In addition, invasive approaches are used, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, and radiofrequency ablation. Also, clinical trials have been conducted on systemic chemotherapy using chemotherapeutic agents such as fluorouracil (5-FU), uracil-tegafur (UFT), mitomycin C (MMC), mitoxantrone (DHAD), adriamycin (ADR), epirubicin (EPI), and cisplatin (CDDP) either alone or in combination with interferon (IFN) (Non Patent Literature 4).

25 **[0004]** Meanwhile, an orally active form of sorafenib (Nexavar, BAY43-9006) has been approved, which is more advantageously effective than the chemotherapeutic agents described above in such a way that this agent blocks the growth of cancer cells by inhibiting Raf kinase in the Raf/MEK/ERK signal transduction while the agent exerts antiangiogenic effects by targeting VEGFR-2, VEGFR-3, and PDGFR- β tyrosine kinases. The efficacy of sorafenib has been studied in two phase-III multicenter placebo-controlled trials (Sorafenib HCC Assessment Randomized Protocol (SHARP) trial and Asia-Pacific trial) targeting advanced hepatocellular cancer. Sorafenib was confirmed to prolong survival durations, with HR of 0.68, in both of these trials. In the SHARP trial, sorafenib prolonged the survival duration to 10.7 months versus 7.9 months with the placebo. In the Asian trial, this agent prolonged the survival duration to 6.5 months versus 4.2 months with the placebo. The agent, however, had a low objective response rate and showed no prolongation of a time to symptomatic progression, though the agent prolonged a time to tumor progression (5.5 months versus 2.8 months in the European and American trial and 2.8 months versus 1.4 months in the Asian trial) on the images. The Asian cohorts exhibited a short duration of life prolongation, which is probably because their treatments were started at a slightly later stage during the disease process in the Asian region compared with Europe and the United States (Non Patent Literatures 5 and 6).

30 **[0005]** As liver cancer progresses, its specific symptoms associated with liver dysfunction are generally observed, such as anorexia, weight loss, general malaise, palpable right hypochondrial mass, right hypochondrial pain, sense of abdominal fullness, fever, and jaundice. The chemotherapeutic agents (e.g., sorafenib), however, have complications to be overcome, including their inherent adverse reactions such as diarrhea or constipation, anemia, suppression of the immune system to cause infection or sepsis (with lethal severity), hemorrhage, cardiac toxicity, hepatic toxicity, renal toxicity, anorexia, and weight loss.

35 **[0006]** Although particular early-stage symptoms are not initially observed in liver cancer, its specific symptoms associated with liver dysfunction, such as anorexia, weight loss, general malaise, palpable right hypochondrial mass, right hypochondrial pain, sense of abdominal fullness, fever, and jaundice, are generally observed with progression of the liver cancer. According to clinical observation, such symptoms are enhanced by use of the chemotherapeutic agents. For example, anorexia in a patient with detectable liver cancer cells and symptoms such as weight loss associated with or independent of the anorexia may be more enhanced by the administration of the chemotherapeutic agents to the

patient than without the use of the chemotherapeutic agents. In some cases, the use of the chemotherapeutic agents must be discontinued for the patient having such symptoms. These enhanced symptoms are impediments to treatments with the chemotherapeutic agents. Thus, there has been a demand for the establishment of excellent therapy from the viewpoint of, for example, improving therapeutic effects or improving QOL of patients to be treated.

5 **[0007]** Glypican 3 (GPC3) is frequently expressed at a high level in liver cancer and as such, seems to be useful in the identification of its functions in liver cancer or as a therapeutic or diagnostic target of liver cancer.

[0008] Under the circumstances described above, drugs are under development with GPC3 as a therapeutic target of liver cancer. A liver cancer drug comprising an anti-GPC3 antibody as an active ingredient has been developed, the antibody having antibody-dependent cellular cytotoxicity (hereinafter, referred to as "ADCC") activity and/or complement-dependent cytotoxicity (hereinafter, referred to as "CDC") activity against cells expressing GPC3 (Patent Literature 1). Also, a GPC3-targeting drug comprising a humanized anti-GPC3 antibody having ADCC activity and CDC activity as an active ingredient has been developed (Patent Literature 2). Further GPC3-targeting drugs have been developed, which comprise a humanized anti-GPC3 antibody with enhanced ADCC activity (Patent Literatures 3 and 4) or an anti-GPC3 antibody having ADCC activity and CDC activity as well as improved plasma dynamics (Patent Literature 5).
15 These anti-GPC3 antibodies in combination therapy with the chemotherapeutic agents such as sorafenib have been found to attenuate the adverse reactions, for example, brought about by the sole therapy of the chemotherapeutic agents (e.g., sorafenib) and also found to exhibit synergistic effects based on these agents (Patent Literature 6). Accordingly, excellent methods for treating liver cancer are in the process of being established using GPC3-targeting drugs as the nucleus from the viewpoint of, for example, improving therapeutic effects or improving QOL of patients to be treated.

20 **[0009]** Meanwhile, GPC3-targeting methods for diagnosing liver cancer are also under development. GPC3 is known to be expressed on cell surface and processed, at the particular site, by convertase, phospholipase D, Notum or unspecified mechanism (Non Patent Literature 7 and 8) during or after expression on cell surface. By use of such a phenomenon, a diagnostic agent or a diagnostic method for liver cancer has been developed, which involves an antibody capable of binding to an epitope in a soluble form of GPC3 secreted into the plasma of a patient after processing (Patent Literature 7). Also, a diagnostic agent or a diagnostic method for liver cancer has been developed, which involves an antibody capable of binding to an epitope in an anchored form of GPC3 still existing on cell surface after processing in a tissue preparation or the like isolated from a patient (Patent Literature 8). These diagnostic agents or diagnostic methods, however, are means for detecting the presence of liver cancer in a patient to be tested. Neither a method for determining the efficacy of GPC3-targeting drug therapy for a patient treated with the GPC3-targeting drug therapy nor
25 a method for determining the continuation of GPC3-targeting drug therapy for the patient has been known yet.

[0010] References cited herein are as listed below. The contents described in these literatures are incorporated herein by reference in their entirety. It should be noted that none of these literatures are admitted to be the prior art to the present invention.

35 [Citation List]

[Patent Literature]

[0011]

40	[Patent Literature 1]	WO2003/000883
	[Patent Literature 2]	WO2006/006693
	[Patent Literature 3]	WO2006/046751
	[Patent Literature 4]	WO2007/047291
45	[Patent Literature 5]	WO2009/041062
	[Patent Literature 6]	WO2009/122667
	[Patent Literature 7]	WO2004/038420
	[Patent Literature 8]	WO2009/116659

50 [Non Patent Literature]

[0012]

55 [Non Patent Literature 1] Llovet JM, Burroughs A, Bruix J; Lancet (2003), 362, 1907-17
 [Non Patent Literature 2] Bosch FX, Ribes J, Cleries R; Gastroenterology (2004), 127, S5-16
 [Non Patent Literature 3] Takenaka K, Kawahara N, Yamamoto K, Kajiyama K, Maeda T, Itasaka H, Shirabe K,

Nishizaki T, Yanaga K, Sugimachi K; Arch Surg (1996), 131, 71-6

[Non Patent Literature 4] Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ; J Natl Cancer Inst (2005), 97, 1532-8

5 [Non Patent Literature 5] Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. New Eng. J. Med. (2008) 359, 378-90

[Non Patent Literature 6] Cheng AL, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo- controlled trial. Lancet Oncol. (2009) 10, 25-34

10 [Non Patent Literature 7] De Cat B, Muyldermans S-Y, Coomans C, Degeest G, Vanderschueren B, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J. Cell. Biol. (2003) 163, 625-635

[Non Patent Literature 8] Traister A, Shi W and Filmus J. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem. J. (2008) 410, 503-511

15 [Summary of Invention]

[Technical Problem]

20 **[0013]** The present invention has been made in light of the situations as described above, and an object of the present invention is to provide a method for determining the efficacy of GPC3-targeting drug therapy for a patient treated with the GPC3-targeting drug therapy or determining the continuation of GPC3-targeting drug therapy for the patient. Another object of the present invention is to provide a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

25 [Solution to Problem]

30 **[0014]** The present inventors have conducted diligent studies under the situations as described above and consequently created a method comprising monitoring a concentration of free GPC3 in a biological sample isolated from a patient treated with GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value or when the concentration of free GPC3 has been increased as a result of receiving the GPC3-targeting drug therapy, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present inventors have also created a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined. It has been expected from the previous findings that the concentration of free GPC3 detected in plasma is decreased over time with the continuation of the treatment, if the GPC3-targeting drug therapy has efficacy. Surprisingly, the present inventors have found that the concentration of free GPC3 is stabilized or increased, rather than decreased, in plasma isolated from a patient with stable disease that may respond to the GPC3-targeting drug therapy.

40 **[0015]** More specifically, the present invention provides the following aspects:

[1] a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient or determining the continuation of GPC3-targeting drug therapy for a patient, comprising monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined,

[2] the method according to [1], wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the patient,

50 [3] the method according to [2], wherein the concentration of free GPC3 in the biological sample isolated from the patient is a concentration in the plasma sample or the serum sample,

[4] the method according to any of [1] to [3], wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL,

55 [5] the method according to any of [1] to [4], wherein the concentration of free GPC3 is measured using an immunological method,

[6] the method according to any of [1] to [5], wherein the concentration of free GPC3 is larger than that in a biological sample isolated before the start of the GPC3-targeting drug therapy from the patient,

[7] the method according to any of [1] to [6], wherein the patient shows high expression of GPC3 in an immunohis-

tochemical staining score,

[8] the method according to any of [1] to [7], wherein the cancer is liver cancer,

[9] the method according to any of [1] to [8], wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient,

5 [10] the method according to any of [1] to [9], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient,

[11] the method according to [10], wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity,

10 [12] the method according to [10] or [11], wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):

(1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;

15 (2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;

(3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;

20 (4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and

25 (5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively,

[13] The method according to any of [10] to [12], wherein the anti-GPC3 antibody comprises any of the following (1) to (6):

30 (1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

35 (3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

40 (5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73,

45 [14] the method according to [10], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance,

[15] a GPC3-targeting drug which is to be administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy,

50 [16] a GPC3-targeting drug which is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy,

[17] the drug according to [15] or [16], wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the cancer patient,

55 [18] the drug according to [17], wherein the concentration of free GPC3 in the biological sample isolated from the cancer patient is a concentration in the plasma sample or the serum sample,

[19] the drug according to any of [15] to [18], wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 60 ng/mL,

[20] the drug according to any of [15] to [19], wherein the concentration of free GPC3 is measured using an immunological method,

[21] the drug according to any of [15] to [20], wherein the concentration of free GPC3 has been increased as a result of receiving the GPC3-targeting drug therapy,

5 [22] the drug according to any of [15] to [21], wherein the patient shows high expression of GPC3 in an immunohistochemical staining score,

[23] the drug according to any of [15] to [22], wherein the cancer patient is a liver cancer patient,

[24] the drug according to any of [15] to [23], wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient,

10 [25] the drug according to any of [15] to [24], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient,

[26] the drug according to [25], wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity,

15 [27] the drug according to [25] or [26], wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):

(1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;

20 (2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;

(3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;

25 (4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and

30 (5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively,

[28] the drug according to any of [25] to [27], wherein the anti-GPC3 antibody comprises any of the following (1) to (6):

35 (1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

40 (3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

45 (5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73,

50 [29] the drug according to [25], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance,

[30] a preparation for GPC3-targeting treatment, comprising an instruction stating that the preparation is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy,

55 [31] a preparation for GPC3-targeting treatment, comprising an instruction stating that the preparation is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy,

[32] the preparation according to [30] or [31], wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the cancer patient,

[33] the preparation according to [32], wherein the concentration of free GPC3 in the biological sample isolated from the cancer patient is a concentration in the plasma sample or the serum sample,

[34] the preparation according to any of [30] to [33], wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL,

[35] the preparation according to any of [30] to [34], wherein the concentration of free GPC3 is measured using an immunological method,

[36] the preparation according to any of [30] to [35], wherein the concentration of free GPC3 has been increased as a result of receiving the GPC3-targeting drug therapy,

[37] the preparation according to any of [30] to [36], wherein the patient shows high expression of GPC3 in an immunohistochemical staining score,

[38] the preparation according to any of [30] to [37], wherein the cancer patient is a liver cancer patient,

[39] the preparation according to any of [30] to [38], wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient,

[40] the preparation according to any of [30] to [39], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient,

[41] the preparation according to [40], wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity,

[42] the preparation according to [40] or [41], wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):

(1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;

(2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;

(3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;

(4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and

(5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively,

[43] the preparation according to any of [40] to [42], wherein the anti-GPC3 antibody comprises any of the following (1) to (6):

(1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

(3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

(5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73,

[44] the preparation according to [40], wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance,

[45] a method for treating cancer, comprising administering a GPC3-targeting drug to a patient determined by a method according to any of [1] to [14].

[Effect of Invention]

[0016] According to the present invention, whether GPC3-targeting drug therapy has efficacy or whether GPC3-targeting drug therapy should be continued can be determined conveniently and accurately. This can improve the effects of the GPC3-targeting drug therapy and improve QOL of a patient to be treated. As a result, the better treatment of cancer is achieved.

[Brief Description of Drawings]

[0017]

[FIG. 1A] FIG. 1A is a diagram showing the histochemical staining images of tissues evaluated as having high expression in a staining score of GPC3-IHC (staining method 1). The numeral shown in the upper part of each staining image represents a patient number.

[FIG. 1B] FIG. 1B is a diagram showing the histochemical staining images of tissues evaluated as being negative or having low expression in a staining score of GPC3-IHC (staining method 1). The numeral shown in the upper part of each staining image represents a patient number.

[FIG. 2] FIG. 2 is a diagram showing the durations of GC33 administration to 20 cases. Each cycle involves four doses of GC33 (administered once a week).

[FIG. 3] FIG. 3 is a diagram showing a difference in progression-free survival duration among a patient group from which samples divided into two groups (with a total score of 7 or higher and with a total score lower than 7) according to a staining method based on epitope retrieval using autoclaving were isolated. The solid line represents the progression-free survival duration of the group with a total score of 7 or higher (9 cases). The broken line represents the progression-free survival duration of the group with a total score lower than 7 (7 cases). The hazard ratio of the group with a total score of 7 or higher to the group with a total score lower than 7 was 0.376 (95% confidence interval: 0.116-1.227, $p = 0.0852$).

[FIG. 4A] FIG. 4A is a diagram showing the correlation between the concentration of free GPC3 detected in serum and the GPC3-IHC score of tumor tissues, in a group evaluated as having high expression of GPC3. The ordinate shows the serum concentration (ng/mL) of free GPC3. The abscissa shows the number of lapsed days (day) after the start of GPC3-targeting drug therapy.

[FIG. 4B] FIG. 4B is a diagram showing the correlation between the concentration of free GPC3 detected in serum and the GPC3-IHC score of tumor tissues, in a group evaluated as having low expression of GPC3 or being negative. The ordinate shows the serum concentration (ng/mL) of free GPC3. The abscissa shows the number of lapsed days (day) after the start of GPC3-targeting drug therapy.

[FIG. 5A] FIG. 5A is a diagram showing the correlation between the concentration of free GPC3 in serum isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients. The ordinate shows a survival rate. The abscissa shows progression-free survival duration (day) after the start of GPC3-targeting drug therapy. The solid line represents the progression-free survival duration of a group having a measurable level of free GPC3 (6 cases). The broken line represents the progression-free survival duration of a group having a GPC3 level below the measurement limit (0.4 ng/mL) (14 cases).

[FIG. 5B] FIG. 5B is a diagram showing the correlation between the concentration of free GPC3 in serum isolated from serum collected from patients during a test period (including before and after the start of GPC3-targeting drug therapy) and the progression-free survival duration of the patients. The ordinate shows a survival rate. The abscissa shows progression-free survival duration (day) after the start of GPC3-targeting drug therapy. The solid line represents the progression-free survival duration of a group having a measurable level of free GPC3 (9 cases) in serum isolated from serum collected from the patients before or during GPC3-targeting drug therapy. The broken line represents the progression-free survival duration of a group having a GPC3 level below the measurement limit (0.4 ng/mL) (both before and after the start of GPC3-targeting drug therapy) (11 cases) in serum isolated from serum collected from the patients treated with the therapy.

[FIG. 6A] FIG. 6A is a diagram showing the correlation between the concentration of free GPC3 in serum isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients. The ordinate shows a survival rate. The abscissa shows progression-free survival duration (day) after the start of GPC3-targeting drug therapy. The solid line represents the progression-free survival duration of a group having a measurable level of free GPC3 (8 cases). The broken line represents the progression-free survival duration of a group having a GPC3 level below the measurement limit (0.4 ng/mL) (19 cases). The hazard ratio of the group with a detectable level of GPC3 to the group with a GPC3 level below the detection limit was 0.265 (95% confidence interval: 0.077-0.914, $p = 0.0219$).

[FIG. 6B] FIG. 6B is a diagram showing the correlation between the concentration of free GPC3 in serum isolated

from serum collected from patients during a test period (including before and after the start of GPC3-targeting drug therapy) and the progression-free survival duration of the patients. The ordinate shows a survival rate. The abscissa shows progression-free survival duration (day) after the start of GPC3-targeting drug therapy. The solid line represents the progression-free survival duration of a group having a measurable level of free GPC3 (13 cases) in serum isolated from serum collected from the patients before or during GPC3-targeting drug therapy. The broken line represents the progression-free survival duration of a group having a GPC3 level below the measurement limit (0.4 ng/mL) (both before and after the start of GPC3-targeting drug therapy) (14 cases) in serum isolated from serum collected from the patients treated with the therapy. The hazard ratio of the group with a detectable level of GPC3 to the group with a GPC3 level below the detection limit was 0.283 (95% confidence interval: 0.112-0.715, $p = 0.0038$). [FIG. 7A] FIG. 7A is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 lower than the median value (1129.7 pg/mL). The solid line represents the progression-free survival duration of a placebo group (34 cases). The broken line represents the progression-free survival duration of a group with a putative trough level of GC33 lower than the median value (low-GC33-exposed group: 19 cases). The dotted line represents the progression-free survival duration of a group with a putative trough level of GC33 equal to or higher than the median value (high-GC33-exposed group: 34 cases). The median value of the progression-free survival duration was 83 days for the placebo group, 43.5 days for the low-GC33-exposed group, and 124 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.803 ($p = 0.397$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.425 ($p = 0.010$).

[FIG. 7B] FIG. 7B is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 equal to or higher than the median value (1129.7 pg/mL). The solid line represents the progression-free survival duration of a placebo group (24 cases). The broken line represents the progression-free survival duration of a low-GC33-exposed group (40 cases). The dotted line represents the progression-free survival duration of a high-GC33-exposed group (24 cases). The median value of the progression-free survival duration was 44 days for the placebo group, 46.5 days for the low-GC33-exposed group, and 87 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.510 ($p = 0.036$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.572 ($p = 0.056$).

[FIG. 7C] FIG. 7C is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 lower than the median value (1129.7 pg/mL). The solid line represents the overall survival duration of a placebo group (34 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (19 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (34 cases). The median value of the overall survival duration was 203 days for the placebo group, 86 days for the low-GC33-exposed group, and 295 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.590 ($p = 0.200$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.329 ($p = 0.008$).

[FIG. 7D] FIG. 7D is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 equal to or higher than the median value (1129.7 pg/mL). The solid line represents the overall survival duration of a placebo group (24 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (40 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (24 cases). The median value of the overall survival duration was 121 days for the placebo group, 177 days for the low-GC33-exposed group, and 308 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.303 ($p = 0.005$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.280 ($p = 0.002$).

[FIG. 7E] FIG. 7E is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 higher than 175 pg/mL. The solid line represents the progression-free survival duration of a placebo group (51 cases). The broken line represents the progression-free survival duration of a low-GC33-exposed group (56 cases). The dotted line represents the progression-free survival duration of a high-GC33-exposed group (47 cases). The median value of the progression-free survival duration was 51 days for the placebo group, 45 days for the low-GC33-exposed group, and 124 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.597 ($p = 0.0184$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was

0.439 ($p = 0.0003$).

[FIG. 7F] FIG. 7F is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 higher than 175 pg/mL. The solid line represents the overall survival duration of a placebo group (51 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (56 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (47 cases). The median value of the overall survival duration was 203 days for the placebo group, 141 days for the low-GC33-exposed group, and 308 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.402 ($p = 0.0037$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.238 ($p < 0.0001$).

[FIG. 8A] FIG. 8A is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 lower than the median value (1161.5 pg/mL). The solid line represents the progression-free survival duration of a placebo group (31 cases). The broken line represents the progression-free survival duration of a low-GC33-exposed group (20 cases). The dotted line represents the progression-free survival duration of a high-GC33-exposed group (36 cases). The median value of the progression-free survival duration was 82 days for the placebo group, 43 days for the low-GC33-exposed group, and 124 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.713 ($p = 0.197$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.392 ($p = 0.004$).

[FIG. 8B] FIG. 8B is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 equal to or higher than the median value (1161.5 pg/mL). The solid line represents the progression-free survival duration of a placebo group (27 cases). The broken line represents the progression-free survival duration of a low-GC33-exposed group (39 cases). The dotted line represents the progression-free survival duration of a high-GC33-exposed group (22 cases). The median value of the progression-free survival duration was 45 days for the placebo group, 47 days for the low-GC33-exposed group, and 87 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.588 ($p = 0.092$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.626 ($p = 0.116$).

[FIG. 8C] FIG. 8C is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 lower than the median value (1161.5 pg/mL). The solid line represents the overall survival duration of a placebo group (31 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (20 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (36 cases). The median value of the overall survival duration was 203 days for the placebo group, 86 days for the low-GC33-exposed group, and 295 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.508 ($p = 0.100$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.287 ($p = 0.002$).

[FIG. 8D] FIG. 8D is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 equal to or higher than the median value (1161.5 pg/mL). The solid line represents the overall survival duration of a placebo group (27 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (39 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (22 cases). The median value of the overall survival duration was 176 days for the placebo group, 177 days for the low-GC33-exposed group, and 291 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.300 ($p = 0.022$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.324 ($p = 0.005$).

[FIG. 8E] FIG. 8E is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the progression-free survival duration of the patients in a group with the serum concentration of free GPC3 higher than 259.7 pg/mL. The solid line represents the progression-free survival duration of a placebo group (50 cases). The broken line represents the progression-free survival duration of a low-GC33-exposed group (55 cases). The dotted line represents the progression-free survival duration of a high-GC33-exposed group (47 cases). The median value of the progression-free survival duration was 46.5 days for the placebo group, 45.5 days for the low-GC33-exposed group, and 124 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.567 ($p = 0.010$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group

was 0.467 ($p = 0.0009$).

[FIG. 8F] FIG. 8F is a diagram showing the correlation between the serum concentration of free GPC3 isolated from serum collected from patients before the start of GPC3-targeting drug therapy and the overall survival duration of the patients in a group with the serum concentration of free GPC3 higher than 259.7 pg/mL. The solid line represents the overall survival duration of a placebo group (50 cases). The broken line represents the overall survival duration of a low-GC33-exposed group (55 cases). The dotted line represents the overall survival duration of a high-GC33-exposed group (47 cases). The median value of the overall survival duration was 185 days for the placebo group, 156 days for the low-GC33-exposed group, and 308 days for the high-GC33-exposed group. The hazard ratio of the high-GC33-exposed group to the placebo group was 0.414 ($p = 0.0043$), whereas the hazard ratio of the high-GC33-exposed group to the low-GC33-exposed group was 0.304 ($p = <0.0001$).

[0018] The present specification encompasses the contents described in the specification of Japanese Patent Application No. 2012-280304 on which the priority of the present application is based.

[Description of Embodiments]

Definition

[0019] Chemical terms and technical terms used in relation to the present invention have meanings generally understood by those skilled in the art, unless otherwise defined herein.

Indefinite article

[0020] In the present invention, the indefinite articles "a" and "an" refer to one or two or more (i.e., at least one) object(s) grammatically represented by the indefinite articles. For example, "a factor" means one factor or two or more factors.

Amino acid

[0021] Each amino acid is indicated herein by single-letter code or three-letter code, or both, as represented by, for example, Ala/A, Leu/L, Arg/R, Lys/K, Asn/N, Met/M, Asp/D, Phe/F, Cys/C, Pro/P, Gln/Q, Ser/S, Glu/E, Thr/T, Gly/G, Trp/W, His/H, Tyr/Y, Ile/I, and Val/V.

Amino acid modification

[0022] An amino acid in the amino acid sequence of an antigen-binding molecule can be modified by an appropriately adopted method known in the art such as site-directed mutagenesis (Kunkel et al., Proc. Natl. Acad. Sci. USA (1985) 82, 488-492) or overlap extension PCR. Also, a plurality of methods known in the art can be adopted as methods for modifying an amino acid to substitute the amino acid by an amino acid other than natural one (Annu. Rev. Biophys. Biomol. Struct. (2006) 35, 225-249; and Proc. Natl. Acad. Sci. U.S.A. (2003) 100 (11), 6353-6357). For example, a tRNA-containing cell-free translation system (Clover Direct (Protein Express, an R & D oriented company)) comprising a non-natural amino acid bound with an amber suppressor tRNA complementary to UAG codon (amber codon), which is a stop codon, is also preferably used.

[0023] The term "and/or" used herein to represent amino acid modification sites is meant to include every combination appropriately represented by "and" and "or". Specifically, for example, the phrase "amino acids 43, 52, and/or 105 are substituted" includes the following variations of amino acid modification:

(a) position 43, (b) position 52, (c) position 105, (d) positions 43 and 52, (e) positions 43 and 105, (f) positions 52 and 105, and (g) positions 43, 52, and 105.

EU numbering and Kabat numbering

[0024] According to a method used in the present invention, amino acid positions assigned to antibody CDRs and FRs are defined by the Kabat method (Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, Md., 1987 and 1991). When the antigen-binding molecule described herein is an antibody or an antigen-binding fragment, amino acids in variable and constant regions are indicated according to the Kabat numbering and the EU numbering conforming to the Kabat amino acid positions, respectively.

Biological sample

[0025] In the present invention, the term "biological sample" refers to a sample of a tissue or a fluid isolated from a subject. In a non-limiting aspect, examples of such samples include plasma, serum, spinal fluid, lymph, external sections of skin, respiratory tract, intestinal tract, and genitourinary tract, tear, saliva, sputum, milk, whole blood or any blood fraction, blood derivatives, blood cells, tumor, nervous tissues, organs or any type of tissue, any sample obtained by lavage (e.g., samples derived from the bronchi), and samples of components constituting cell cultures *in vitro*.

[0026] The concentration of free GPC3 can be measured in a biological sample isolated from a patient. The concentration of free GPC3 may be measured in, for example, a whole blood sample or a blood fraction (e.g., serum or plasma) sample (also referred to as a whole blood sample, a serum sample, or a plasma sample, respectively, herein). In a non-limiting aspect, the concentration of free GPC3 in a whole blood sample, a serum sample, or a plasma sample from a patient can be measured using, for example, commercially available Human Glypican-3 ELISA kit (BioMosaics Inc.) or Enzyme-linked Immunosorbent Assay Kit For Glypican 3 (GPC3) (USCN Life Science Inc.) and the whole blood sample, the serum sample, or the plasma sample treated with EDTA.

[0027] The term "isolated" refers to causing "artificial" change from a natural state, i.e., shifting and/or removing a naturally occurring substance from its original environment. In the present invention, the term "isolated" means that, for example, a polynucleotide or a polypeptide present in an organism is unisolated, whereas the same polynucleotide or polypeptide thereas is isolated when separated from a material present with the polynucleotide or the polypeptide in a natural state. A polynucleotide or a polypeptide introduced into an organism by transformation, genetic manipulation, or any other recombination method is in an isolated state even when present in the organism (regardless of being alive or dead).

Free GPC3

[0028] In the present invention, the term "free GPC3" refers to GPC3 unanchored to GPC3-expressing cells and includes fragments of secretory GPC3 that can be easily dissociated from GPC3 anchored to GPC3-expressing cells under particular conditions *in vivo* or *in vitro*. In a non-limiting aspect, examples of the "free GPC3" can include a polypeptide from the amino terminus to position 358 in GPC3 consisting of the polypeptide defined by SEQ ID NO: 1, a polypeptide from the amino terminus to position 374 in GPC3 consisting of the polypeptide defined by SEQ ID NO: 1, a GPC3 polypeptide liberated by the degradation of a GPI anchor present at the carboxy terminus, and their fragments (Patent Literature 7). Those skilled in the art can appropriately select an approach known in the art for determining the structure of free GPC3. In a non-limiting aspect, a method therefor that may be appropriately used involves, for example, directly detecting free GPC3 present in the serum or the plasma of a patient or a model animal by the method described in Patent Literature 7 and analyzing its structure or involves, for example, allowing an enzyme dissociating free GPC3, such as convertase, phospholipase D, or Notum, to act on GPC3 expressed in cells cultured *in vitro*, detecting the resulting free GPC3, and analyzing its structure (e.g., J. Cell. Biol. (2003) 163 (3), 625-635).

Method for measuring concentration of free GPC3

[0029] The concentration of free GPC3 can be measured by one or more methods selected from the group consisting of the following: spectroscopic methods such as nuclear magnetic resonance (NMR) and mass spectrometry (MS); and SELDI(-TOF), MALDI(-TOF), 1D gel-based analysis, 2D gel-based analysis, liquid chromatography (e.g., highpressure liquid chromatography (HPLC) or low-pressure liquid chromatography (LPLC)), thin-layer chromatography, and LC-MS-based techniques. Examples of appropriate LCMS techniques can include ICAT(R) (Applied Biosystems, Inc.) and iTRAQ(R) (Applied Biosystems, Inc.). Also, a method which involves detecting a further fragment of free GPC3 further digested with an appropriate enzyme may be appropriately adopted.

[0030] The assay of free GPC3 can be carried out by a direct or indirect detection method. Free GPC3 can be detected directly or indirectly via the interaction of a ligand or a ligand group with, for example, an enzyme, a bond, a receptor or a transport protein, an antibody, a peptide, an aptamer or an oligonucleotide, or an arbitrary synthetic chemical receptor or compound capable of specifically binding to free GPC3. The ligand may be modified with a detectable label such as a luminescent label, a fluorescent label, or a radioactive label, and/or an affinity tag.

Immunological method

[0031] Examples of preferred methods for assaying free GPC3 can include immunological methods using an antibody capable of binding to an epitope present in GPC3. Examples of the immunological methods include enzyme immunoassay (ELISA or EIA), fluorescence immunoassay (FIA), radioimmunoassay (RIA), luminescence immunoassay (LIA), immunoenzymatic technique, fluorescent antibody technique, immunochromatography, immunoturbidimetry, latex turbidim-

etry, and latex agglutination assay. In the immunological method of the present invention, free GPC3 may be assayed by procedures of manual operation or using an apparatus such as an analyzer.

5 [0032] The immunological method of the present invention can be performed according to, for example, a method known in the art such as sandwich technique. For example, a primary antibody immobilized on a carrier, a biological sample, and a secondary antibody modified with a labeling material are reacted simultaneously or in order. This reaction forms a complex of the primary antibody immobilized on a carrier, free GPC3, and the secondary antibody modified with a labeling material. The labeling material conjugated with the secondary antibody contained in this complex can be quantified to thereby measure the amount (concentration) of the free GPC3 contained in the biological sample.

10 [0033] In the case of, for example, the enzyme immunoassay, a primary antibody-immobilized microplate, serially diluted biological samples, a secondary antibody modified with an enzyme such as HRP, a washing buffer, and a solution containing a substrate reactive with the enzyme such as HRP are preferably used. In a non-limiting aspect of assay, the enzyme modifying the secondary antibody is reacted under the optimum conditions thereof with the substrate. The amount of the resulting enzymatic reaction product can be measured by an optical method or the like. In the case of the fluorescence immunoassay, a primary antibody-immobilized optical waveguide, serially diluted biological samples, a secondary antibody modified with a fluorescent material, and a washing buffer may be preferably used. In a non-limiting aspect of assay, the fluorescent material modifying the secondary antibody can be irradiated with excitation light to thereby emit fluorescence, the intensity of which is then measured.

15 [0034] The radioimmunoassay involves measuring the amount of radiation from a radioactive substance. The luminescence immunoassay involves measuring luminescence intensity derived from a luminescent reaction system. For example, the immunoturbidimetry, the latex turbidimetry, or the latex agglutination assay involves measuring transmitted light or scattering light by an endpoint or rate method. The immunochromatography, for example, which is based on visual observation, involves visually measuring the color of the labeling material appearing on a test line. Alternatively, an instrument such as an analyzer may be appropriately used instead of this visual measurement.

20 [0035] In the immunological method of the present invention, the primary antibody for immobilization on a carrier can be adsorbed or bound to the carrier by a method such as physical adsorption, chemical binding, or a combination thereof. A method known in the art may be appropriately used for immobilizing the antibody by physical adsorption. Examples of the method include a method which involves contacting the antibody with the carrier by mixing in a solution such as a buffer solution, and a method which involves contacting the antibody dissolved in a buffer or the like with the carrier. Alternatively, the antibody may be immobilized onto the carrier by chemical binding. Examples of the method include a method which involves contacting the antibody and the carrier by mixing with a divalent cross-linking reagent such as glutaraldehyde, carbodiimide, imide ester, or maleimide to react the reagent with amino groups, carboxyl groups, thiol groups, aldehyde groups, or hydroxy groups in both the antibody and the carrier. Such immobilization may require treatment for suppressing nonspecific reaction or the natural aggregation or the like of the antibody-immobilized carrier. In such a case, the aftertreatment of the immobilization can be performed by a method known in the art. Examples of the method include a method which involves coating the surface or inner wall of the antibody-immobilized carrier by contacting with, for example, a protein (e.g., bovine serum albumin (BSA), casein, gelatin, egg albumin, or a salt thereof), a surfactant, or a skimmed milk.

30 [0036] In the immunological method of the present invention, the secondary antibody for modification with a labeling material can be adsorbed or bound to the labeling material by a method such as physical adsorption, chemical binding, or a combination thereof. A method known in the art may be appropriately used for binding the antibody to the labeling material by physical adsorption. Examples of the method include a method which involves contacting the antibody with the labeling material by mixing in a solution such as a buffer solution, and a method which involves contacting the antibody dissolved in a buffer or the like with the labeling material. When the labeling material is, for example, gold colloid or latex, the physical adsorption method is effective. The antibody can be mixed and contacted with the gold colloid in a buffer to obtain a gold colloid-labeled antibody. Alternatively, the antibody may be modified with the labeling material by chemical binding. Examples of the method include a method which involves contacting the antibody and the labeling material by mixing with a divalent cross-linking reagent such as glutaraldehyde, carbodiimide, imide ester, or maleimide to react the reagent with amino groups, carboxyl groups, thiol groups, aldehyde groups, or hydroxy groups in both the antibody and the labeling material. When the labeling material is, for example, a fluorescent material, an enzyme, or a chemiluminescent material, the chemical binding method is effective. Such modification may require treatment for suppressing nonspecific reaction or the natural aggregation or the like of the antibody modified with the labeling material. In such a case, the aftertreatment of the labeling can be performed by a method known in the art. Examples of the method include a method which involves coating the labeling material-bound antibody by contacting with, for example, a protein (e.g., bovine serum albumin (BSA), casein, gelatin, egg albumin, or a salt thereof), a surfactant, or a skimmed milk.

55 [0037] For example, peroxidase (POD), alkaline phosphatase (ALP), β -galactosidase, urease, catalase, glucose oxidase, lactate dehydrogenase, or amylase can be used as the labeling material for enzyme immunoassay. For example, fluorescein isothiocyanate, tetramethylrhodamine isothiocyanate, substituted rhodamine isothiocyanate, dichlorotriazine

isothiocyanate, cyanine, or merocyanine can be used for fluorescence immunoassay. For example, tritium, iodine 125, or iodine 131 can be used for radioimmunoassay. For example, a luminol system, a luciferase system, an acridinium ester system, or a dioxetane compound system can be used for luminescence immunoassay. Alternatively, fine particles made of a material such as polystyrene, a styrene-styrene sulfonate copolymer, an acrylonitrile-butadiene-styrene copolymer, a vinyl chloride-acrylic acid ester copolymer, a vinyl acetate-acrylic acid copolymer, polyacrolein, a styrene-methacrylic acid copolymer, a styrene-glycidyl (meth)acrylate copolymer, a styrene-butadiene copolymer, a methacrylic acid polymer, an acrylic acid polymer, latex, gelatin, liposome, a microcapsule, silica, alumina, carbon black, a metal compound, a metal, a metal colloid, a ceramic, or a magnetic substance can be used for immunochromatography, immunoturbidimetry, latex turbidimetry, or latex agglutination assay.

[0038] A solid-phase carrier in the form of, for example, beads, a microplate, a test tube, a stick, a membrane, or a test pieces made of a material such as polystyrene, polycarbonate, polyvinyltoluene, polypropylene, polyethylene, polyvinyl chloride, nylon, polymethacrylate, polyacrylamide, latex, liposome, gelatin, agarose, cellulose, Sepharose, glass, a metal, a ceramic, or a magnetic substance can be appropriately used as the carrier in the immunological method of the present invention.

[0039] The present invention also provides an assay kit comprising components for use in the immunological method of the present invention. The assay kit comprises at least one type of antibody capable of binding to an epitope present in GPC3. The antibody may be provided in a state immobilized on the carrier mentioned above or may be provided independently of the carrier. The kit may additionally comprise standard solutions of serially diluted free GPC3. The assay kit may further comprise at least one type of antibody capable of binding to an epitope different from that present in GPC3. Assay principles, etc., for use in the immunoassay kit of the present invention are the same as in the immunological method mentioned above. In the immunoassay kit of the present invention, various aqueous solvents may be used. Examples of the aqueous solvents include purified water, saline, and various buffers such as tris buffers, phosphate buffers, and phosphate-buffered saline. The pH of this buffer can be appropriately selected from among suitable pHs. The pH value used is not limited and is generally selected within the range of pH 3 to 12.

[0040] The immunoassay kit of the present invention may further appropriately contain, in addition to the components mentioned above, one or two or more components selected from proteins (e.g., bovine serum albumin (BSA), human serum albumin (HSA), casein, and salts thereof), various salts, various sugars, skimmed milk, various animal sera (e.g., normal rabbit serum), various antiseptics (e.g., sodium azide and antibiotics), activating substances, reaction-promoting substances, sensitivity-increasing substances (e.g., polyethylene glycol), nonspecific reaction-inhibiting substances, and various surfactants such as nonionic surfactants, amphoteric surfactants, and anionic surfactants. The concentrations of these components contained in the assay reagent are not limited and are preferably 0.001 to 10% (W/V). Particularly preferred concentrations are appropriately selected within the range of 0.01 to 5% (W/V).

[0041] The immunoassay kit of the present invention may be further combined with other reagents, in addition to the components mentioned above. Examples of these other reagents include buffers, diluting solutions for biological samples, reagent diluting solutions, reagents containing labeling materials, reagents containing substances that generate signals such as color, reagents containing substances involved in the generation of signals such as color, reagents containing substances for calibration, and reagents containing substances for accuracy control.

[0042] The immunoassay kit of the present invention can have any form without limitations and may be provided as an integral-type diagnostic kit comprising all of the components constituting the immunoassay kit of the present invention in order to carry out assay conveniently in a short time. Examples of the integral-type diagnostic kit include ELISA kits, fluorescence immunoassay kits, and immunochromatography kits. The ELISA kit form comprises, for example, a primary antibody-immobilized microplate, standard solutions of serially diluted free GPC3, a secondary antibody modified with an enzyme such as HRP, a washing buffer, and a substrate solution for the enzymatic reaction. The fluorescence immunoassay kit comprises, for example, a primary antibody-immobilized optical waveguide, standard solutions of serially diluted free GPC3, a secondary antibody modified with a fluorescent material, and a washing buffer. The immunochromatography kit comprises a membrane housed in a reaction cassette. In one exemplary aspect, the primary antibody is immobilized at one end (downstream) of the membrane; a developing solution is placed at the other end (upstream) of the membrane; a pad supplemented with a substrate for the labeling agent is disposed in proximity (downstream) to the developing solution; and a pad supplemented with the secondary antibody labeled as described above is disposed in the central part of the membrane.

[0043] In the present invention, preferred examples of biological samples used for detecting the expression level of GPC3 in tissues include test subject-derived preparations. The test subject-derived preparation is preferably a tissue obtained from the test subject, more preferably a liver cancer or hepatocellular cancer tissue of the test subject. The liver cancer or hepatocellular cancer tissue is collected preferably using a biopsy method known in the art. The liver biopsy refers to a method of directly inserting a thin long needle into the liver from skin surface and collecting liver tissues. The needling site is typically the intercostal space of the right lower chest. The safety of the needling site is confirmed before operation using an ultrasonic examination apparatus. Then, the needling site is disinfected. A region from the skin to the surface of the liver is subjected to anesthesia. After small incision of the skin at the needling site, a puncture

needle is inserted thereto.

[0044] For microscopic observation by transmitted beams, the tissue preparation is sliced to a degree that allows beams of light for use in the microscope to sufficiently penetrate the tissue slice. At a stage prior to the slicing, the tissue preparation is fixed. Specifically, proteins in tissues or cells are coagulated by dehydration or denaturation to thereby rapidly kill the cells constituting the tissues. The resulting structure is stabilized and insolubilized. First, the tissue preparation to be fixed is cut into a fragment with a size and a shape suitable for the preparation of paraffin-embedded sections by use of a knife such as a surgical knife. Subsequently, the fragment is dipped in a fixative, which is a reagent used for carrying out fixation. Formalin, more preferably neutral buffered formalin, is preferably used as the fixative. The concentration of the neutral buffered formalin is appropriately selected according to the characteristics or physical properties of the tissue preparation. The concentration used may be appropriately changed between 1 and 50%, preferably 5 and 25%, more preferably 10 and 15%. The fixative with the tissue preparation dipped therein is appropriately degassed using a vacuum pump. For fixation, the tissue preparation is left for several hours in the fixative under conditions of ordinary pressure and room temperature. The time required for the fixation can be appropriately selected within the range of 1 hour to 7 days, preferably 2 hours to 3 days, more preferably 3 hours to 24 hours, further preferably 4 hours to 16 hours. The tissue preparation thus fixed is appropriately dipped in a phosphate buffer solution or the like for additional several hours (which can be appropriately selected within the range of 2 hours to 48 hours, preferably 3 hours to 24 hours, more preferably 4 hours to 16 hours).

[0045] Next, sections can be preferably prepared by freeze sectioning or paraffin sectioning from the tissue preparation thus fixed. Preferred examples of the freeze sectioning include a method which involves adding tissues into O.C.T. Compound (Miles Inc.), freezing the mixture, and slicing the frozen mixture using a cryostat (frozen section preparation apparatus). In the paraffin sectioning, the fixed tissue preparation is dipped in an embedding agent, which is then solidified to thereby impart thereto uniform and appropriate hardness. Paraffin can be preferably used as the embedding agent. The fixed tissue preparation is dehydrated using ethanol. Specifically, the tissue preparation is dipped in 70% ethanol, 80% ethanol, and 100% ethanol in this order and thereby dehydrated. The time required for the dipping and the number of runs can be appropriately selected within the ranges of 1 hour to several days and 1 to 3 times, respectively. The tissue preparation may be dipped therein at room temperature or 4°C. In the case of dipping at 4°C, a longer dipping time (e.g., overnight) is more preferred. After replacement of the liquid phase with xylene, the tissue preparation is embedded in paraffin. The time required for the replacement of the liquid phase with xylene can be appropriately selected within the range of 1 hour to several hours. This replacement may be performed at room temperature or 4°C. In the case of replacement at 4°C, a longer replacement time (e.g., overnight) is more preferred. The time required for the embedding in paraffin and the number of runs can be appropriately selected within the ranges of 1 hour to several hours and 1 to 4 times, respectively. This embedding may be performed at room temperature or 4°C. In the case of embedding at 4°C, a longer embedding time (e.g., overnight) is more preferred. Alternatively, the tissue preparation may be preferably embedded in paraffin using paraffin embedding apparatus (EG1160, Leica, etc.) that automatically performs paraffin embedding reaction.

[0046] The tissue preparation thus paraffin-embedded is bonded to a block base to prepare a "block". This block is sliced into the desired thickness selected from thicknesses of 1 to 20 μm by use of a microtome. The sliced tissue section is left standing on a glass slide as a permeable support and thereby fixed thereon. In this case, the glass slide coated with 0.01% poly-L-lysine (Sigma-Aldrich Corp.) and then dried may be preferably used in order to prevent the tissue section from coming off. The fixed tissue section is dried in air for an appropriate time selected from between several minutes and 1 hour.

Epitope retrieval

[0047] In a preferred aspect, an epitope in an antigen whose reactivity with an antibody has been attenuated due to formalin fixation is retrieved. In the present invention, protease-induced epitope retrieval (PIER) or heat-induced epitope retrieval (HIER) may be applied to the retrieval. In a non-limiting aspect, PIER may be applied to one of "two identifiable tissue preparations" prepared as shown below, while HIER may be applied to the other preparation. In this case, a difference in the degree of staining between these preparations reacted with antibodies can be digitized.

[0048] In a non-limiting aspect, a set of two tissue preparations is prepared, which are prepared as shown in the paragraph "Biological sample" and attached onto permeable supports. The tissue preparations are desirably two histologically identifiable tissue preparations. The term "identifiable" means that two tissue preparations to be mutually compared are composed of substantially the same cells or tissues in test subject-derived preparations serving as origins of the tissue preparations. For example, two tissue preparations prepared as adjacent sections correspond to two identifiable tissue preparations. In the present invention as well, the "two identifiable tissue preparations" refer to two tissue preparations prepared as adjacent sections, unless otherwise specified. In addition, two tissue preparations composed of cells or tissues structurally identifiable between the preparations correspond to "two identifiable tissue preparations", even if the tissue preparations are not prepared as adjacent sections. Preferred examples of such two tissue preparations

composed of cells or tissues structurally identifiable therebetween include (1) tissue sections containing cells derived from the same cells at the same positions on plane coordinates in the sections, and (2) tissue sections in which at least 50% or more, preferably 60% or more, more preferably 70% or more, further preferably 80% or more, still further preferably 90% or more, particularly preferably 95% or more of the cells are present at the same positions on the plane coordinates.

5 **[0049]** The heat-induced epitope retrieval appropriately employs, for example, a heating method using microwave, a heating method using an autoclave, or a heating method using boiling treatment. In the case of boiling treatment at an output of 780 W so as to keep a liquid temperature at approximately 98°C, the time required for the retrieval including the treatment is appropriately selected from between 5 minutes and 60 minutes and is, for example, 10 minutes. The epitope retrieval treatment can be performed in a 10 mM sodium citrate buffer solution as well as commercially available
10 Target Retrieval Solution (DakoCytomation), for example. Target Retrieval Solution is used in Examples described below. Any buffer solution or aqueous solution is preferably used as long as an epitope in the antigen that is recognized by an anti-GPC3 antibody acquires the ability to bind to the antibody as a result of the retrieval treatment so that an antigen-antibody complex mentioned later can be detected.

15 **[0050]** The protease for use in the protease-induced epitope retrieval is not limited by its type or origin. Generally available protease can be appropriately selected for use. Preferred examples of the protease used include pepsin with 0.05% concentration in 0.01 N hydrochloric acid, trypsin with 0.1% concentration further containing CaCl₂ with 0.01% concentration in a tris buffer solution (pH 7.6), and protease K with a concentration of 1 to 50 µg/ml in a 10 mM tris-HCl buffer solution (pH 7.8) containing 10 mM EDTA and 0.5% SDS. In the case of using protease K, the pH of the reaction solution is appropriately selected from between 6.5 and 9.5, and an SH reagent, a trypsin inhibitor, or a chymotrypsin
20 inhibitor may be appropriately used. Specific examples of such preferred protease also include protease attached to Histofine HER2 kit (MONO) (Nihon Bioreagents Inc.). The protease-induced epitope retrieval is usually performed at 37°C. The reaction temperature may be appropriately changed within the range of 25°C to 50°C. The reaction time of the protease-induced epitope retrieval performed at 37°C is appropriately selected from between, for example, 1 minute and 5 hours and is, for example, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, or 4 hours. After the
25 completion of the retrieval treatment, the tissue preparation thus treated is washed with a washing buffer solution. Phosphate-buffered saline (PBS) is preferably used as the washing buffer solution. Alternatively, a tris-HCl buffer solution may be preferably used. The washing conditions adopted in this method usually involve three runs of washing at room temperature for 5 minutes. The washing time and temperature may be appropriately changed.

30 Reaction between tissue preparation and anti-GPC3 antibody

[0051] The tissue preparation thus treated by the heat-induced epitope retrieval and/or the tissue preparation thus treated by the protease-induced epitope retrieval are reacted with an anti-GPC3 antibody mentioned later as a primary antibody. The reaction is carried out under conditions appropriate for the recognition of an epitope in the antigen by the
35 anti-GPC3 antibody and the subsequent formation of an antigen-antibody complex. The reaction is usually carried out overnight at 4°C or at 37°C for 1 hour. The reaction conditions may be appropriately changed within a range appropriate for the recognition of an epitope in the antigen by the antibody and the subsequent formation of an antigen-antibody complex. For example, the reaction temperature may be changed within the range of 4°C to 50°C, while the reaction time may be changed between 1 minute and 7 days. A longer reaction time is more preferred for the reaction carried
40 out at a low temperature. After the completion of the primary antibody reaction, each tissue preparation is washed with a washing buffer solution. Phosphate-buffered saline (PBS) is preferably used as the washing buffer solution. Alternatively, a tris-HCl buffer solution may be preferably used. The washing conditions adopted in this method usually involve three runs of washing at room temperature for 5 minutes. The washing time and temperature may be appropriately changed.

45 **[0052]** Subsequently, each tissue preparation thus reacted with the primary antibody is reacted with a secondary antibody that recognizes the primary antibody. A secondary antibody labeled in advance with a labeling material for visualizing the secondary antibody is usually used. Preferred examples of the labeling material include: fluorescent dyes such as fluorescein isothiocyanate (FITC), Cy2 (Amersham Biosciences Corp.), and Alexa 488 (Molecular Probes Inc.); enzymes such as peroxidase and alkaline phosphatase; and gold colloid.

50 **[0053]** The reaction with the secondary antibody is carried out under conditions appropriate for the formation of an antigen-antibody complex between the anti-GPC3 antibody and the secondary antibody that recognizes the anti-GPC3 antibody. The reaction is usually carried out at room temperature or 37°C for 30 minutes to 1 hour. The reaction conditions may be appropriately changed within a range appropriate for the formation of an antigen-antibody complex between the anti-GPC3 antibody and the secondary antibody. For example, the reaction temperature may be changed within the
55 range of 4°C to 50°C, while the reaction time may be changed between 1 minute and 7 days. A longer reaction time is more preferred for the reaction carried out at a low temperature. After the completion of the secondary antibody reaction, each tissue preparation is washed with a washing buffer solution. Phosphate-buffered saline (PBS) is preferably used as the washing buffer solution. Alternatively, a tris-HCl buffer solution may be preferably used. The washing conditions

adopted in this method usually involve three runs of washing at room temperature for 5 minutes. The washing time and temperature may be appropriately changed.

[0054] Next, each tissue preparation thus reacted with the secondary antibody is reacted with a substance capable of visualizing the labeling material. When peroxidase is used as the labeling material in the secondary antibody, a 0.02% aqueous hydrogen peroxide solution and a diaminobenzidine (DAB) solution concentration-adjusted to 0.1% with a 0.1 M tris-HCl buffer solution (pH 7.2) are mixed in equal amounts immediately before incubation and the tissue preparation is incubated in the resulting reaction solution. A chromogenic substrate such as DAB-Ni or AEC+ (both from Dako Japan Inc.) may be appropriately selected instead of DAB. During the course of incubation, the visualization reaction can be stopped by the dipping of the tissue preparation in PBS at the stage where appropriate color development is confirmed by the occasional microscopic observation of the degree of color development.

[0055] When alkaline phosphatase is used as the labeling material in the secondary antibody, each tissue preparation is incubated in a 5-bromo-4-chloro-3-indolyl phosphoric acid (BCIP)/nitro blue tetrazolium (NBT) (Zymed Laboratories, Inc.) substrate solution (solution of NBT and BCIP dissolved at concentrations of 0.4 mM and 0.38 mM, respectively, in a 50 mM sodium carbonate buffer solution (pH 9.8) containing 10 mM MgCl₂ and 28 mM NaCl). Alternatively, for example, Permanent Red, Fast Red, or Fuchsin+ (all from Dako Japan Inc.) may be appropriately used instead of BCIP and NBT. Prior to the incubation, the tissue preparation may be preincubated at room temperature for 1 minute to several hours with a 0.1 M tris-HCl buffer solution (pH 9.5) containing levamisole chloride (Nacalai Tesque, Inc.), an inhibitor of endogenous alkaline phosphatase, with a concentration of 1 mM, 0.1 M sodium chloride, and 50 mM magnesium chloride. During the course of incubation, the tissue preparation is washed with water or with TBST (TBS containing 0.1% Tween 20) after stop of the reaction by the addition of TBS containing 2% polyvinyl alcohol, at the stage where the deposition of a final reaction product purple formazan is confirmed by occasional microscopic observation. When gold colloid is used as the label in the secondary antibody, metallic silver is attached to gold particles by silver intensification to thereby visualize the gold colloid. The silver intensification method is generally known to those skilled in the art.

[0056] When a fluorescent dye such as fluorescein isothiocyanate (FITC), Cy2 (Amersham Biosciences Corp.), or Alexa 488 (Molecular Probes Inc.) is used as the labeling material in the secondary antibody, the reaction step of the visualizing substance is unnecessary. Each tissue preparation is irradiated with light at an excitation wavelength for the fluorescent material. Emitted light can be appropriately detected using a fluorescence microscope.

Immunohistochemical staining score

[0057] In a non-limiting aspect, the present invention also provides a method for determining the efficacy of GPC3-targeting drug therapy or determining the continuation of GPC3-targeting drug therapy from the concentration of free GPC3 as well as the expression level of GPC3 detected in tissues by the method described above. In a non-limiting aspect, the expression of GPC3 detected in tissues by the method described above is digitized by, for example, a non-limiting method exemplified below. In the present invention, such a digitized expression level of GPC3 in tissues is referred to as an "immunohistochemical staining score of GPC3".

[0058] The respective scores of positive cell rate (PR), staining intensity of cytoplasm (SI-cp) or staining intensity of cell membrane (SI-cm), and staining pattern of cell membrane (Sp-cm) are calculated according to the criteria shown in Table 1 by a method described in WO2009116659 and added on the basis of calculation expressions 1 and 2. The resulting score is exemplified as the non-limiting immunohistochemical staining score of GPC3 (referred to as "composite score 1" for the sake of convenience) of the present invention.

[Table 1-1]

Criterion	Evaluation	Score
Positive cell rate (PR)	0	0
	1% or more and less than 20%	1
	20% or more and less than 50%	2
	50% or more	3
Staining intensity (SI) - Cytoplasm (SI-cp) - Cell membrane (SI-cm)	Slightly positive	0
	Weakly positive	1
	Moderately positive and/or weakly positive with strong positivity	2
	Moderately positive	3
	Strongly positive	4

EP 2 937 697 A1

(continued)

Criterion	Evaluation	Score
Staining pattern of cell membrane (SP-cm)	Negative	0
	When only a portion of the cell membranes of cells was stained	1
	When a portion of the cell membranes of most of these cells was stained and the cell membranes of some of the cells were circumferentially stained	2
	When the cell membranes of most of these cells were circumferentially stained	3

(Sp-cm scores were calculated by the evaluation of cell staining in the visual field under microscope using an objective lens with a magnification of 4 or 10.)

[Expression 1]

$$\text{IHC total} = \text{PR} + \text{SI-Cp} + \text{SI-Cm} + \text{Sp-Cm}$$

[Expression 2]

$$\text{IHC cm} = \text{PR} + \text{SI-Cm} + \text{Sp-Cm}$$

[Table 1-2]

Composite score 1	IHC total score
High expression	7 or higher
Low or moderate expression	Lower than 7

[0059] In addition, the H-score is known (literature: KS. McCarty Jr. et al., Use of a monoclonal anti-Estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. Suppl. (1986) 46, 4244s-4248s), which is calculated on the basis of the proportion of cells that exhibit each staining intensity (staining intensity of cell membrane or cytoplasm) classified into 0 to 3.

[0060] Another example of the immunohistochemical staining score includes the following scoring algorithm for classification of 0 to 3+ on the basis of the staining intensity of membrane, the staining intensity of cytoplasm, and the degree of staining, and an evaluation score based on the algorithm (composite score 2).

[Table 2]

Score	Evaluation
0	When cell membranes were not stained
	When less than 10% of tumor cells exhibited intracytoplasmic staining
1+	When less than 10% of tumor cells exhibited cell membrane staining and/or
	When 10% or more of tumor cells exhibited intracytoplasmic staining (note that strong intracytoplasmic staining, if any, remains at less than 50% of the tumor cells)
2+	When 10% or more of tumor cells exhibited weak or moderate cell membrane staining (note that strong cell membrane staining, if any, remains at less than 10% of the tumor cells) regardless of the presence or absence of intracytoplasmic staining in 10% or more of the tumor cells (note that intracytoplasmic staining, if any, remains at less than 50% of the tumor cells)

(continued)

Score	Evaluation
3+	When 10% or more of tumor cells exhibited strong cell membrane staining regardless of the presence or absence of intracytoplasmic staining
	or
	When 50% or more of tumor cells exhibited strong intracytoplasmic staining

[0061] In the present invention, for example, the composite score 1, the H-score, and the composite score 2 may be used alone or in combination as the "immunohistochemical staining score of GPC3". In a non-limiting aspect, the composite score 1 may be used as the "immunohistochemical staining score of GPC3". In another non-limiting aspect, the composite score 2 may be used as the "immunohistochemical staining score of GPC3".

GPC3-targeting drug

[0062] In the present invention, the term "GPC3-targeting drug" refers to every molecule that blocks, suppresses, inhibits, or reduces the biological activity of GPC3 including a signal pathway mediated by GPC3 or is cytotoxic to cells expressing GPC3. The term "targeting treatment" does not suggest a certain mechanism having biological effects and conceptually includes every possible effect of the pharmacological, physiological, and biochemical interactions of GPC3. Examples of the GPC3-targeting drug include: (1) antagonistic or non-antagonistic inhibitors of the binding of GPC3 to a GPC3-binding ligand, i.e., active substances that interfere with the binding of GPC3 to its ligand; (2) active substances that do not interfere with the binding of GPC3 to its ligand but instead inhibit or decrease activity brought about by the binding of GPC3 to its ligand; (3) active substances that decrease GPC3 expression; and (4) active substances capable of eliciting cytotoxic activity against cells expressing GPC3. In a non-limiting aspect, examples of the ligand can include *wnt* (Cancer Res. (2005) 65, 6245-6254), IGF-II (Carcinogenesis (2008) 29 (7), 1319-1326), and fibroblast growth factor 2 (Int. J. Cancer (2003) 103 (4), 455-465). In a non-limiting aspect, such active substances can include, for example, antibodies (including their antigen-binding domains), nucleic acid molecules (antisense or RNAi molecules, etc.), peptides, non-peptidic low-molecular-weight organic materials.

[0063] In a non-limiting aspect, examples of the non-peptidic low-molecular-weight organic material that may be used as the GPC3-targeting drug of the present invention include non-peptidic low-molecular-weight quinoline derivatives (WO2008/046085) which act on methylation suppressor genes. Further examples thereof can include HLA-A2-restricted GPC3 peptide 144-152 (SEQ ID NO: 2) and HLA-A24-restricted GPC3 peptide 298-306 (SEQ ID NO: 3) (Clin. Cancer Res. (2006) 12 (9), 2689-2697) which elicit the cytotoxic activity of cytotoxic T cells.

Anti-GPC3 antibody

[0064] In a non-limiting aspect, examples of the anti-GPC3 antibody that may be used as the GPC3-targeting drug of the present invention can include an antibody-drug conjugate (ADC) (WO2007/137170) comprising a 1G12 antibody (WO2003/100429) (sold under catalog No. B0134R by BioMosaics Inc.) conjugated with a cytotoxic substance.

[0065] In an alternative non-limiting aspect, examples of the anti-GPC3 antibody include a humanized anti-GPC3 antibody described in WO2006/006693 or WO2009/041062. Specifically, a humanized anti-GPC3 antibody comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively, can be used as the GPC3-targeting drug of the present invention. The humanized anti-GPC3 antibody can be prepared using, as templates for humanization, appropriately selected human framework sequences having high sequence identity to a heavy chain framework sequence represented by SEQ ID NO: 10 or a light chain framework sequence represented by SEQ ID NO: 11.

[0066] In a further alternative non-limiting aspect, an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively, can be used as the GPC3-targeting drug of the present invention. The humanized anti-GPC3 antibody can be prepared using, as templates for humanization, appropriately selected human framework sequences having high sequence identity to a heavy chain framework sequence represented by SEQ ID NO: 18 or a light chain framework sequence represented by SEQ ID NO: 19.

[0067] In an alternative non-limiting aspect, an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and

22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively, can be used as the GPC3-targeting drug of the present invention. The humanized anti-GPC3 antibody can be prepared using, as templates for humanization, appropriately selected human framework sequences having high sequence identity to a heavy chain framework sequence represented by SEQ ID NO: 26 or a light chain framework sequence represented by SEQ ID NO: 27.

[0068] In a further alternative non-limiting aspect, an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively, can be used as the GPC3-targeting drug of the present invention. The humanized anti-GPC3 antibody can be prepared using, as templates for humanization, appropriately selected human framework sequences having high sequence identity to a heavy chain framework sequence represented by SEQ ID NO: 34 or a light chain framework sequence represented by SEQ ID NO: 35.

[0069] In an alternative non-limiting aspect, an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively, can be used as the GPC3-targeting drug of the present invention. The humanized anti-GPC3 antibody can be prepared using, as templates for humanization, appropriately selected human framework sequences having high sequence identity to a heavy chain framework sequence represented by SEQ ID NO: 42 or a light chain framework sequence represented by SEQ ID NO: 43.

[0070] In a further alternative non-limiting aspect, a humanized anti-GPC3 antibody comprising a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51 can be used as the GPC3-targeting drug of the present invention. In a further alternative non-limiting aspect, a humanized anti-GPC3 antibody comprising a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66 can be used as the GPC3-targeting drug of the present invention.

[0071] In a further alternative non-limiting aspect, a humanized anti-GPC3 antibody comprising a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68, a humanized anti-GPC3 antibody comprising a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70, a humanized anti-GPC3 antibody comprising a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72, or a humanized anti-GPC3 antibody comprising a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73 can also be used as the GPC3-targeting drug of the present invention.

Cytotoxic activity

[0072] Alternative examples of the anti-GPC3 antibody of the present invention include an anti-GPC3 antibody having cytotoxic activity. In the present invention, non-limiting examples of the cytotoxic activity include antibody-dependent cell-mediated cytotoxicity or antibody-dependent cellular cytotoxicity (ADCC) activity, complement-dependent cytotoxicity (CDC) activity, and cytotoxic activity based on T cells. In the present invention, the CDC activity means cytotoxic activity brought about by the complement system. On the other hand, the ADCC activity means the activity of damaging target cells by, for example, immunocytes, through the binding of the immunocytes via Fc γ receptors expressed on the immunocytes to the Fc regions of antigen-binding molecules comprising antigen-binding domains capable of binding to membrane molecules expressed on the cell membranes of the target cells. Whether or not the antigen-binding molecule of interest has ADCC activity or has CDC activity can be determined by a method known in the art (e.g., Current protocols in Immunology, Chapter 7. Immunologic studies in humans, Coligan et al., ed. (1993)).

[0073] Specifically, effector cells, a complement solution, and target cells are first prepared.

(1) Preparation of effector cells

[0074] The spleens are excised from CBA/N mice or the like, and spleen cells are separated therefrom in an RPMI1640 medium (Invitrogen Corp.). The spleen cells can be washed with this medium containing 10% fetal bovine serum (FBS, HyClone Laboratories, Inc.) and then concentration-adjusted to 5×10^6 cells/mL to prepare the effector cells.

(2) Preparation of complement solution

[0075] Baby Rabbit Complement (CEDARLANE Laboratories Ltd.) can be diluted 10-fold with a medium (Invitrogen

Corp.) containing 10% FBS to prepare the complement solution.

(3) Preparation of target cells

[0076] Antigen-expressing cells can be cultured at 37°C for 1 hour, together with 0.2 mCi ⁵¹Cr-sodium chromate (GE Healthcare Bio-Sciences Corp.), in a DMEM medium containing 10% FBS to thereby radiolabel the target cells. The cells thus radiolabeled can be washed three times with an RPMI1640 medium containing 10% FBS and then concentration-adjusted to 2 x 10⁵ cells/mL to prepare the target cells.

[0077] The ADCC or CDC activity can be assayed by a method described below. For the ADCC activity assay, the target cells and the antigen-binding molecule (each 50 μl/well) are added to a U-bottom 96-well plate (Becton, Dickinson and Company) and reacted for 15 minutes on ice. Then, 100 μl of the effector cells is added to each well, and the plate is left standing for 4 hours in a CO₂ incubator. The final concentration of the antibody (antigen-binding molecule) can be set to, for example, 0 or 10 μg/ml. The radioactivity of 100 μl of the supernatant recovered from each well of the plate thus left standing is measured using a gamma counter (COBRA II AUTO-GAMMA, MODEL D5005, Packard Instrument Company). The cytotoxic activity (%) can be calculated on the basis of the calculation expression (A - C) / (B - C) x 100 using the measurement value, wherein A represents radioactivity (cpm) from each sample; B represents radioactivity (cpm) from a sample supplemented with 1% NP-40 (Nacalai Tesque, Inc.); and C represents radioactivity (cpm) from a sample containing only the target cells.

[0078] For the CDC activity assay, the target cells and the antigen-binding molecule (each 50 μl/well) are added to a flat-bottomed 96-well plate (Becton, Dickinson and Company) and reacted for 15 minutes on ice. Then, 100 μl of the complement solution is added to each well, and the plate is left standing for 4 hours in a CO₂ incubator. The final concentration of the antibody (antigen-binding molecule) can be set to, for example, 0 or 3 μg/ml. The radioactivity of 100 μl of the supernatant recovered from each well of the plate thus left standing is measured using a gamma counter. The cytotoxic activity based on the CDC activity can be calculated in the same way as in the ADCC activity assay.

Cytotoxic substance

[0079] In a non-limiting aspect, alternative examples of the anti-GPC3 antibody of the present invention include an anti-GPC3 antibody conjugated with a cytotoxic substance. Such an anti-GPC3 antibody-drug conjugate (ADC) is specifically disclosed in, for example, WO2007/137170, though the conjugate of the present invention is not limited to those described therein. Specifically, the cytotoxic substance may be any of chemotherapeutic agents listed below or may be a compound disclosed in Alley et al. (Curr. Opin. Chem. Biol. (2010) 14, 529-537) or WO2009/140242. Antigen-binding molecules are conjugated with these compounds via appropriate linkers or the like.

[0080] Examples of chemotherapeutic agents that may be conjugated to the anti-GPC3 antibody of the present invention can include the following: azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, camptothecin, 10-hydroxycamptothecin, carmustine, Celebrex, chlorambucil, cisplatin, irinotecan, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, floxuridine, fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, leucovorin, lomustine, maytansinoid, mechlorethamine, medroxyprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, phenylbutyrate, prednisone, procarbazine, paclitaxel, pentostatin, semustine, streptozocin, tamoxifen, taxanes, Taxol, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinblastine, vinorelbine, and vincristine.

[0081] In the present invention, a preferred chemotherapeutic agent is a low-molecular-weight chemotherapeutic agent. The low-molecular-weight chemotherapeutic agent is unlikely to interfere with the functions of the anti-GPC3 antibody even after forming the anti-GPC3 antibody-drug conjugate of the present invention. In the present invention, the low-molecular-weight chemotherapeutic agent has a molecular weight of usually 100 to 2000, preferably 200 to 1000. All of the chemotherapeutic agents listed herein are low-molecular-weight chemotherapeutic agents. These chemotherapeutic agents according to the present invention include prodrugs that are converted to active chemotherapeutic agents *in vivo*. The prodrugs may be activated through enzymatic conversion or nonenzymatic conversion.

[0082] Alternative examples of the conjugated cytotoxic substance in the anti-GPC3 antibody-drug conjugate of the present invention can include toxic peptides (toxins) such as *Pseudomonas* exotoxin A, saporin-s6, diphtheria toxin, and cnidarian toxin, radioiodine, and photosensitizers. Examples of the toxic peptides preferably include the following:

diphtheria toxin A chain (Langone et al., Methods in Enzymology (1983) 93, 307-308);
Pseudomonas exotoxin (Nature Medicine (1996) 2, 350-353); ricin A chain (Fulton et al., J. Biol. Chem. (1986) 261, 5314-5319; Sivam et al., Cancer Res. (1987) 47, 3169-3173; Cumber et al., J. Immunol. Methods (1990) 135, 15-24;

Wawrzynczak et al., *Cancer Res.* (1990) 50, 7519-7562; and Gheeite et al., *J. Immunol. Methods* (1991) 142, 223-230);
 deglycosylated ricin A chain (Thorpe et al., *Cancer Res.* (1987) 47, 5924-5931);
 abrin A chain (Wawrzynczak et al., *Br. J. Cancer* (1992) 66, 361-366; Wawrzynczak et al., *Cancer Res.* (1990) 50,
 5 7519-7562; Sivam et al., *Cancer Res.* (1987) 47, 3169-3173; and Thorpe et al., *Cancer Res.* (1987) 47, 5924-5931);
 gelonin (Sivam et al., *Cancer Res.* (1987) 47, 3169-3173; Cumber et al., *J. Immunol. Methods* (1990) 135, 15-24;
 Wawrzynczak et al., *Cancer Res.*, (1990) 50, 7519-7562; and Bolognesi et al., *Clin. exp. Immunol.* (1992) 89,
 341-346);
 pokeweed anti-viral protein from seeds (PAP-s) (Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 10 bryodin (Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 saporin (Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 momordin (Cumber et al., *J. Immunol. Methods* (1990) 135, 15-24; Wawrzynczak et al., *Cancer Res.* (1990) 50,
 7519-7562; and Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 momorcochin (Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 15 dianthin 32 (Bolognesi et al., *Clin. exp. Immunol.* (1992) 89, 341-346);
 dianthin 30 (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 modeccin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 viscumin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 volkensin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 20 dodecandrin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 tritin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8);
 luffin (Stirpe F., Barbieri L., *FEBS letter* (1986) 195, 1-8); and
 trichokirin (Casellas et al., *Eur. J. Biochem.* (1988) 176, 581-588; and Bolognesi et al., *Clin. exp. Immunol.*, (1992)
 89, 341-346).

[0083] In the case of assaying the cytotoxic activity of the anti-GPC3 antibody-drug conjugate of the present invention, the target cells and the anti-GPC3 antibody-drug conjugate (each 50 μ l/well) are added to a flat-bottomed 96-well plate (Becton, Dickinson and Company) and reacted for 15 minutes on ice. The plate is incubated for 1 to 4 hours in a CO₂ incubator. The anti-GPC3 antibody-drug conjugate can be appropriately used at a final concentration ranging from 0 to 3 μ g/ml. After the culture, 100 μ l of the supernatant is recovered from each well, and the radioactivity of the supernatant is measured using a gamma counter. The cytotoxic activity can be calculated in the same way as in the ADCC activity assay.

Fc region

[0084] An Fc region contained in a constant region contained in the anti-GPC3 antibody of the present invention may be obtained from human IgG, though the Fc region of the present invention is not limited by a particular subclass of IgG. The Fc region refers to an antibody heavy chain constant region comprising a hinge region and CH2 and CH3 domains from the hinge region N terminus which is a papain cleavage site (about amino acid 216 based on the EU numbering). Preferred examples of the Fc region include Fc regions having binding activity against Fc γ receptors as mentioned later. In a non-limiting aspect, examples of such Fc regions include Fc regions contained in constant regions represented by SEQ ID NO: 74 for human IgG1, SEQ ID NO: 75 for IgG2, SEQ ID NO: 76 for IgG3, and SEQ ID NO: 77 for IgG4.

Fc γ receptor (Fc γ R)

[0085] The Fc γ receptor (also referred to as Fc γ R) refers to a receptor capable of binding to the Fc region of an IgG1, IgG2, IgG3, or IgG4 monoclonal antibody and substantially means even any member of protein family encoded by Fc γ receptor genes. In humans, this family includes, but not limited to: Fc γ RI (CD64) including isoforms Fc γ RIa, Fc γ RIb, and Fc γ RIc; Fc γ RII (CD32) including isoforms Fc γ RIIa (including allotypes H131 and R131; i.e., Fc γ RIIa (H) and Fc γ RIIa (R)), Fc γ RIIb (including Fc γ RIIb-1 and Fc γ RIIb-2), and Fc γ RIIc; Fc γ RIII (CD16) including isoforms Fc γ RIIIa (including allotypes V158 and F158; i.e., Fc γ RIIIa (V) and Fc γ RIIIa (F)) and Fc γ RIIIb (including allotypes Fc γ RIIIb-NA1 and Fc γ RIIIb-NA2); and even any unfound human Fc γ R or Fc γ R isoform or allotype. Fc γ R includes human, mouse, rat, rabbit, and monkey Fc γ receptors. The Fc γ R of the present invention is not limited to these receptors and may be derived from any organism. The mouse Fc γ R includes, but not limited to, Fc γ RI (CD64), Fc γ RII (CD32), Fc γ RIII (CD16), and Fc γ RIII-2 (Fc γ RIV, CD16-2), and even any unfound mouse Fc γ R or Fc γ R isoform or allotype. Preferred examples of such Fc γ receptors include human Fc γ RI (CD64), Fc γ RIIa (CD32), Fc γ RIIb (CD32), Fc γ RIIIa (CD16), and/or Fc γ RIIIb (CD16). The polypeptide sequence of human Fc γ RI is described in SEQ ID NO: 78 (NP_000557.1); the polypeptide sequence of human Fc γ RIIa (allotype H131) is described in SEQ ID NO: 79 (AAH20823.1) (allotype R131 has a sequence with

substitution by Arg at amino acid 166 in SEQ ID NO: 79); the polypeptide sequence of Fc γ RIIb is described in SEQ ID NO: 80 (AAI46679.1); the polypeptide sequence of Fc γ RIIIa is described in SEQ ID NO: 81 (AAH33678.1); and the polypeptide sequence of Fc γ RIIIb is described in SEQ ID NO: 82 (AAI28563.1) (registration numbers of a database such as RefSeq are shown within the parentheses). Whether or not the Fc γ receptor has binding activity against the Fc region of an IgG1, IgG2, IgG3, or IgG4 monoclonal antibody can be confirmed by a method known in the art such as FACS or ELISA formats as well as BIACORE method using amplified luminescent proximity homogeneous assay (ALPHA) screening or surface plasmon resonance (SPR) phenomena (Proc. Natl. Acad. Sci. U.S.A. (2006) 103 (11), 4005-4010).

[0086] In Fc γ RI (CD64) including isoforms Fc γ RIa, Fc γ RIb, and Fc γ RIc and Fc γ RIII (CD16) including isoforms Fc γ RIIIa (including allotypes V158 and F158) and Fc γ RIIIb (including allotypes Fc γ RIIIb-NA1 and Fc γ RIIIb-NA2), an α chain capable of binding to the IgG Fc region associates with a common γ chain having ITAM that transduces activating signals into cells. On the other hand, Fc γ RII (CD32) including isoforms Fc γ RIIa (including allotypes H131 and R131) and Fc γ RIIc contains ITAM in its cytoplasmic domain. These receptors are expressed in many immunocytes, such as macrophages, mast cells, and antigen-displaying cells. These receptors bind to IgG Fc regions and thereby transduce activating signals, which in turn promote the phagocytic capacity of macrophages, the production of inflammatory cytokines, the degranulation of mast cells, and the increased function of antigen-displaying cells. The Fc γ receptors that are able to transduce activating signals as described above are referred to as active Fc γ receptors herein.

[0087] On the other hand, Fc γ RIIb (including Fc γ RIIb-1 and Fc γ RIIb-2) contains ITIM that transduces inhibitory signals, in its intracytoplasmic domain. In B cells, activating signals from B cell receptors (BCRs) are inhibited by the cross-linking of BCR with Fc γ RIIb, resulting in the suppressed antibody production of BCR. The phagocytic capacity of macrophages or their ability to produce inflammatory cytokines is suppressed by the cross-linking of Fc γ RIII and Fc γ RIIb. The Fc γ receptors that are able to transduce inhibitory signals as described above are referred to as inhibitory Fc γ receptors herein.

Binding activity of Fc region against Fc γ R

[0088] As mentioned above, examples of the Fc region contained in the anti-GPC3 antibody of the present invention include Fc regions having binding activity against Fc γ receptors. In a non-limiting aspect, examples of such Fc regions include Fc regions contained in constant regions represented by SEQ ID NO: 74 for human IgG1, SEQ ID NO: 75 for IgG2, SEQ ID NO: 76 for IgG3, and SEQ ID NO: 77 for IgG4. Whether or not the Fc γ receptor has binding activity against the Fc region of an IgG1, IgG2, IgG3, or IgG4 monoclonal antibody can be confirmed by a method known in the art such as FACS or ELISA formats as well as BIACORE method using amplified luminescent proximity homogeneous assay (ALPHA) screening or surface plasmon resonance (SPR) phenomena (Proc. Natl. Acad. Sci. U.S.A. (2006) 103 (11), 4005-4010).

[0089] The ALPHA screening is carried out on the basis of the following principles according to ALPHA technology using two beads, a donor and an acceptor. Luminescence signals are detected only when these two beads are located in proximity through the biological interaction between a molecule bound with the donor bead and a molecule bound with the acceptor bead. A laser-excited photosensitizer in the donor bead converts ambient oxygen to singlet oxygen in an excited state. The singlet oxygen diffuses around the donor bead and reaches the acceptor bead located in proximity thereto to thereby cause chemiluminescent reaction in the bead, which finally emits light. In the absence of the interaction between the molecule bound with the donor bead and the molecule bound with the acceptor bead, singlet oxygen produced by the donor bead does not reach the acceptor bead. Thus, no chemiluminescent reaction occurs.

[0090] For example, a biotin-labeled anti-GPC3 antibody comprising the Fc region is bound to the donor bead, while a glutathione S transferase (GST)-tagged Fc γ receptor is bound to the acceptor bead. In the absence of a competing anti-GPC3 antibody comprising a modified Fc region, the anti-GPC3 antibody having the native Fc region interacts with the Fc γ receptor to generate signals of 520 to 620 nm. An anti-GPC3 antibody comprising an untagged modified Fc region competes with the anti-GPC3 antibody having the native Fc region for the interaction with the Fc γ receptor. Decrease in fluorescence caused as a result of the competition can be quantified to thereby determine relative binding affinity. The antibody biotinylation using sulfo-NHS-biotin or the like is known in the art. The Fc γ receptor can be tagged with GST by an appropriately adopted method which involves, for example: fusing a polynucleotide encoding the Fc γ receptor in frame with a polynucleotide encoding GST; operably ligating the resulting fusion gene with a vector; and allowing cells or the like carrying the vector to express the GST-tagged Fc γ receptor, which is then purified using a glutathione column. The obtained signals are preferably analyzed using, for example, software GRAPHPAD PRISM (GraphPad Software, Inc., San Diego) adapted to a one-site competition model based on nonlinear regression analysis.

[0091] One (ligand) of the substances between which the interaction is to be observed is immobilized on a thin gold film of a sensor chip. The sensor chip is irradiated with light from the back such that total reflection occurs at the interface between the thin gold film and glass. As a result, a site having a drop in reflection intensity (SPR signal) is formed in a portion of reflected light. The other (analyte) of the substances between which the interaction is to be observed is flowed on the surface of the sensor chip and bound to the ligand so that the mass of the immobilized ligand molecule is increased to change the refractive index of the solvent on the sensor chip surface. This change in the refractive index shifts the

position of the SPR signal (on the contrary, the dissociation of the bound molecules gets the signal back to the original position). The Biacore system plots on the ordinate the amount of the shift, i.e., change in mass on the sensor chip surface, and displays time-dependent change in mass as assay data (sensorgram). Kinetics: an association rate constant (k_a) and a dissociation rate constant (k_d) can be determined from the curve of the sensorgram, and affinity (KD) can be determined from the ratio between these constants. Inhibition assay is also preferably used in the BIACORE method. Examples of the inhibition assay are described in Lazor et al. (Proc. Natl. Acad. Sci. U.S.A. (2006) 103 (11), 4005-4010).

Fc γ receptor (Fc γ R)-binding modified Fc region

[0092] In addition to the Fc regions contained in constant regions represented by SEQ ID NO: 74 for human IgG1, SEQ ID NO: 75 for IgG2, SEQ ID NO: 76 for IgG3, and SEQ ID NO: 77 for IgG4, an Fc γ R-binding modified Fc region having higher binding activity against Fc γ receptors than that of the Fc region of native human IgG against Fc γ receptors may be appropriately used as the Fc region contained in the anti-GPC3 antibody of the present invention. The "Fc region of native human IgG" described herein means an Fc region having a fucose-containing sugar chain as a sugar chain bound to position 297 (EU numbering) of the Fc region contained in the human IgG1, IgG2, IgG3, or IgG4 constant region represented by SEQ ID NO: 74, 75, 76, or 77. Such an Fc γ R-binding modified Fc region can be prepared by the amino acid modification of the native human IgG Fc region. Whether or not the Fc γ R-binding modified Fc region has higher binding activity against Fc γ R than that of the native human IgG Fc region against Fc γ R can be appropriately confirmed by a method known in the art such as FACS or ELISA formats as well as BIACORE method using amplified luminescent proximity homogeneous assay (ALPHA) screening or surface plasmon resonance (SPR) phenomena as described above.

[0093] In the present invention, the "modification of amino acid(s)" or "amino acid modification" of the Fc region includes modification to an amino acid sequence different from the amino acid sequence of the starting Fc region. Any Fc region can be used as the starting Fc region as long as the modified form of the starting Fc region can bind to the human Fc γ receptor in a neutral region of pH. Alternatively, an Fc region further modified from an already modified Fc region as the starting Fc region may be preferably used as the Fc region of the present invention. The starting Fc region may mean the polypeptide itself, a composition containing the starting Fc region, or an amino acid sequence encoding the starting Fc region. The starting Fc region can include Fc regions known in the art produced by recombination reviewed in the paragraph about the antibody. The starting Fc region is not limited by its origin and can be obtained from an arbitrary nonhuman animal organism or a human. Preferred examples of the arbitrary organism include an organism selected from mice, rats, guinea pigs, hamsters, gerbils, cats, rabbits, dog, goats, sheep, cattle, horses, camels, and nonhuman primates. In another aspect, the starting Fc region may be obtained from a cynomolgus monkey, a marmoset, a rhesus monkey, a chimpanzee, or a human. Preferably, the starting Fc region can be obtained from human IgG1, though the starting Fc region of the present invention is not limited by a particular class of IgG. This means that the Fc region of human IgG1, IgG2, IgG3, or IgG4 can be appropriately used as the starting Fc region. Likewise, this means herein that the Fc region of arbitrary IgG class or subclass from the arbitrary organism can be preferably used as the starting Fc region. Examples of variants of naturally occurring IgG or manipulated forms thereof are described in literatures known in the art (Curr. Opin. Biotechnol. (2009) 20 (6), 685-91; Curr. Opin. Immunol. (2008) 20 (4), 460-470; Protein Eng. Des. Sel. (2010) 23 (4), 195-202; and International Publication Nos. WO2009/086320, WO2008/092117, WO2007/041635, and WO2006/105338), though the variants or the manipulated forms of the present invention are not limited to those described therein.

[0094] Examples of the modification include one or more variations, for example, a variation that substitutes amino acid(s) in the starting Fc region by amino acid residue(s) different therefrom, the insertion of one or more amino acid residues into the amino acid sequence of the starting Fc region, and/or the deletion of one or more amino acids from the amino acid sequence of the starting Fc region. Preferably, the amino acid sequence of the Fc region thus modified comprises an amino acid sequence containing at least a nonnatural portion of the Fc region. Such a variant inevitably has less than 100% sequence identity or similarity to the starting Fc region. In a preferred embodiment, the variant has an amino acid sequence with approximately 75% to less than 100% sequence identity or similarity, more preferably approximately 80% to less than 100%, further preferably approximately 85% to less than 100%, still further preferably approximately 90% to less than 100%, most preferably approximately 95% to less than 100% sequence identity or similarity to the amino acid sequence of the starting Fc region. In a non-limiting aspect of the present invention, the starting Fc region and the Fc γ R-binding modified Fc region of the present invention differ by at least one amino acid. The difference in amino acid between the starting Fc region and the Fc γ R-binding modified Fc region of the present invention may be preferably determined by a difference in amino acid with the identified position of its amino acid residue defined particularly by the EU numbering.

[0095] The amino acid(s) in the Fc region can be modified by an appropriately adopted method known in the art such as site-directed mutagenesis (Kunkel et al., Proc. Natl. Acad. Sci. USA (1985) 82, 488-492) or overlap extension PCR. Also, a plurality of methods known in the art can be adopted as methods for modifying an amino acid to substitute the

amino acid by an amino acid other than natural one (Annu. Rev. Biophys. Biomol. Struct. (2006) 35, 225-249; and Proc. Natl. Acad. Sci. U.S.A. (2003) 100 (11), 6353-6357). For example, a tRNA-containing cell-free translation system (Clover Direct (Protein Express, an R & D oriented company)) comprising a non-natural amino acid bound with an amber suppressor tRNA complementary to UAG codon (amber codon), which is a stop codon, is also preferably used.

5 **[0096]** The Fc γ R-binding modified Fc region (contained in the antigen-binding molecule of the present invention) having higher binding activity against Fc γ receptors than that of the native human IgG Fc region against Fc γ receptors can be obtained by any method. Specifically, the Fc γ R-binding modified Fc region can be obtained by the amino acid modification of a human IgG immunoglobulin Fc region used as the starting Fc region. Examples of the IgG immunoglobulin Fc region preferred for the modification include Fc regions contained in human IgG (IgG1, IgG2, IgG3, and IgG4, and modified forms thereof) constant regions represented by SEQ ID NOs: 74, 75, 76, and 77.

10 **[0097]** The modification to other amino acids can include amino acid modification at any position as long as the resulting Fc region has higher binding activity against Fc γ receptors than that of the native human IgG Fc region against Fc γ receptors. When the antigen-binding molecule contains a human IgG1 Fc region as a human Fc region, the modification preferably allows the Fc region to contain a fucose-containing sugar chain as a sugar chain bound to position 297 (EU numbering) and is effective for producing higher binding activity against Fc γ receptors than that of the native human IgG Fc region against Fc γ receptors. Such amino acid modification has been reported in, for example, International Publication Nos. WO2007/024249, WO2007/021841, WO2006/031370, WO2000/042072, WO2004/029207, WO2004/099249, WO2006/105338, WO2007/041635, WO2008/092117, WO2005/070963, WO2006/020114, WO2006/116260, and WO2006/023403.

20 **[0098]** Examples of amino acids that may undergo such modification include at least one or more amino acids selected from the group consisting of position 221, position 222, position 223, position 224, position 225, position 227, position 228, position 230, position 231, position 232, position 233, position 234, position 235, position 236, position 237, position 238, position 239, position 240, position 241, position 243, position 244, position 245, position 246, position 247, position 249, position 250, position 251, position 254, position 255, position 256, position 258, position 260, position 262, position 263, position 264, position 265, position 266, position 267, position 268, position 269, position 270, position 271, position 272, position 273, position 274, position 275, position 276, position 278, position 279, position 280, position 281, position 282, position 283, position 284, position 285, position 286, position 288, position 290, position 291, position 292, position 293, position 294, position 295, position 296, position 297, position 298, position 299, position 300, position 301, position 302, position 303, position 304, position 305, position 311, position 313, position 315, position 317, position 318, position 320, position 322, position 323, position 324, position 325, position 326, position 327, position 328, position 329, position 330, position 331, position 332, position 333, position 334, position 335, position 336, position 337, position 339, position 376, position 377, position 378, position 379, position 380, position 382, position 385, position 392, position 396, position 421, position 427, position 428, position 429, position 434, position 436 and position 440 based on the EU numbering. The modification of these amino acids can yield the Fc region (Fc γ R-binding modified Fc region) having higher binding activity against Fc γ receptors than that of the native human IgG Fc region against Fc γ receptors.

35 **[0099]** Examples of particularly preferred modification for use in the present invention include at least one or more amino acid modifications selected from the group consisting of modifications of amino acid 221 to Lys or Tyr,
amino acid 222 to Phe, Trp, Glu, or Tyr,
40 amino acid 223 to Phe, Trp, Glu, or Lys,
amino acid 224 to Phe, Trp, Glu, or Tyr,
amino acid 225 to Glu, Lys, or Trp,
amino acid 227 to Glu, Gly, Lys, or Tyr,
amino acid 228 to Glu, Gly, Lys, or Tyr,
45 amino acid 230 to Ala, Glu, Gly, or Tyr,
amino acid 231 to Glu, Gly, Lys, Pro, or Tyr,
amino acid 232 to Glu, Gly, Lys, or Tyr,
amino acid 233 to Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 234 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
50 amino acid 235 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 236 to Ala, Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 237 to Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 238 to Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 239 to Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, or Tyr,
55 amino acid 240 to Ala, Ile, Met, or Thr,
amino acid 241 to Asp, Glu, Leu, Arg, Trp, or Tyr,
amino acid 243 to Leu, Glu, Leu, Gln, Arg, Trp, or Tyr,
amino acid 244 to His,

EP 2 937 697 A1

- amino acid 245 to Ala,
amino acid 246 to Asp, Glu, His, or Tyr,
amino acid 247 to Ala, Phe, Gly, His, Ile, Leu, Met, Thr, Val, or Tyr,
amino acid 249 to Glu, His, Gln, or Tyr,
5 amino acid 250 to Glu, or Gln,
amino acid 251 to Phe,
amino acid 254 to Phe, Met, or Tyr,
amino acid 255 to Glu, Leu, or Tyr,
amino acid 256 to Ala, Met, or Pro,
10 amino acid 258 to Asp, Glu, His, Ser, or Tyr,
amino acid 260 to Asp, Glu, His, or Tyr,
amino acid 262 to Ala, Glu, Phe, Ile, or Thr,
amino acid 263 to Ala, Ile, Met, or Thr,
amino acid 264 to Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Trp, or Tyr,
15 amino acid 265 to Ala, Leu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 266 to Ala, Ile, Met, or Thr,
amino acid 267 to Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, or Tyr,
amino acid 268 to Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Pro, Gln, Arg, Thr, Val, or Trp,
amino acid 269 to Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
20 amino acid 270 to Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Gln, Arg, Ser, Thr, Trp, or Tyr,
amino acid 271 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 272 to Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 273 to Phe, or Ile,
amino acid 274 to Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
25 amino acid 275 to Leu, or Trp,
amino acid 276 to Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 278 to Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, or Trp,
amino acid 279 to Ala,
amino acid 280 to Ala, Gly, His, Lys, Leu, Pro, Gln, Trp, or Tyr,
30 amino acid 281 to Asp, Lys, Pro, or Tyr,
amino acid 282 to Glu, Gly, Lys, Pro, or Tyr,
amino acid 283 to Ala, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, or Tyr,
amino acid 284 to Asp, Glu, Leu, Asn, Thr, or Tyr,
amino acid 285 to Asp, Glu, Lys, Gln, Trp, or Tyr,
35 amino acid 286 to Glu, Gly, Pro, or Tyr,
amino acid 288 to Asn, Asp, Glu, or Tyr,
amino acid 290 to Asp, Gly, His, Leu, Asn, Ser, Thr, Trp, or Tyr,
amino acid 291 to Asp, Glu, Gly, His, Ile, Gln, or Thr, amino acid 292 to Ala, Asp, Glu, Pro, Thr, or Tyr,
amino acid 293 to Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
40 amino acid 294 to Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 295 to Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 296 to Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, or Val,
amino acid 297 to Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
amino acid 298 to Ala, Asp, Glu, Phe, His, Ile, Lys, Met, Asn, Gln, Arg, Thr, Val, Trp, or Tyr,
45 amino acid 299 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp, or Tyr,
amino acid 300 to Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, or Trp,
amino acid 301 to Asp, Glu, His, or Tyr,
amino acid 302 to Ile,
amino acid 303 to Asp, Gly, or Tyr,
50 amino acid 304 to Asp, His, Leu, Asn, or Thr,
amino acid 305 to Glu, Ile, Thr, or Tyr,
amino acid 311 to Ala, Asp, Asn, Thr, Val, or Tyr,
amino acid 313 to Phe,
amino acid 315 to Leu,
55 amino acid 317 to Glu or Gln,
amino acid 318 to His, Leu, Asn, Pro, Gln, Arg, Thr, Val, or Tyr,
amino acid 320 to Asp, Phe, Gly, His, Ile, Leu, Asn, Pro, Ser, Thr, Val, Trp, or Tyr,
amino acid 322 to Ala, Asp, Phe, Gly, His, Ile, Pro, Ser, Thr, Val, Trp, or Tyr,

EP 2 937 697 A1

amino acid 323 to Ile,
 amino acid 324 to Asp, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Thr, Val, Trp, or Tyr,
 amino acid 325 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
 amino acid 326 to Ala, Asp, Glu, Gly, Ile, Leu, Met, Asn, Pro, Gln, Ser, Thr, Val, Trp, or Tyr,
 5 amino acid 327 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Thr, Val, Trp, or Tyr,
 amino acid 328 to Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
 amino acid 329 to Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
 amino acid 330 to Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, or Tyr,
 amino acid 331 to Asp, Phe, His, Ile, Leu, Met, Gln, Arg, Thr, Val, Trp, or Tyr,
 10 amino acid 332 to Ala, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr,
 amino acid 333 to Ala, Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Ser, Thr, Val, or Tyr,
 amino acid 334 to Ala, Glu, Phe, Ile, Leu, Pro, or Thr,
 amino acid 335 to Asp, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Val, Trp, or Tyr,
 amino acid 336 to Glu, Lys, or Tyr,
 15 amino acid 337 to Glu, His, or Asn,
 amino acid 339 to Asp, Phe, Gly, Ile, Lys, Met, Asn, Gln, Arg, Ser, or Thr,
 amino acid 376 to Ala, or Val,
 amino acid 377 to Gly, or Lys,
 amino acid 378 to Asp,
 20 amino acid 379 to Asn,
 amino acid 380 to Ala, Asn, or Ser,
 amino acid 382 to Ala, or Ile,
 amino acid 385 to Glu,
 amino acid 392 to Thr,
 25 amino acid 396 to Leu,
 amino acid 421 to Lys,
 amino acid 427 to Asn,
 amino acid 428 to Phe, or Leu,
 amino acid 429 to Met,
 30 amino acid 434 to Trp,
 amino acid 436 to Ile, or
 amino acid 440 to Gly, His, Ile, Leu, or Tyr based on the EU numbering in the Fc region. The number of amino acids to be modified is not limited. Only one amino acid may be modified, or two or more amino acids may be modified. Examples of combinations of amino acid modifications at two or more positions include combinations as described in Table 3 (Tables 3-1 to 3-3). Also, WO2007/047291 discloses specific examples of the anti-GPC3 antibody comprising the Fc γ R-binding modified Fc region having higher binding activity against Fc γ receptors than that of the native human IgG Fc region against Fc γ receptors.

[Table 3-1]

	Combination of amino acids	Combination of amino acids
	K370E/P396L/D270E	S239Q/I332Q
	Q419H/P396L/D270E	S267D/I332E
45	V240A/P396L/D270E	S267E/I332E
	R255L/P396L/D270E	S267L/A327S
	R255L/P396L/D270E	S267Q/A327S
	R255L/P396L/D370E/R292G	S298A/I332E
50	R255L/P396L/D270E	S304T/I332E
	R255L/P396L/D270E/Y300L	S324G/I332D
	F243L/D270E/K392N/P396L	S324G/I332E
55	F243L/R255L/D270E/P396L	S324I/I332D
	F243L/R292P/Y300L/V305I/P396L	S324I/I332E
	F243L/R292P/Y300L/P396L	T260H/I332E

EP 2 937 697 A1

(continued)

5

10

15

20

25

30

Combination of amino acids	Combination of amino acids
F243L/R292P/Y300L	T335D/I332E
F243L/R292P/P396L	V240I/V266I
F243L/R292P/V305I	Y264I/I332E
F243L/R292P	D265F/N297E/I332E
S298A/E333A/R334A	D265Y/N297D/I332E
E380A/T307A	F243L/V262I/V264W
K326M/E333S	N297D/A330Y/I332E
K326A/E333A	N297D/T299E/I332E
S317A/K353A	N297D/T299F/I332E
A327D/I332E	N297D/T299H/I332E
A330L/I332E	N297D/T299I/I332E
A330Y/I332E	N297D/T299L/I332E
E258H/I332E	N297D/T299V/I232E
E272H/I332E	P230A/E233D/I332E
E272I/N276D	P244H/P245A/P247V
E272R/I332E	S239D/A330L/I332E
E283H/I332E	S239D/A330Y/I332E
E293R/I332E	S239D/H268E/A330Y
F241L/V262I	S239D/I332E/A327A
F241W/F243W	S239D/I332E/A330I

35

[Table 3-2]

40

45

50

55

F243L/V264I	S239D/297D/I332E
H268D/A330Y	S239D/S298A/I332E
H268E/A330Y	S239D/V264I/I332E
K246H/I332E	S239E/N297D/I332E
L234D/I332E	S239E/V264I/I332E
L234E/I332E	S239N/A330L/I332E
L234G/I332E	S239N/A330Y/I332E
L234I/I332E	S239N/S298A/I332E
L234I/L235D	S239Q/V264I/I332E
L234Y/I332E	V264E/N297D/I332E
L235D/I332E	V264I/A330L/I332E
L235F/I332E	V264I/A330Y/I332E
L235I/I332E	V264I/S298A/I332E
L235S/I332E	Y296D/N297D/I332E
L328A/I332D	Y296E/N297D/I332E

EP 2 937 697 A1

(continued)

5

10

15

20

25

30

L328D/I332D	Y296H/N297D/I332E
L328D/I332E	Y296N/N297D/I332E
L328E/I332D	Y296Q/N297D/I332E
L328E/I332E	Y296T/N297D/I332E
L328F/I332D	D265Y/N297D/T299L/I332E
L328F/I332E	F241E/F243Q/V262T/V264E
L328H/I332E	F241E/F243R/V262E/V264R
L328I/I332D	F241E/F243Y/V262T/V264R
L328I/I332E	F241L/F243L/V262I/V264I
L328M/I332D	F241R/F243Q/V262T/V264R
L328M/I332E	F241S/F243H/V262T/V264T
L328N/I332D	F241W/F243W/V262A/V264A
L328N/I332E	F241Y/F243Y/V262T/V264T
L328Q/I332D	I332E/A330Y/H268E/A327A
L328Q/I332E	N297D/I332E/S239D/A330L
L328T/I332D	N297D/S298A/A330Y/I332E
L328T/I332E	S299D/A330Y/I332E/K326E
L328V/I332D	S239D/A330Y/I332E/K326T
L328V/I332E	S239D/A330Y/I332E/L234I
L328Y/I332D	S239D/A330Y/I332E/L235D

[Table 3-3]

35

40

45

50

55

L328V/I332E	S239D/A330Y/I332E/V240I
N297D/I332E	S239D/A330Y/I332E/V264T
N291E/I332E	S239D/A330Y/I332E/V266I
N297S/I332E	S339D/D265F/N297D/I332E
P227G/I332E	S239D/D265H/N297D/I332E
P230A/E233D	S239D/D265I/N297D/I332E
Q295E/I3332E	S239D/D265L/N297D/I332E
R255Y/I332E	S230D/D265T/N297D/I332E
S239D/I333D	S239D/D265V/N297D/I332E
S239D/I333E	S239D/D265Y/N297D/L332E
S239D/I332N	S239D/I332E/A330Y/A327A
S239D/I332Q	S239D/I332E/H268E/A327A
S239E/D265G	S239D/I332E/H268E/A330Y
S239E/D265N	S239D/N297D/I332E/A330Y
S239E/D265Q	S239D/N297D/I335E/K326E
B239E/S332D	S239D/N297D/I332E/L235D

(continued)

S239E/I332E	S239D/V264I/A330L/I332E
S239E/I332N	S239D/V264I/S298A/I332E
S239E/I332Q	S239E/V264I/A330Y/I332E
S239N/I332D	F241E/H243Q/V262T/V264E/I332E
S239N/I332E	F241E/V243R/V262E/V264R/I332E
S239N/I332N	F241E/F243Y/V262T/V264R/I332E
S239N/I332Q	F241R/F243Q/V262T/V264R/I332E
S239Q/I332D	S239D/I332E/H268E/A330Y/A327A
S239Q/I332E	S239E/V264I/S298A/A330Y/I332E
S239Q/I332N	F241Y/F243Y/V262T/N297D/I332E
S267E/L328F	G236D/S267E
S239D/S267E	

[0100] The Fc γ receptor-binding domain contained in the anti-GPC3 antibody of the present invention can be assayed for its binding activity against the Fc γ receptor appropriately using pH conditions selected from acidic to neutral regions of pH. The acidic to neutral regions of pH as the conditions under which the Fc γ receptor-binding domain contained in the antigen-binding molecule of the present invention is assayed for its binding activity against the Fc γ receptor usually mean pH 5.8 to pH 8.0. The pH range is preferably indicated by arbitrary pH values from pH 6.0 to pH 7.4 and is preferably selected from pH 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, and 7.4. Particularly, a pH range of 6.15 to 7.4, which is close to the pH of cancer tissues, is preferred (Vaupel et al., Cancer Res. (1989) 49, 6449-6665). The binding affinity of the Fc region for the human Fc γ receptor can be evaluated under assay conditions involving an arbitrary temperature of 10°C to 50°C. Preferably, a temperature of 15°C to 40°C is used for determining the binding affinity of the Fc region for the human Fc γ receptor. More preferably, an arbitrary temperature of 20°C to 35°C, for example, any one temperature of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35°C, is also used for determining the binding affinity of the Fc region for the Fc γ receptor. The temperature 25°C is one non-limiting example in an aspect of the present invention.

[0101] The phrase "Fc γ R-binding modified Fc region having higher binding activity against Fc γ receptors than that of the native Fc region against Fc γ receptors" described herein means that the Fc γ R-binding modified Fc region has higher binding activity against any of the human Fc γ receptors Fc γ RI, Fc γ RIIa, Fc γ RIIb, Fc γ RIIIa, and /or Fc γ RIIIb than that of the native Fc region against the human Fc γ receptor. The phrase means that, for example, on the basis of the analysis method described above, the anti-GPC3 antibody comprising the Fc γ R-binding modified Fc region exhibits 105% or more, preferably 110% or more, 115% or more, 120% or more, or 125% or more, particularly preferably 130% or more, 135% or more, 140% or more, 145% or more, 150% or more, 155% or more, 160% or more, 165% or more, 170% or more, 175% or more, 180% or more, 185% or more, 190% or more, 195% or more, 2 times or more, 2.5 times or more, 3 times or more, 3.5 times or more, 4 times or more, 4.5 times or more, 5 times or more, 7.5 times or more, 10 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times or more, 60 times or more, 70 times or more, 80 times or more, 90 times or more, 100 times or more binding activity compared with the binding activity of an anti-GPC3 antibody comprising the native Fc region of human IgG serving as a control. The native Fc region used may be the starting Fc region or may be the native Fc region of an antibody of the same subclass as the anti-GPC antibody concerned.

[0102] In the present invention, a native human IgG Fc region having a fucose-containing sugar chain as a sugar chain bound to amino acid 297 (EU numbering) is preferably used as the native Fc region of human IgG serving as a control. Whether or not the sugar chain bound to amino acid 297 (EU numbering) is a fucose-containing sugar chain can be confirmed using an approach known in the art. Whether or not the sugar chain bound to the native human IgG Fc region is a fucose-containing sugar chain can be determined by, for example, a method as shown below. The native human IgG to be tested liberates a sugar chain through reaction with N-Glycosidase F (Roche Diagnostics K.K.) (Weitzhandler et al., J. Pharma. Sciences (1994) 83, 12, 1670-1675). Next, proteins are removed through reaction with ethanol, and the resulting reaction solution (Schenk et al., J. Clin. Investigation (2001) 108 (11) 1687-1695) is evaporated to dryness and then fluorescently labeled with 2-aminobenzamide (Bigge et al., Anal. Biochem. (1995) 230 (2) 229-238). After removal of the reagent by solid-phase extraction using a cellulose cartridge, the 2-AB-fluorescently labeled sugar chain is analyzed by normal-phase chromatography. The detected peak in the chromatogram can be observed to thereby

determine whether or not the sugar chain bound to the native Fc region of human IgG is a fucose-containing sugar chain.

[0103] An anti-GPC3 antibody having an IgG monoclonal antibody Fc region can be appropriately used as the anti-GPC3 antibody comprising the native Fc region of an antibody of the same subclass serving as a control. Structural examples of the Fc region include Fc regions contained in constant regions represented by SEQ ID NOs: 74 (having A added to the N terminus of the sequence of database registration No. AAC82527.1), 75 (having A added to the N terminus of the sequence of database registration No. AAB59393.1), 76 (database registration No. CAA27268.1), and 77 (having A added to the N terminus of the sequence of database registration No. AAB59394.1). In the case of using a certain isotype of anti-GPC3 antibody as a test substance, the anti-GPC3 antibody comprising the Fc region to be tested is studied for its effect of binding activity against Fc γ receptors by use of an anti-GPC3 antibody of the certain isotype as a control. The anti-GPC3 antibody comprising the Fc region thus confirmed to have higher binding activity against Fc γ receptors is appropriately selected.

[0104] Fc region having higher binding activity against active Fc γ receptor than its binding activity against inhibitory Fc γ receptor

[0105] As described above, preferred examples of the active Fc γ receptors include Fc γ RI (CD64) including Fc γ RIa, Fc γ RIb, and Fc γ RIc, Fc γ RIIa, and Fc γ RIII (CD16) including isoforms Fc γ RIIIa (including allotypes V158 and F158) and Fc γ RIIIb (including allotypes Fc γ RIIIb-NA1 and Fc γ RIIIb-NA2). Preferred examples of the inhibitory Fc γ receptors include Fc γ RIIb (including Fc γ RIIb-1 and Fc γ RIIb-2).

[0106] In a non-limiting aspect, alternative examples of the anti-GPC3 antibody of the present invention include an anti-GPC3 antibody comprising an Fc region having higher binding activity against active Fc γ receptors than its binding activity against inhibitory Fc γ receptors. In this case, the phrase "having higher binding activity against active Fc γ receptors than its binding activity against inhibitory Fc γ receptors" means that the Fc region has higher binding activity against any of the human Fc γ receptors Fc γ RIa, Fc γ RIIa, Fc γ RIIIa, and/or Fc γ RIIIb than its binding activity against Fc γ RIIb. The phrase means that, for example, on the basis of the analysis method described above, the antigen-binding molecule comprising the Fc region exhibits 105% or more, preferably 110% or more, 120% or more, 130% or more, or 140% or more, particularly preferably 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, 200% or more, 250% or more, 300% or more, 350% or more, 400% or more, 450% or more, 500% or more, 750% or more, 10 times or more, 20 times or more, 30 times or more, 40 times or more, 50 times, 60 times, 70 times, 80 times, 90 times, or 100 times or more binding activity against any of the human Fc γ receptors Fc γ RIa, Fc γ RIIa, Fc γ RIIIa, and/or Fc γ RIIIb compared with its binding activity against Fc γ RIIb. The IgG antibody comprising such an Fc region is known to have enhancement in the ADCC activity. Thus, the anti-GPC3 antibody comprising the Fc region is useful as the GPC3-targeting drug of the present invention.

[0107] In a non-limiting aspect of the present invention, examples of the Fc region having higher binding activity against active Fc γ receptors than its binding activity against inhibitory Fc γ receptors (having selective binding activity against active Fc γ receptors) preferably include Fc regions in which at least one or more amino acids selected from the group consisting of position 221, position 222, position 223, position 224, position 225, position 227, position 228, position 230, position 231, position 232, position 233, position 234, position 235, position 236, position 237, position 238, position 239, position 240, position 241, position 243, position 244, position 245, position 246, position 247, position 249, position 250, position 251, position 254, position 255, position 256, position 258, position 260, position 262, position 263, position 264, position 265, position 266, position 267, position 268, position 269, position 270, position 271, position 272, position 273, position 274, position 275, position 276, position 278, position 279, position 280, position 281, position 282, position 283, position 284, position 285, position 286, position 288, position 290, position 291, position 292, position 293, position 294, position 295, position 296, position 297, position 298, position 299, position 300, position 301, position 302, position 303, position 304, position 305, position 311, position 313, position 315, position 317, position 318, position 320, position 322, position 323, position 324, position 325, position 326, position 327, position 328, position 329, position 330, position 331, position 332, position 333, position 334, position 335, position 336, position 337, position 339, position 376, position 377, position 378, position 379, position 380, position 382, position 385, position 392, position 396, position 421, position 427, position 428, position 429, position 434, position 436 and position 440 (EU numbering)

are modified to amino acids different from those in the native Fc region.

[0108] In a non-limiting aspect of the present invention, further examples of the Fc region having higher binding activity against active Fc γ receptors than its binding activity against inhibitory Fc γ receptors (having selective binding activity against active Fc γ receptors) preferably include Fc regions in which a plurality of amino acids described in Tables 3-1 to 3-3 are modified to amino acids different from those in the native Fc region.

Fc region having modified sugar chain

[0109] The Fc region contained in the anti-GPC3 antibody provided by the present invention can also include an Fc region modified such that a higher proportion of fucose-deficient sugar chains is bound to the Fc region or a higher

proportion of bisecting N-acetylglucosamine is added to the Fc region in the composition of sugar chains bound to the Fc region. The removal of a fucose residue from N-acetylglucosamine at the reducing end of a N-glycoside-linked complex sugar chain bound to an antibody Fc region is known to enhance its affinity for Fc γ R1IIa (Sato et al., Expert Opin. Biol. Ther. (2006) 6 (11), 1161-1173). An IgG1 antibody comprising such an Fc region is known to have enhancement in the ADCC activity. Thus, the antigen-binding molecule comprising the Fc region is also useful as the antigen-binding molecule contained in the pharmaceutical composition of the present invention. Examples of an antibody that lacks a fucose residue in N-acetylglucosamine at the reducing end of a N-glycoside-linked complex sugar chain bound to the antibody Fc region include the following antibodies: glycosylated antibodies (e.g., International Publication No. WO1999/054342); and antibodies deficient in fucose added to the sugar chain (e.g., International Publication Nos. WO2000/061739, WO2002/031140, and WO2006/067913).

Also, WO2006/046751 and WO2009/041062 disclose specific examples of the anti-GPC3 antibody comprising the Fc region modified such that a higher proportion of fucose-deficient sugar chains is bound to the Fc region or a higher proportion of bisecting N-acetylglucosamine is added to the Fc region in the composition of sugar chains bound to the Fc region.

[0110] More specifically, in an alternative non-limiting aspect of the antibody that lacks a fucose residue in N-acetylglucosamine at the reducing end of a N-glycoside-linked complex sugar chain bound to the antibody Fc region, the antibody deficient in fucose added to the sugar chain (e.g., International Publication Nos. WO2000/061739, WO2002/031140, and WO2006/067913) may be prepared. For this purpose, host cells less able to add fucose to sugar chains are prepared as a result of altering the activity of forming the sugar chain structures of polypeptides that undergo sugar chain modification. The host cells are allowed to express the desired antibody gene, and the antibody deficient in fucose in its sugar chain can be recovered from the culture solution of the host cells. Non-limiting preferred examples of the activity of forming the sugar chain structures of polypeptides can include the activity of an enzyme or a transporter selected from the group consisting of fucosyltransferase (EC 2.4.1.152), fucose transporter (SLC35C1), GDP-mannose 4,6-dehydratase (GMD) (EC 4.2.1.47), GDP-keto-6-deoxymannose 3,5-epimerase/4-reductase (Fx) (EC 1.1.1.271), and GDP- β -L-fucose pyrophosphorylase (GFPP) (EC 2.7.7.30). These enzymes or transporters are not necessarily limited by their structures as long as the enzymes or the transporters can exert their activity. These proteins capable of exerting such activity are referred to as functional proteins herein. In a non-limiting aspect, examples of methods for altering the activity include the deletion of the activity. Host cells that lack the activity can be prepared by an appropriately adopted method known in the art such as a method which involves disrupting the genes of these functional proteins to render the genes unfunctional (e.g., International Publication Nos. WO2000/061739, WO2002/031140, and WO2006/067913). Such host cells that lack the activity may be prepared by, for example, a method which involves disrupting the endogenous genes of these functional proteins in cells such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, HEK293 cells, or hybridoma cells to render the genes unfunctional.

[0111] Antibodies containing sugar chains having bisecting GlcNAc (e.g., International Publication No. WO2002/079255) are known in the art. In a non-limiting aspect, host cells expressing genes encoding functional proteins having β -1,4-mannosyl-glycoprotein 4- β -N-acetylglucosaminyltransferase (GnTIII) (EC 2.4.1.144) activity or β -1,4-galactosyltransferase (GalT) (EC 2.4.1.38) activity are prepared in order to prepare such an antibody containing sugar chains having bisecting GlcNAc. In another non-limiting preferred aspect, host cells coexpressing a gene encoding a functional protein having human mannosidase II (ManII) (3.2.1.114) activity, a gene encoding a functional protein having β -1,2-acetylglucosaminyltransferase I (GnTI) (EC 2.4.1.94) activity, a gene encoding a functional protein having β -1,2-acetylglucosaminyltransferase II (GnTII) (EC 2.4.1.143) activity, a gene encoding a functional protein having mannosidase I (ManI) (EC 3.2.1.113) activity, and an α -1,6-fucosyltransferase (EC 2.4.1.68) gene, in addition to the functional proteins described above, are prepared (International Publication Nos. WO2004/065540).

[0112] The host cells less able to add fucose to sugar chains and the host cells having the activity of forming sugar chains having bisecting GlcNAc structures as described above can be transformed with antibody gene-containing expression vectors to respectively prepare the antibody that lacks a fucose residue in N-acetylglucosamine at the reducing end of a N-glycoside-linked complex sugar chain bound to the antibody Fc region and the antibody containing sugar chains having bisecting GlcNAc. The methods for producing these antibodies are also applicable to a method for producing the antigen-binding molecule comprising the Fc region modified such that a higher proportion of fucose-deficient sugar chains is bound to the Fc region or a higher proportion of bisecting N-acetylglucosamine is added to the Fc region in the composition of sugar chains bound to the Fc region of the present invention. The composition of sugar chains bound to the Fc region contained in the antigen-binding molecule of the present invention prepared by such a production method can be confirmed by the method described in the paragraph "Fc γ receptor (Fc γ R)-binding modified Fc region".

Anti-GPC3 antibody having altered isoelectric point

[0113] In a non-limiting aspect, further examples of the anti-GPC3 antibody that may be used in the present invention

include an anti-GPC3 antibody having an amino acid residue modified to alter its isoelectric point (pI). Preferred examples of the "alteration of the electric charge of an amino acid residue" in the anti-GPC3 antibody provided by the present invention are as follows: alteration to increase the pI value can be performed by, for example, at least one substitution selected from the substitution of Q by K at position 43, the substitution of D by N at position 52, and the substitution of Q by R at position 105 based on the Kabat numbering in the anti-GPC3 antibody heavy chain variable region represented by SEQ ID NO: 50, which is consequently modified to, for example, the amino acid sequence represented by SEQ ID NO: 67. Also, this alteration can be performed by, for example, at least one substitution selected from the substitution of E by Q at position 17, the substitution of Q by R at position 27, and the substitution of Q by R at position 105 based on the Kabat numbering in the anti-GPC3 antibody light chain variable region represented by SEQ ID NO: 51 or 66, which is consequently modified to, for example, the amino acid sequence represented by SEQ ID NO: 68. On the other hand, alteration to decrease the pI value can be performed by at least one substitution selected from the substitution of K by T at position 19, the substitution of Q by E at position 43, the substitution of G by E at position 61, the substitution of K by S at position 62, the substitution of K by Q at position 64, and the substitution of G by D at position 65 based on the Kabat numbering in the anti-GPC3 antibody heavy chain variable region represented by SEQ ID NO: 50, which is consequently modified to, for example, the amino acid sequence represented by SEQ ID NO: 69 or 71. Also, this alteration can be performed by, for example, at least one substitution selected from the substitution of R by Q at position 24, the substitution of Q by E at position 27, the substitution of K by T at position 74, the substitution of R by S at position 77, and the substitution of K by E at position 107 based on the Kabat numbering in the anti-GPC3 antibody light chain variable region represented by SEQ ID NO: 51 or 66, which is consequently modified to, for example, the amino acid sequence represented by SEQ ID NO: 70, 72, or 73. Further examples of the alteration to decrease the pI value include the substitution of at least one amino acid selected from amino acids 268, 274, 355, 356, 358, and 419 based on the EU numbering in the heavy chain constant region represented by SEQ ID NO: 74. Preferred examples of these substitutions can include at least one substitution selected from the substitution of H by Q at position 268, the substitution of K by Q at position 274, the substitution of R by Q at position 355, the substitution of D by E at position 356, the substitution of L by M at position 358, and the substitution of Q by E at position 419 based on the EU numbering in the heavy chain constant region represented by SEQ ID NO: 31. As a result of these substitutions, a chimera having human antibody IgG1 and IgG4 constant regions is constructed. Specifically, these substitutions can yield an antibody having the desired pI without influencing the immunogenicity of the modified antibody.

Modification to reduce heterogeneity

[0114] An IgG constant region deficient in Gly at position 446 and Lys at position 447 based on the EU numbering in the IgG constant region represented by SEQ ID NO: 74, 75, 76, or 77 may also be used as the constant region contained in the anti-GPC3 antibody of the present invention. Deficiency in both of these amino acids can reduce heterogeneity derived from the end of the heavy chain constant region of the antibody.

Antibody modification

[0115] The posttranslational modification of a polypeptide refers to chemical modification given to the polypeptide translated during polypeptide biosynthesis. Since the primary structure of an antibody is composed of a polypeptide, the anti-GPC3 antibody of the present invention also includes a modified form that has received the posttranslational modification of the polypeptide constituting the primary structure of the anti-GPC3 antibody. The posttranslational modification of a polypeptide can be broadly classified into the addition of a functional group, the addition of a polypeptide or a peptide (ISGylation, SUMOylation, or ubiquitination), the conversion of the chemical properties of an amino acid (silylation, deamination, or deamidation), and structural conversion (disulfidation or protease degradation). In a non-limiting aspect, examples of the posttranslational modification according to the present invention include the addition of a peptide or a functional group to an amino acid residue as a unit constituting the polypeptide. Examples of such modification can specifically include phosphorylation (serine, threonine, tyrosine, aspartic acid, etc.), glucosylation (serine, threonine, aspartic acid, etc.), acylation (lysine), acetylation (lysine), hydroxylation (lysine and proline), prenylation (cysteine), palmitoylation (cysteine), alkylation (lysine and arginine), polyglutamylation (glutamic acid), carboxylation (glutamic acid), polyglycylation (glutamic acid), citrullination (arginine), and succinimide formation (aspartic acid). For example, an anti-GPC3 antibody that has received the modification of N-terminal glutamine to pyroglutamic acid by pyroglutamylation is also included in the anti-GPC3 antibody of the present invention, as a matter of course. Also, for example, a posttranslationally modified anti-GPC3 antibody comprising heavy and light chains or heavy chains linked via a "disulfide bond", which means a covalent bond formed between two sulfur atoms is included in the anti-GPC3 antibody of the present invention. A thiol group contained in an amino acid cysteine can form a disulfide bond or crosslink with a second thiol group. In general IgG molecules, CH1 and CL regions are linked via a disulfide bond, and two polypeptides constituting heavy chains are linked via a disulfide bond between cysteine residues at positions 226 and 229 based on the EU

numbering. A posttranslationally modified anti-GPC3 antibody having such a linkage via a disulfide bond is also included in the anti-GPC3 antibody of the present invention.

GPC3-targeting drug therapy

[0116] The term "GPC3-targeting drug therapy" refers to the administration of a GPC3-targeting drug to a patient.

[0117] The phrase "efficacy of GPC3-targeting drug therapy for cancer" or "GPC3-targeting drug therapy has efficacy for cancer" means that the GPC3-targeting drug therapy produces desired or beneficial effects on a patient diagnosed with cancer. The desired or beneficial effects can include: (1) the inhibition of the further growth or diffusion of cancer cells; (2) the killing of cancer cells; (3) the inhibition of cancer recurrence; (4) the alleviation, reduction, mitigation, or inhibition of cancer-related symptoms (pain, etc.) or reduction in the frequency of the symptoms; and (5) improvement in the survival rate of the patient. The inhibition of cancer recurrence includes the inhibition of the growth of cancer already treated by radiation, chemotherapy, surgical operation, or other techniques, at the primary site of the cancer and its neighboring tissues, and the absence of the growth of cancer at a new distal site. The desired or beneficial effects may be subjectively perceived by the patient or may be objectively found. In the case of, for example, a human patient, the human is able to recognize improvement in energy or vitality or reduction in pain as improvement or a therapy-responsive sign perceived by the patient. Alternatively, a clinician is able to notice decrease in tumor size or the amount of tumor tissues on the basis of findings gained by physical examination, experimental parameters, tumor markers, or X-ray photography. Some experimental signs that can be observed by the clinician in response to treatment include normalized test results of, for example, leukocyte counts, erythrocyte counts, platelet counts, erythrocyte sedimentation rates, and levels of various enzymes. The clinician is further able to observe decrease in detectable tumor marker level. Alternatively, other tests, such as sonography, nuclear magnetic resonance test, and positron emission test, may be used for evaluating objective improvement.

[0118] Any cancer having high expression of targeted GPC3 corresponds to the cancer to be treated by the GPC3-targeting drug therapy of the present invention. One example of such cancer include cancer selected from breast cancer, uterine cervix cancer, colon cancer, uterine body cancer, head and neck cancer, liver cancer, lung cancer, malignant carcinoid, malignant glioma, malignant lymphoma, malignant melanoma, ovary cancer, pancreatic cancer, prostatic cancer, renal cancer, skin cancer, gastric cancer, testicle cancer, thyroid cancer, urothelial cancer, and the like.

Method for determining efficacy of GPC3-targeting drug therapy or method for determining continuation of GPC3-targeting drug therapy

[0119] In a non-limiting aspect, the present invention provides a method comprising monitoring a concentration of free GPC3 in a biological sample isolated from a patient before the start of GPC3-targeting drug therapy and/or a patient treated with GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the therapy is determined. The "patient before the start of GPC3-targeting drug therapy" refers to a patient diagnosed with cancer, having no history of administration of the GPC3-targeting drug. The patient may be a patient for which the efficacy of the GPC3-targeting drug therapy has been determined from the expression level of GPC3 in the tissues. Further, the "patient treated with GPC3-targeting drug therapy" refers to a patient having a history of administration of the GPC3-targeting drug. The administration route of the GPC3-targeting drug can be appropriately selected from administration routes suitable for the properties, etc., of the GPC3-targeting drug to be administered. Examples of the administration route include parenteral administration. Further examples of the parenteral administration include injection, transnasal administration, transpulmonary administration, and percutaneous administration. Further examples of the injection include systemic or local administration based on intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection.

[0120] Known results gained by conventional techniques before the completion of the present invention show that free GPC3 secreted into plasma by processing at a particular site in the polypeptide sequence of GPC3 by an enzyme such as convertase, phospholipase D, or Notum is detected in plasma isolated from liver cancer patients, whereas free GPC3 is not detected in plasma isolated from healthy individuals (Patent Literature 7, etc.). It has been expected from such results that the concentration of free GPC3 detected in serum or plasma is decreased over time with the continuation of the treatment, if the GPC3-targeting drug therapy has efficacy. As a result of conducting diligent studies under such circumstances, surprisingly, the present inventors have found that the concentration of free GPC3 is stabilized or increased, rather than decreased, in serum or plasma isolated from a patient with stable disease that may respond to the GPC3-targeting drug therapy. The present inventors have also found that when the concentration of free GPC3 detected in serum or plasma before administration of GPC3-targeting drug therapy is equal to or higher than the predetermined concentration, the efficacy of the GPC3-targeting drug therapy is determined.

[0121] In a non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in a biological sample isolated from the patient, wherein when the concentration is a predetermined value, the efficacy

of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined. The predetermined value may be determined from particular values such as 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, 1.0 ng/mL, 2.0 ng/mL, 3.0 ng/mL, 4.0 ng/mL, 5.0 ng/mL, 6.0 ng/mL, 7.0 ng/mL, 8.0 ng/mL, 9.0 ng/mL, 10.0 ng/mL, 15.0 ng/mL, 20.0 ng/mL, 25.0 ng/mL, 30.0 ng/mL, 35.0 ng/mL, 40.0 ng/mL, 45.0 ng/mL, 50.0 ng/mL, 55.0 ng/mL, 60.0 ng/mL, 65.0 ng/mL, 70.0 ng/mL, 75.0 ng/mL, 80.0 ng/mL, 85.0 ng/mL, 90.0 ng/mL, 100.0 ng/mL or may be determined as a numerical range containing particular values arbitrarily selected as the upper and lower limits from the above group of particular values. As an example, such a numerical range can be appropriately selected from numerical ranges of 0.1 ng/mL to 100 ng/mL. Examples of the numeric range include 0.1 to 100 ng/mL, 0.5 to 80 ng/mL, 1.0 to 60 ng/mL, 2.0 to 55 ng/mL, 3.0 to 50 ng/mL, 4.0 to 45 ng/mL, 5.0 to 40 ng/mL, 6.0 to 35 ng/mL, 7.0 to 30 ng/mL, 8.0 to 25 ng/mL, 9.0 to 20 ng/mL, and 10 to 20 ng/mL. The numerical range is, for example, preferably 0.1 to 0.35 ng/mL, more preferably 0.15 to 0.3 ng/mL, though the numerical range of the present invention is not limited to these ranges. The predetermined value of the concentration of free GPC3 can slightly vary depending on many factors, for example, the assay method used, the type of a sample for free GPC3 assay, storage conditions (e.g., temperature and duration) of the sample, and the ethnic identity of the patient. In the method for predicting, expecting, or determining the efficacy or determining the continuation of the therapy, a concentration in a blood, plasma, or serum sample isolated from the patient is measured as the concentration of free GPC3.

[0122] The concentration of free GPC3 can be measured in a sample isolated before and/or after the start of the GPC3-targeting drug therapy and may be measured in a plurality of samples collected at predetermined time intervals. When the concentration of free GPC3 in any one of the plurality of samples collected at predetermined time intervals is the predetermined concentration, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined. The predetermined time intervals are appropriately set. In a non-limiting aspect of the intervals, the samples can be collected at intervals of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days (i.e., 1 week), 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days (i.e., 2 weeks), 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days (i.e., 3 weeks), 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days (i.e., 4 weeks), 29 days, 30 days, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 2 months, 3 months, 4 months, 5 months, or 6 months after the initial administration of the GPC3-targeting drug, or at arbitrary points in time between the start and completion of the therapy, for example, after 1, 2, 3, 4 or more treatment cycles. The dosing intervals, i.e., the treatment cycles, can be appropriately set. One non-limiting example thereof includes 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days (i.e., 1 week), 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days (i.e., 2 weeks), 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days (i.e., 3 weeks), 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days (i.e., 4 weeks), 29 days, 30 days, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0123] In a non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the efficacy of the GPC3-targeting drug therapy is determined.

[0124] In a non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the continuation of the GPC3-targeting drug therapy is determined.

[0125] In another non-limiting aspect of the present invention, the concentration of free GPC3 can be compared with a concentration of free GPC3 ("baseline concentration") measured in a blood, plasma, or serum sample isolated before the start of the GPC3-targeting drug therapy from the patient. In this aspect, the "predetermined value" of the concentration of free GPC3 means that the concentration of free GPC3 in the biological sample isolated from the patient treated with the GPC3-targeting drug therapy is equal to or higher than the baseline concentration. Specifically, when the concentration of free GPC3 after the start of the GPC3-targeting drug therapy is equal to or larger than that before the start of the therapy in one patient, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined. The rate at which the concentration of free GPC3 after the start of the GPC3-targeting drug therapy is equal to or larger than that before the start of the therapy can be

appropriately selected by those skilled in the art and is not limited to a particular value. Such a rate can be appropriately selected from a numerical range of 1 time to 10^6 times. When the rate is, for example, 1 time or more, 1.05 times or more, 1.1 times or more, 1.2 times or more, 1.3 times or more, 1.4 times or more, 1.5 times or more, 1.6 times or more, 1.7 times or more, 1.8 times or more, 1.9 times or more, 2 times or more, 2.1 times or more, 2.2 times or more, 2.3 times or more, 2.4 times or more, 2.5 times or more, 2.6 times or more, 2.7 times or more, 2.8 times or more, 2.9 times or more, 3 times or more, 3.1 times or more, 3.2 times or more, 3.3 times or more, 3.4 times or more, 3.5 times or more, 3.6 times or more, 3.7 times or more, 3.8 times or more, 3.9 times or more, 4 times or more, 4.1 times or more, 4.2 times or more, 4.3 times or more, 4.4 times or more, 4.5 times or more, 4.6 times or more, 4.7 times or more, 4.8 times or more, 4.9 times or more, 5 times or more, 5.1 times or more, 5.2 times or more, 5.3 times or more, 5.4 times or more, 5.5 times or more, 5.6 times or more, 5.7 times or more, 5.8 times or more, 5.9 times or more, 6 times or more, 6.1 times or more, 6.2 times or more, 6.3 times or more, 6.4 times or more, 6.5 times or more, 6.6 times or more, 6.7 times or more, 6.8 times or more, 6.9 times or more, 7 times or more, 7.1 times or more, 7.2 times or more, 7.3 times or more, 7.4 times or more, 7.5 times or more, 7.6 times or more, 7.7 times or more, 7.8 times or more, 7.9 times or more, 8 times or more, 8.1 times or more, 8.2 times or more, 8.3 times or more, 8.4 times or more, 8.5 times or more, 8.6 times or more, 8.7 times or more, 8.8 times or more, 8.9 times or more, 9 times or more, 9.1 times or more, 9.2 times or more, 9.3 times or more, 9.4 times or more, 9.5 times or more, 9.6 times or more, 9.7 times or more, 9.8 times or more, 9.9 times or more, 10 times or more, 11 times or more, 12 times or more, 13 times or more, 14 times or more, 15 times or more, 16 times or more, 17 times or more, 18 times or more, 19 times or more, 20 times or more, 21 times or more, 22 times or more, 23 times or more, 24 times or more, 25 times or more, 26 times or more, 27 times or more, 28 times or more, 29 times or more, 30 times or more, 31 times or more, 32 times or more, 33 times or more, 34 times or more, 35 times or more, 36 times or more, 37 times or more, 38 times or more, 39 times or more, 40 times or more, 41 times or more, 42 times or more, 43 times or more, 44 times or more, 45 times or more, 46 times or more, 47 times or more, 48 times or more, 49 times or more, 50 times or more, 55 times or more, 60 times or more, 65 times or more, 70 times or more, 75 times or more, 80 times or more, 85 times or more, 90 times or more, 95 times or more, 100 times or more, 105 times or more, 110 times or more, 120 times or more, 130 times or more, 140 times or more, 150 times or more, 160 times or more, 170 times or more, 180 times or more, 190 times or more, 200 times or more, 220 times or more, 240 times or more, 260 times or more, 280 times or more, 300 times or more, 320 times or more, 340 times or more, 360 times or more, 380 times or more, 400 times or more, 420 times or more, 440 times or more, 460 times or more, 480 times or more, 500 times or more, 550 times or more, 600 times or more, 650 times or more, 700 times or more, 750 times or more, 800 times or more, 850 times or more, 900 times or more, 950 times or more, 1000 times or more, 2000 times or more, 3000 times or more, 4000 times or more, 5000 times or more, 6000 times or more, 7000 times or more, 8000 times or more, 9000 times or more, 10^4 times or more, 2×10^4 times or more, 4×10^4 times or more, 6×10^4 times or more, 8×10^4 times or more, 10^5 times or more, 2×10^5 times or more, 4×10^5 times or more, 6×10^5 times or more, 8×10^5 times or more, or 10^6 times or more, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined.

[0126] In a non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is equal to or larger than the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined.

[0127] As described above, when the concentration of free GPC3 is equal to or larger than the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined. In this procedure, the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient may be taken into consideration. Specifically, when the concentration of free GPC3 in the patient is equal to or larger than the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a particular evaluation score, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score, the efficacy of the GPC3-targeting drug therapy is determined.

[0128] In a non-limiting aspect, examples of the case where the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score can include high expression and low or moderate expression (IHC total score: 7

or higher and lower than 7, respectively) in a composite score calculated as a result of staining according to the staining method 1. In a non-limiting aspect, alternative examples of the case where the expression level of GPC3 is equal to or larger than a predetermined immunohistochemical staining score can include GPC3-IHC scores of 1+, 2+, and 3+ calculated as a result of staining according to the staining method 2.

5 **[0129]** In a non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is equal to or larger than the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3
10 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined.

[0130] As described above, when the concentration of free GPC3 is equal to or larger than the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined. In this procedure, the expression level of GPC3 in
15 a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient may be taken into consideration. Specifically, when the concentration of free GPC3 in the patient is equal to or larger than the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a particular evaluation score, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the method of the present invention comprises monitoring a
20 concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a
25 predetermined immunohistochemical staining score, the continuation of the GPC3-targeting drug therapy is determined.

[0131] In a non-limiting aspect, examples of the case where the expression level of GPC3 in a tissue, particularly, a
25 cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score can include high expression and low or moderate expression (IHC total score: 7 or higher and lower than 7, respectively) in a composite score calculated as a result of staining according to the staining method 1. In a non-limiting aspect, alternative examples of the case where the expression level of GPC3 is equal to or
30 larger than a predetermined immunohistochemical staining score can include GPC3-IHC scores of 1+, 2+, and 3+ calculated as a result of staining according to the staining method 2.

Drug and preparation

35 **[0132]** In the present invention, the drug usually refers to an agent for the treatment or prevention of a disease or for examination or diagnosis. In the present invention, the phrase "GPC3-targeting drug which is to be administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy" may be translated into a "method for treating cancer, comprising administering a GPC3-targeting drug to a cancer patient having a predetermined value of a concentration
40 of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy" or may be translated into "use of a GPC3-targeting drug which is to be administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy, for production of an agent for the treatment of cancer". In the present invention, the phrase "GPC3-targeting drug which is to be further administered to a cancer patient having a predetermined value
45 of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy" may be translated into a "method for treating cancer, comprising further administering a GPC3-targeting drug to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy" or may be translated into "use of a GPC3-targeting drug which is to be further administered to a cancer patient having a predetermined value of a concentration of free
50 GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy, for production of an agent for the treatment of cancer". The phrase "having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy" may be translated into the phrase "the concentration of free GPC3 in the biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy has been increased as a result of receiving the GPC3-targeting drug therapy".

55 **[0133]** The drug of the present invention can be formulated using a method generally known to those skilled in the art. For example, the drug of the present invention can be parenterally used in the form of an injection in a sterile solution or suspension with water or any other pharmaceutically acceptable solution. For example, the active ingredient can be appropriately combined with pharmacologically acceptable carriers or media, specifically, sterile water or saline, a plant

oil, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavor, an excipient, a vehicle, an antiseptic, a binder, and the like and mixed therewith in a unit dosage form required for generally accepted pharmaceutical practice to produce preparations. The amount of the active ingredient in these preparations is set to give an appropriate volume within a prescribed range.

5 **[0134]** Sterile compositions for injection can be formulated according to usual pharmaceutical practice using a vehicle such as injectable distilled water. Examples of injectable aqueous solutions include saline and isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannose, D-mannitol, and sodium chloride). An appropriate solubilizer, for example, an alcohol (ethanol, etc.), a polyalcohol (propylene glycol, polyethylene glycol, etc.), or a nonionic surfactant (Polysorbate 80(TM), HCO-50, etc.) may be used in combination therewith.

10 **[0135]** Examples of oil solutions include sesame oil and soybean oil. Benzyl benzoate and/or benzyl alcohol may be used as a solubilizer in combination therewith. These injectable solutions may be mixed with a buffer (e.g., a phosphate buffer solution and a sodium acetate buffer solution), a soothing agent (e.g., procaine hydrochloride), a stabilizer (e.g., benzyl alcohol and phenol), and an antioxidant. The prepared injections are usually charged into appropriate ampules.

15 **[0136]** The drug of the present invention is preferably administered by parenteral administration. For example, the drug is administered in a dosage form of an injection, a transnasal agent, a transpulmonary agent, or a percutaneous agent. The drug can be administered systemically or locally by, for example, intravenous injection, intramuscular injection, intraperitoneal injection, or subcutaneous injection.

20 **[0137]** The administration method can be appropriately selected according to the age and symptoms of the patient. The single dose of a pharmaceutical preparation containing the drug can be set within the range of, for example, 0.0001 mg to 1000 mg per kg body weight. Alternatively, the dose can be set to, for example, 0.001 to 100000 mg per patient, though the dose of the present invention is not necessarily limited to these numeric values. The dose and the administration method vary depending on the body weight, age, symptoms, etc. of the patient. Those skilled in the art can set an appropriate dose and administration method in consideration of these conditions. As a preferred example of the dose and the administration method of the present invention, the drug of the present invention can be administered to achieve
25 a blood trough level equal to or higher than a predetermined level in the patient. Preferred examples of the blood trough level can include 150 $\mu\text{g/mL}$ or higher, 160 $\mu\text{g/mL}$ or higher, 170 $\mu\text{g/mL}$ or higher, 180 $\mu\text{g/mL}$ or higher, 190 $\mu\text{g/mL}$ or higher, 200 $\mu\text{g/mL}$ or higher, 210 $\mu\text{g/mL}$ or higher, 220 $\mu\text{g/mL}$ or higher, 230 $\mu\text{g/mL}$ or higher, 240 $\mu\text{g/mL}$ or higher, 250 $\mu\text{g/mL}$ or higher, 260 $\mu\text{g/mL}$ or higher, 270 $\mu\text{g/mL}$ or higher, 280 $\mu\text{g/mL}$ or higher, 290 $\mu\text{g/mL}$ or higher, 300 $\mu\text{g/mL}$ or higher, and 400 $\mu\text{g/mL}$ or higher. More preferred examples thereof can include 200 $\mu\text{g/mL}$ or higher.

30 **[0138]** The preparation of the present invention comprises an instruction stating that the preparation is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy. In another non-limiting aspect, the preparation of the present invention comprises an instruction stating that the preparation is to be further administered to a cancer patient in which the concentration of free GPC3 in the biological sample isolated from the cancer patient
35 after the start of GPC3-targeting drug therapy has been increased as a result of receiving the GPC3-targeting drug therapy.

[0139] In a non-limiting aspect, the present invention provides the preparation comprising an instruction stating that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in a biological sample isolated from the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of
40 the therapy is determined.

[0140] In a non-limiting aspect, the present invention provides the preparation comprising an instruction stating that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in a biological sample isolated from the patient, wherein when the concentration is a predetermined value, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy
45 is determined. The predetermined value may be determined from particular values such as 0.1 ng/mL, 0.2 ng/mL, 0.3 ng/mL, 0.4 ng/mL, 0.5 ng/mL, 0.6 ng/mL, 0.7 ng/mL, 0.8 ng/mL, 0.9 ng/mL, 1.0 ng/mL, 2.0 ng/mL, 3.0 ng/mL, 4.0 ng/mL, 5.0 ng/mL, 6.0 ng/mL, 7.0 ng/mL, 8.0 ng/mL, 9.0 ng/mL, 10.0 ng/mL, 15.0 ng/mL, 20.0 ng/mL, 25.0 ng/mL, 30.0 ng/mL, 35.0 ng/mL, 40.0 ng/mL, 45.0 ng/mL, 50.0 ng/mL, 55.0 ng/mL, 60.0 ng/mL, 65.0 ng/mL, 70.0 ng/mL, 75.0 ng/mL, 80.0 ng/mL, 85.0 ng/mL, 90.0 ng/mL, 100.0 ng/mL or may be determined as a numerical range containing particular values arbitrarily selected as the upper and lower limits from the above group of particular values. As an example, such a numerical range can be appropriately selected from numerical ranges of 0.1 ng/mL to 100 ng/mL. Examples of the numeric range include 0.1 to 100 ng/mL, 0.5 to 80 ng/mL, 1.0 to 60 ng/mL, 2.0 to 55 ng/mL, 3.0 to 50 ng/mL, 4.0 to 45 ng/mL, 5.0 to 40 ng/mL, 6.0 to 35 ng/mL, 7.0 to 30 ng/mL, 8.0 to 25 ng/mL, 9.0 to 20 ng/mL, and 10 to 20 ng/mL. The numerical range is, for example, preferably 0.1 to 0.35 ng/mL, more preferably 0.15 to 0.3 ng/mL, though the numerical
50 range of the present invention is not limited to these ranges. The predetermined value of the concentration of free GPC3 can slightly vary depending on many factors, for example, the assay method used, the type of a sample for free GPC3 assay, storage conditions (e.g., temperature and duration) of the sample, and the ethnic identity of the patient. In the method for predicting, expecting, or determining the efficacy or determining the continuation of the therapy, a concen-

tration in a blood, plasma, or serum sample isolated from the patient is measured as the concentration of free GPC3.

[0141] The concentration of free GPC3 can be measured in a sample isolated before and/or after the start of the GPC3-targeting drug therapy and may be measured in a plurality of samples collected at predetermined time intervals. When the concentration of free GPC3 in any one of the plurality of samples collected at predetermined time intervals is the predetermined concentration, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined. The predetermined time intervals at which the sample is collected after the start of the GPC3-targeting drug therapy are appropriately set. In a non-limiting aspect of the intervals, the samples can be collected at intervals of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days (i.e., 1 week), 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days (i.e., 2 weeks), 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days (i.e., 3 weeks), 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days (i.e., 4 weeks), 29 days, 30 days, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 2 months, 3 months, 4 months, 5 months, or 6 months after the initial administration of the GPC3-targeting drug, or at arbitrary points in time between the start and completion of the therapy, for example, after 1, 2, 3, 4 or more treatment cycles. The dosing intervals, i.e., the treatment cycles, can be appropriately set. One non-limiting example thereof includes 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days (i.e., 1 week), 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days (i.e., 2 weeks), 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days (i.e., 3 weeks), 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days (i.e., 4 weeks), 29 days, 30 days, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0142] In a non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the efficacy of the GPC3-targeting drug therapy is determined.

[0143] In a non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL, the continuation of the GPC3-targeting drug therapy is determined.

[0144] In another non-limiting aspect of the present invention, the concentration of free GPC3 can be compared with a concentration of free GPC3 ("baseline concentration") measured in a blood, plasma, or serum sample isolated before the start of the GPC3-targeting drug therapy from the patient. In this aspect, the "predetermined value" of the concentration of free GPC3 means that the concentration of free GPC3 in the biological sample isolated from the patient treated with the GPC3-targeting drug therapy is equal to or higher than the baseline concentration. Specifically, when the concentration of free GPC3 after the start of the GPC3-targeting drug therapy is equal to or larger than that before the start of the therapy in one patient, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined. The rate at which the concentration of free GPC3 after the start of the GPC3-targeting drug therapy is equal to or larger than that before the start of the therapy can be appropriately selected by those skilled in the art and is not limited to a particular value. Such a rate can be appropriately selected from a numerical range of 1 time to 10^6 times. When the rate is, for example, 1 time or more, 1.05 times or more, 1.1 times or more, 1.2 times or more, 1.3 times or more, 1.4 times or more, 1.5 times or more, 1.6 times or more, 1.7 times or more, 1.8 times or more, 1.9 times or more, 2 times or more, 2.1 times or more, 2.2 times or more, 2.3 times or more, 2.4 times or more, 2.5 times or more, 2.6 times or more, 2.7 times or more, 2.8 times or more, 2.9 times or more, 3 times or more, 3.1 times or more, 3.2 times or more, 3.3 times or more, 3.4 times or more, 3.5 times or more, 3.6 times or more, 3.7 times or more, 3.8 times or more, 3.9 times or more, 4 times or more, 4.1 times or more, 4.2 times or more, 4.3 times or more, 4.4 times or more, 4.5 times or more, 4.6 times or more, 4.7 times or more, 4.8 times or more, 4.9 times or more, 5 times or more, 5.1 times or more, 5.2 times or more, 5.3 times or more, 5.4 times or more, 5.5 times or more, 5.6 times or more, 5.7 times or more, 5.8 times or more, 5.9 times or more, 6 times or more, 6.1 times or more, 6.2 times or more, 6.3 times or more, 6.4 times or more, 6.5 times or more, 6.6 times or more, 6.7 times or more, 6.8 times or more, 6.9 times or more, 7 times or more, 7.1 times or more, 7.2 times or more, 7.3 times or more, 7.4 times or more, 7.5 times or more, 7.6 times or more, 7.7 times or more, 7.8 times or more, 7.9 times or more, 8 times or more, 8.1 times or more, 8.2 times or more, 8.3 times or more, 8.4 times or more, 8.5 times or more, 8.6 times or more, 8.7 times or more, 8.8 times or more, 8.9 times or more, 9 times or more, 9.1 times or more, 9.2 times or more,

9.3 times or more, 9.4 times or more, 9.5 times or more, 9.6 times or more, 9.7 times or more, 9.8 times or more, 9.9 times or more, 10 times or more, 11 times or more, 12 times or more, 13 times or more, 14 times or more, 15 times or more, 16 times or more, 17 times or more, 18 times or more, 19 times or more, 20 times or more, 21 times or more, 22 times or more, 23 times or more, 24 times or more, 25 times or more, 26 times or more, 27 times or more, 28 times or more, 29 times or more, 30 times or more, 31 times or more, 32 times or more, 33 times or more, 34 times or more, 35 times or more, 36 times or more, 37 times or more, 38 times or more, 39 times or more, 40 times or more, 41 times or more, 42 times or more, 43 times or more, 44 times or more, 45 times or more, 46 times or more, 47 times or more, 48 times or more, 49 times or more, 50 times or more, 55 times or more, 60 times or more, 65 times or more, 70 times or more, 75 times or more, 80 times or more, 85 times or more, 90 times or more, 95 times or more, 100 times or more, 105 times or more, 110 times or more, 120 times or more, 130 times or more, 140 times or more, 150 times or more, 160 times or more, 170 times or more, 180 times or more, 190 times or more, 200 times or more, 220 times or more, 240 times or more, 260 times or more, 280 times or more, 300 times or more, 320 times or more, 340 times or more, 360 times or more, 380 times or more, 400 times or more, 420 times or more, 440 times or more, 460 times or more, 480 times or more, 500 times or more, 550 times or more, 600 times or more, 650 times or more, 700 times or more, 750 times or more, 800 times or more, 850 times or more, 900 times or more, 950 times or more, 1000 times or more, 2000 times or more, 3000 times or more, 4000 times or more, 5000 times or more, 6000 times or more, 7000 times or more, 8000 times or more, 9000 times or more, 10^4 times or more, 2×10^4 times or more, 4×10^4 times or more, 6×10^4 times or more, 8×10^4 times or more, 10^5 times or more, 2×10^5 times or more, 4×10^5 times or more, 6×10^5 times or more, 8×10^5 times or more, or 10^6 times or more, the efficacy of the GPC3-targeting drug therapy for cancer in the patient is predicted, expected, or determined or the continuation of the therapy is determined.

[0145] In a non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is equal to or larger than the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined.

[0146] As described above, the instruction states that when the concentration of free GPC3 is equal to or larger than the baseline concentration, the efficacy of the GPC3-targeting drug therapy is determined. In this case, the instruction may state that the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is also taken into consideration. Specifically, the instruction may state that when the concentration of free GPC3 in the patient is equal to or larger than the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a particular evaluation score, the efficacy of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction can state that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score, the efficacy of the GPC3-targeting drug therapy is determined.

[0147] In a non-limiting aspect, examples of the case where the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score can include high expression and low or moderate expression (IHC total score: 7 or higher and lower than 7, respectively) in a composite score calculated as a result of staining according to the staining method 1. In a non-limiting aspect, alternative examples of the case where the expression level of GPC3 is equal to or larger than a predetermined immunohistochemical staining score can include GPC3-IHC scores of 1+, 2+, and 3+ calculated as a result of staining according to the staining method 2.

[0148] In a non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 30 days or 1 month after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is equal to or larger than the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction states that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined.

[0149] As described above, the instruction states that when the concentration of free GPC3 is equal to or larger than the baseline concentration, the continuation of the GPC3-targeting drug therapy is determined. In this case, the instruction may state that the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is also taken into consideration. Specifically, the instruction may state that when the concentration of free GPC3 in the patient is equal to or larger than the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a particular evaluation score, the continuation of the GPC3-targeting drug therapy is determined. In another non-limiting aspect, the instruction can state that the patient is selected on the basis of a method comprising monitoring a concentration of free GPC3 in blood, plasma, or serum isolated 2 months, 3 months, 4 months, 5 months, or 6 months after the start of GPC3-targeting drug therapy from the patient treated with the therapy, wherein when the concentration of free GPC3 is 1 time or more to 10^6 times or more the baseline concentration and the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score, the continuation of the GPC3-targeting drug therapy is determined.

[0150] In a non-limiting aspect, examples of the case where the expression level of GPC3 in a tissue, particularly, a cancer tissue (including a liver cancer tissue), isolated from the patient is equal to or larger than a predetermined immunohistochemical staining score can include high expression and low or moderate expression (IHC total score: 7 or higher and lower than 7, respectively) in a composite score calculated as a result of staining according to the staining method 1. In a non-limiting aspect, alternative examples of the case where the expression level of GPC3 is equal to or larger than a predetermined immunohistochemical staining score can include GPC3-IHC scores of 1+, 2+, and 3+ calculated as a result of staining according to the staining method 2.

[0151] Hereinafter, the present invention will be described specifically with reference to Examples. However, the present invention is not limited by these Examples.

[Example 1]

[0152] GC33 is a recombinant humanized IgG1 monoclonal antibody capable of binding to human GPC3 with high affinity (WO2006/006693). In order to confirm the dose limiting toxicity (DLT) of GC33 in patients with advanced and/or recurrent hepatocellular cancer (HCC), a phase-I multicenter clinical trial was carried out (GC-001US test). In this test aimed at confirming safety and/or tolerability in the patients with advanced and/or recurrent HCC, the pharmacokinetic profiles of GC33, and its antitumor effects, and searching for biomarkers, GC33 (2.5 mg/kg to 20 mg/kg) was administered by injection through an intravenous drip to each HCC patient once a week.

[0153] The HCC patients subjected to the administration had histologically or cytologically confirmed advanced or metastatic HCC unsuitable for surgical operation and/or curative treatment. Eligible patients were at least 18 years old and exhibited Eastern Cooperative Oncology Group Performance Status of 0 or 1 and Child-Pugh class A or B. The patients also had at least one lesion that was evaluable according to the response evaluation criteria in solid tumors (RECIST). The provision of HCC tumor tissues (needle biopsy preparations) for use in GPC3 immunohistochemical staining (GPC3-IHC), appropriate hematopoietic functions (absolute neutrophil count $\geq 1500/\mu\text{l}$, platelet $\geq 50000/\mu\text{l}$), hepatic functions (total bilirubin ≤ 3 times the normal level, aspartate aminotransferase and alanine aminotransferase ≤ 5 times the normal level, PT-INR ≤ 2.0), and renal functions (serum creatinine \leq twice the normal level) were evaluated as other criteria. The registered subjects excluded pregnant, nursing, or pregnancy test-positive (women who underwent menstruation within 12 months from the registration date were subjected to the pregnancy test) patients, patients who did not plan to use appropriate fertility control, HIV antibody-positive patients, patients having active infection requiring treatment except for HBV or HCV, patients having other active malignant tumors with a disease-free interval shorter than 5 years, patients having a past history of transplantation, patients confirmed to have brain metastasis with symptoms, patients having central nervous system disorder or other mental disorders that interfered with consent or understanding of the protocol, patients who presented central nervous system symptoms attributed to hepatic encephalopathy, and patients who exhibited known hypersensitivity to other antibody drugs or pharmaceutical agents produced using CHO cells. Alternatively, patients who received treatment including major surgical operation, radiation therapy, and other chemotherapies within 4 weeks before the administration of the GPC3-targeting drug, patients who received treatment with sorafenib within 2 weeks before the administration, or patients who received needle biopsy within 1 week before the administration were excluded from the subjects registered in the GPC3-targeting drug therapy, but were subjected to the GPC3-targeting treatment after a predetermined wash-out period. The protocol was carried out according to the guideline of the Good Clinical Practice (GCP) and approved by each participating ethical committee on clinical trials. All patients signed their names on written informed consent before registration. The patients received the continuous administration of GC33 (each cycle involved four doses of GC33) unless the disease progressed or unacceptable toxicity appeared. Tumor was evaluated on the basis of a baseline and repetitively evaluated every two cycles until the disease progressed. The state of the disease was evaluated by principal investigators.

[0154] The expression of GPC3 proteins in HCC tumor tissues was evaluated by GPC3 immunohistochemical staining

EP 2 937 697 A1

(GPC3-IHC). The median measurement of GPC3-IHC was carried out by Charles River Laboratory (USA). Unstained slides of HCC tumor tissues prepared from tumor blocks formalin-fixed and paraffin-embedded after excision by needle biopsy in each hospital were subjected to immunohistochemical staining. The histochemical staining approach such as epitope retrieval for the measurement by Charles River Laboratory (USA) was performed according to a method described in WO2009/116659. The antibodies used were a mouse GC33 antibody and a mouse IgG2a antibody as a negative control antibody (WO2006/006693).

[0155] As for GPC3-IHC (staining method 1) carried out by Charles River Laboratory, the respective scores of positive cell rate (PR), staining intensity of cytoplasm (SI-cp) or staining intensity of cell membrane (SI-cm), and staining pattern of cell membrane (Sp-cm) were calculated according to the criteria shown in Table 4 and added on the basis of calculation expressions 1 and 2 to evaluate each stained preparation. The evaluation of each stained preparation was finalized at the Peer review meeting involving three pathologists.

[Table 4]

Criterion	Evaluation	Score
Positive cell rate (PR)	0	0
	1% or more and less than 20%	1
	20% or more and less than 50%	2
	50% or more	3
Staining intensity (SI) - Cytoplasm (SI-cp) - Cell membrane (SI-cm)	Slightly positive	0
	Weakly positive	1
	Moderately positive and/or weakly positive with strong positivity	2
	Moderately positive	3
	Strongly positive	4
Staining pattern of cell membrane (SP-cm)	Negative	0
	When only a portion of the cell membranes of cells was stained	1
	When a portion of the cell membranes of most of these cells was stained and the cell membranes of some of the cells were circumferentially stained	2
	When the cell membranes of most of these cells were circumferentially stained	3
(Sp-cm scores were calculated by the evaluation of cell staining in the visual field under microscope using an objective lens with a magnification of 4 or 10)		

[Expression 3]

$$\text{IHC total} = \text{PR} + \text{SI-Cp} + \text{SI-Cm} + \text{Sp-Cm}$$

[0156] One out of 20 cases that were registered in this test and received the administration failed to produce a preparation, and 3 of the cases did not contain tumor cells sufficient for evaluation. Finally, 16 cases were able to be evaluated. These cases were divided into two groups on the basis of an IHC total score around 7, which was half the maximum value (14) in staining based on epitope retrieval using autoclaving. The evaluation results of each case are shown in Table 5 and FIG. 1.

[Table 5]

Evaluation by GPC-IHC (IHC total score)	The number of patients (percentage to the total number 20)
High expression (7 or higher)	9 (45%)
Low or moderate expression (Lower than 7)	7 (35%)
Unevaluable	4 (20%)

[Example 2]

[0157] Antitumor effects were evaluated by the administration of GC33 in GPC3-targeting treatment. The durations of GC33 administration to 20 cases as described above are shown in FIG. 2. As a result of evaluating the state of the disease, 5-month or longer stable disease (SD) was confirmed in 4 cases.

[0158] The expression of GPC3 in tumor tissues was examined for its relation to the antitumor effects of GC33. As a result of showing the relation of the IHC total scores of 16 cases evaluable by GPC3-IHC to the duration of administration, all cases confirmed to have SD in a 5-month or longer period were included in a high-value group when the 16 cases were divided into two groups (with an IHC total score of 7 or higher and with an IHC total score lower than 7). In addition, the obtained results showed that the percentage of the long-period SD cases in the high-value group was also high (Table 6).

[Table 6]

IHC total score	High-value group		Low-value group	
6 or higher	36%	(4/11)	0%	(0/5)
7 or higher	44%	(4/9)	0%	(0/7)
8 or higher	50%	(3/6)	10%	(1/10)
9 or higher	50%	(2/4)	17%	(2/12)
10 or higher	50%	(1/2)	21%	(3/14)

[0159] Subsequently, progression-free survival duration or progression-free survival (PFS) was compared between the group with an IHC total score of 7 or higher and the group with an IHC total score lower than 7. The results showed that the group with an IHC total score of 7 or higher had significantly long PFS (FIG. 3).

[0160] Some of the tumor samples thus evaluated were used in the additional evaluation of GPC3-IHC. The median measurement of staining of preparations obtained from 14 cases was carried out by Ventana Medical Systems, Inc. (USA) according to an instruction attached to anti-glypican 3 Mouse GC33 Monoclonal Primary Antibody (Ventana Medical Systems, Inc.) using an automatic staining apparatus BenchMark (manufactured by Ventana Medical Systems, Inc.). In GPC3-IHC (staining method 2) carried out by Ventana Medical Systems, Inc., the preparations were stained according to the attached instruction and then scored on 4 scales of 0 to 3+ in terms of the degree, intensity, etc. of staining in tumor cells. As a result, distribution shown in Table 7 was obtained.

[Table 7]

GPC3-IHC score	The number of patients (percentage to 14 evaluable cases)
3+	3 (21.4%)
2+	1 (7.1%)
1+	7 (50%)
0+	3 (21.4%)

[0161] In the staining method 2, cases exhibiting long-period SD were included at a high percentage and with no omission in a 2+/3+ group when the cases were divided into two groups (with a score of 0 and 1+ and with a score of 2+ and 3+) (Table 8).

[Table 8]

GPC3-IHC score	High-value group		Low-value group	
1+/2+/3+	18%	(2/11)	0%	(0/3)
2+/3+	50%	(2/4)	0%	(0/10)
3+	33%	(1/3)	9%	(1/11)

[Example 3]

[0162] The concentration of free GPC3 was measured in the serum of patients who received the administration of GC33 in GPC3-targeting treatment. Mouse anti-GPC3 monoclonal antibodies M3C11 and L9G11 (WO2004/022739) were each diluted into 7.5 µg/mL with an immobilizing buffer (0.05 mol/L sodium bicarbonate, pH 9.6) and then dispensed to a plate at a concentration of 100 µL/well. Then, the plate was left standing at room temperature for 1 hour. Each well was washed three times with a washing buffer (0.05 mol/L tris-buffered saline, pH 8.0, 0.05% Tween-20). Then, a blocking buffer (25 mmol/L tris-HCl buffer, pH 8.1, 0.5 mmol/L magnesium chloride, 72 mmol/L sodium chloride, 0.05% ProClin 150, 5 mg/mL bovine serum albumin, 0.025% Tween-20, 1% Block Ace) was dispensed thereto at a concentration of 200 µL/well. The plate was left standing at room temperature for 2 hours to prepare an antibody-immobilized plate. If the plate was not immediately used, the plate was stored at 4°C and then used in the measurement.

[0163] The serum of each patient collected in the clinical trial was diluted 4-fold with a diluting buffer (25 mmol/L tris-HCl buffer, pH 8.1, 0.5 mmol/L magnesium chloride, 72 mmol/L sodium chloride, 0.05% ProClin 150, 5 mg/mL bovine serum albumin, 0.025% Tween-20, 0.4% Block Ace) and added to the plate at a concentration of 100 µL/well. The plate was left standing overnight at 4°C. The GPC3 standard used was recombinant GPC3 with serine residues at positions 495 and 509 substituted by alanine residues so as not to permit the binding of heparan sulfate sugar chains (Hippo et al., Cancer Res. (2004) 64, 2418-2423).

[0164] Subsequently, each well of the plate was washed three times with a washing buffer, and a biotin-labeled anti-glypican-3 polyclonal antibody (manufactured by R&D systems, Inc.) diluted into 0.3 µg/mL with a diluting buffer was added thereto at a concentration of 100 µL/well. The plate was further left standing at 25°C for 1 hour, and each well was washed three times with a washing buffer. Then, HRP-labeled streptavidin (Streptavidin-Poly HRP80; manufactured by Stereospecific Detection Technologies (SDT)) diluted with a diluting buffer according to the instruction was added thereto at a concentration of 100 µL/well. The plate was left standing at 25°C for 1 hour. Then, each well of the plate was washed three times with a washing buffer. Then, color was developed using TMB Microwell Peroxidase Substrate System (manufactured by Kirkegaard & Perry Laboratories Inc.) according to the instruction attached to the kit. The absorbance of the reaction solution in each well was measured at 450 nm and 650 nm. A calibration curve prepared on the basis of the standard sample containing the recombinant GPC3 was used to calculate the GPC3 antigen level in the serum of each patient from the obtained absorbance of each well.

[Example 4]

[0165] Change in the serum concentration of detected free GPC3 calculated in Example 3 is shown in FIG. 4 for two groups, i.e., the high-value group and the low-value group, of tumor tissue GPC3-IHC scores determined in Example 2. A large number of cases with a measurable level of free GPC3 was included in the group evaluated as having high expression of GPC3 on the basis of the GPC3-IHC score (FIG. 4A). A rise in the concentration of free GPC3 or stabilization thereof was observed in cases exhibiting long SD. By contrast, a small number of cases with a measurable level of free GPC3 was included in the group evaluated as having low expression of GPC3 or being negative on the basis of the GPC3-IHC score (FIG. 4B).

[0166] Progression-free survival duration or progression-free survival (PFS) was compared between a group having a measurable level of GPC3 in serum collected during screening or before initial administration (GPC3-positive group) and a group with a GPC3 level below the detection limit. The PFS of the serum GPC3-positive group before the practice of GPC3-targeting treatment was confirmed to be longer than that of the negative group (FIG. 5A). A logrank test was further conducted if the serum GPC3-positive group involved serum in which serum GPC3 was measured after the start of administration of the GPC3-targeting drug. The test results showed that the PFS of this group was significantly longer than that of the negative group (cases with a GPC3 level below the measurement limit, regardless of before or after administration of the GPC3-targeting drug) and the positive group (FIG. 5B).

[Example 5]

[0167] As shown in Tables 9 and 10, serum GPC3-positive high-value groups of GPC3-IHC scores evaluated using the staining method 1 and the staining method 2 were shown to have a higher percentage of long SD than that of the high-value group of GPC3-IHC scores (Tables 6 and 8 to 10).

[Table 9]

GPC3-IHC (staining method 1)	Serum GPC3-positive with high IHC value (7 or higher)		Others	
Serum GPC3 before administration GPC3	60%	(3/5)	9%	(1/11)

(continued)

GPC3-IHC (staining method 1)	Serum GPC3-positive with high IHC value (7 or higher)		Others	
Serum GPC3 after administration GPC3	80%	(4/5)	0%	(0/11)

[Table 10]

GPC3-IHC (staining method 2)	Serum GPC3-positive with IHC (2-3+)		Others	
Serum GPC3 before administration GPC3	100%	(2/2)	0%	(0/12)
Serum GPC3 after administration GPC3	67%	(2/3)	0%	(0/11)

[Example 6]

[0168] In the clinical trial, additional 7 cases (one of which was assessed as having an IHC total score of 6 as a result of final evaluation) were further registered as cases having an IHC total score of 7 or higher in GPC3-IHC on the basis of results of the staining method 1 and Child-Pugh score A. Their serum GPC3 levels were measured according to the method of Example 3. A total of 27 cases that received the administration of the GPC3-targeting drug were evaluated for their PFS in the same way as in Example 4. The relation of the serum GPC3 levels to PFS in these cases was studied using the logrank test. The test results showed that the PFS of a group having a measurable level of serum GPC3 before the administration (FIG. 6A) and the PFS of a group having a measurable level of serum GPC3 either before or after the administration (FIG. 6B) were both significantly longer than that of a group with a serum GPC3 level below the measurement limit.

[Example 7]

[0169] In order to confirm the efficacy and safety of GC33 in patients with advanced and/or recurrent hepatocellular cancer (HCC), a phase-II multicenter randomized double-blind placebo-controlled clinical trial which involved administering 1600 mg of GC33 every other week was carried out (NP27884 study), targeting adult patients with unresectable advanced or metastatic hepatocellular cancer having a past history of treatment. These patients were randomized to a GC33 group (the fixed dose of 1600 mg was administered every other week after administration of two doses at a 1-week interval; n = 121 cases) or a placebo group (n = 60 cases) at a ratio of 2:1 and stratified to 3 cohorts on the basis of GPC3 expression levels (0, 1+, and 2+/3+) by IHC staining using GPC3-IHC kit (manufactured by Ventana Medical Systems, Inc.). Primary analysis was carried out at the time of occurrence of progression-free survival (PFS) events in 128 cases planned in the protocol.

[0170] The HCC patients subjected to the administration had histologically confirmed advanced or metastatic HCC (except for fibrolamellar type) unsuitable for curative therapy (surgical resection, liver transplantation, etc.) and/or local therapy or exacerbated after treatment and had a past history of treatment based on systemic therapy with at least one agent. Eligible patients were at least 18 years old with the capability of providing a tumor sample for GPC3 assay and exhibited Eastern Cooperative Oncology Group Performance Status of 0 or 1 and Child-Pugh class A. The patients also had at least one lesion that was evaluable according to the response evaluation criteria in solid tumors (RECIST). Appropriate hematopoietic functions (absolute neutrophil count $\geq 1500/\mu\text{l}$, platelet $\geq 50000/\mu\text{l}$, hemoglobin ≥ 8.0 g/dl), hepatic functions (total bilirubin ≤ 2 mg/dl, aspartate aminotransferase and alanine aminotransferase ≤ 5 times the upper limit of the normal level), and renal functions (serum creatinine \leq twice the upper limit of the normal level) were evaluated as other criteria. Registrable female subjects were premenopausal female patients confirmed to be negative for a serum pregnancy test conducted within 10 days before the start of administration of the study drug, women without the possibility of pregnancy as a result of surgical contraception or after a lapse of 1 year or longer after menopause, and female patients other than the postmenopausal women (12-month or longer absence of menstruation) or the surgically contracepted women (resection of the ovary and/or the uterus), who consented to use two types of appropriate fertility control methods during clinical trial treatment and for at least 3 months or longer after the completion of administration of the study drug. Registrable male subjects were patients who consented to use fertility control based on the barrier method during clinical trial treatment and for at least 40 days after the completion of administration of the study drug. On the other hand, the registered subjects excluded patients who received major surgical operation within 2 weeks before the administration of the GPC3-targeting drug or did not get over severe disorder, patients confirmed to have brain or leptomeningeal metastasis, patients having a past history of malignant tumor within the last 5 years, patients having active infection requiring treatment except for hepatitis B or hepatitis C, patients having a past history of NCI-CTCAE

v4.0 Grade 3 or higher hemorrhage within 4 weeks before the start of administration of the study drug, patients having a past history of organ transplantation including liver transplantation, patients who were scheduled to receive or were receiving the administration of an anticancer agent other than the agent to be administered in this test, patients who received the administration of an anticancer agent within 2 weeks before trial registration, patients who did not completely get over adverse reactions associated with the preceding locoregional or systemic therapy of hepatocellular cancer, patients under interferon therapy, patients who had baseline QTc exceeding 470 ms or exhibited baseline resting bradycardia (less than 45 beats/min.), patients who received the administration of an anticoagulant or a thrombolytic agent for therapeutic purposes within 2 weeks before the start of administration of the study drug (except for the administration of the agent at a low dose for the purpose of removing clogs in a catheter or for preventive purposes), pregnant or nursing patients, HIV-positive patients or patients having an AIDS-related disease, patients having a past history of hypersensitivity for similar agents (monoclonal antibodies, protein-containing preparations, and Chinese hamster ovary-derived preparations), and patients having a serious comorbidity judged by a principal investigator or a sub-investigator as being possibly worsened due to the study drug.

[0171] The protocol was carried out according to the guideline of the Good Clinical Practice (GCP) and approved by each participating ethical committee on clinical trials. All patients signed their names on written informed consent before registration. The patients received the continuous administration of GC33 unless the disease progressed or unacceptable toxicity appeared. Tumor was evaluated on the basis of a baseline and evaluated after 4 cycles, 7 cycles, and 10 cycles from the start of administration and then repetitively every four cycles until the disease progressed. Each cycle involved two weeks. The state of the disease was evaluated by principal investigators.

[0172] The expression of GPC3 proteins in HCC tumor tissues was evaluated by GPC3 immunohistochemical staining (GPC3-IHC). The central measurement of GPC3-IHC was carried out by Ventana Medical Systems, Inc. (USA). Unstained slides of HCC tumor tissues prepared from tumor blocks formalin-fixed and paraffin-embedded after excision by needle biopsy in each hospital were subjected to immunohistochemical staining. The antibody used was a mouse GC33 antibody.

[Example 8]

[0173] In the cases who received GC33 or a placebo in GPC3-targeting treatment, the serum concentration of free GPC3 was measured before the initial administration using a combination of two types of different antibodies capable of binding to free GPC3 (a combination of a GT30 antibody and a GT607 antibody or a combination of GT114 and GT165). GT30, GT607, GT114, and GT165 were prepared according to a method described in WO2004/022739 and selected as antibodies capable of binding to free GPC3. The H and L chains of GT30 are shown in SEQ ID NOs: 83 and 84, respectively. The H and L chains of GT607 are shown in SEQ ID NOs: 85 and 86, respectively. The H and L chains of GT114 are shown in SEQ ID NOs: 87 and 88, respectively. The H and L chains of GT165 are shown in SEQ ID NOs: 89 and 90, respectively.

[0174] An antibody-bound particle solution containing GT30 or GT114 bound to magnetic particle beads (manufactured by JSR Corp.) was added at a concentration of 25 μ L/well to a 96-well microplate. Subsequently, a standard sample solution for a calibration curve (the GPC3 standard described in Example 3 was used) or an appropriately diluted serum sample was added thereto at a concentration of 25 μ L/well, and further, alkaline phosphatase-labeled GT607 or GT165 was added thereto at a concentration of 25 μ L/well. After shaking at 25°C for 20 minutes, each well was washed 5 times with a washing solution, with the magnetic beads collected using Dyna-Mag-96 Side Skirted (manufactured by VERITAS Corp.). A luminescent substrate solution preheated to 37°C was added thereto at a concentration of 50 μ L/well. The plate was shaken at room temperature for 1 minute and then left standing for 4 minutes to emit light. Chemiluminescence intensity was measured using a luminometer (manufactured by VERITAS Corp.).

[0175] A calibration curve (standard curve) prepared on the basis of the standard sample containing the recombinant GPC3 was used to calculate the GPC3 antigen level in the serum of each patient from the obtained chemiluminescence intensity of each well.

[Example 9]

[0176] Once the PFS events of 128 cases were obtained from among 125 GC33-administered cases and 60 placebo-administered cases as described above, the effects of administration of GC33 in GPC3-targeting treatment were evaluated on the basis of PFS. In addition, overall survival (OS) was evaluated as a secondary endpoint when reaching 78 events.

[0177] The GC33-administered group was further divided into two groups (a group exposed to GC33 at a lower level than a cutoff value: low-GC33-exposed group, and a group exposed to GC33 at a higher level than a cutoff value: high-GC33-exposed group) using, as the cutoff value, the median value 230 μ g/ml of projected blood trough levels of GC33 before administration of day 1 in the 3rd cycle (on the 4th week from the start of initial administration) based on population PK models obtained using the serum GC33 concentration values of this phase-II clinical trial. The progression-free

survival duration or progression-free survival (PFS) or the overall survival duration or overall survival (OS) was compared as an index for clinical effects between these groups or between these groups and the placebo group by the Kaplan-Meier method.

5 [Example 10]

[0178] The serum concentrations of detected free GPC3 calculated in Example 8 were divided into two groups, i.e., a low-value group and a high-value group, on the basis of the median value of the concentrations measured in a system having GT30 and GT607 in combination. The PFS or OS curves of low-GC33-exposed, high-GC33-exposed, and placebo groups, as shown in Example 9, are shown in FIGs. 7A to 7D. Likewise, the serum concentrations of free GPC3 were divided into two groups on the basis of the median value of the concentrations measured in a system having GT114 and GT165 in combination. The PFS or OS curves of these groups are shown in FIGs. 8A to 8D.

[0179] In all cases, the group with a low concentration of free GPC3 exhibited the low effect of prolonging the PFS and OS durations, whereas the high-GC33-exposed group with a high concentration of free GPC3 in serum exhibited significantly low hazard ratios of the PFS and OS durations to the low-GC33-exposed group or the placebo group.

[0180] As a result of evaluating the cutoff value of free GPC3 that achieved the smallest significant difference, the cutoff value was 175 pg/mL for the GT30-GT607 system and 259.7 pg/mL for the GT114-GT165 system. The PFS and OS curves of a patient group that exhibited a free GPC3 level higher than the cutoff value in each system are shown in FIGs. 7E and 7F and FIGs. 8E and 8F, respectively. In this case as well, a significantly low hazard ratio, i.e., the prolongation of each survival duration, was exhibited in the high-GC33-exposed group.

[0181] All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

[Industrial Applicability]

[0182] The present invention contributes to improvement in the efficacy of GPC3-targeting drug therapy and improvement in QOL of a patient to be treated, and is useful in the treatment of cancer including liver cancer.

[Free Text for Sequence Listing]

[0183]

- SEQ ID NO: 44: Modified antibody fragment
- SEQ ID NO: 45: Modified antibody fragment
- SEQ ID NO: 46: Modified antibody fragment
- SEQ ID NO: 47: Modified antibody fragment
- SEQ ID NO: 48: Modified antibody fragment
- SEQ ID NO: 49: Modified antibody fragment
- SEQ ID NO: 50: Modified antibody fragment
- SEQ ID NO: 51: Modified antibody fragment
- SEQ ID NO: 52: Modified antibody fragment
- SEQ ID NO: 53: Modified antibody fragment
- SEQ ID NO: 54: Modified antibody fragment
- SEQ ID NO: 55: Modified antibody fragment
- SEQ ID NO: 56: Modified antibody fragment
- SEQ ID NO: 57: Modified antibody fragment
- SEQ ID NO: 58: Modified antibody fragment
- SEQ ID NO: 59: Modified antibody fragment
- SEQ ID NO: 60: Modified antibody fragment
- SEQ ID NO: 61: Modified antibody fragment
- SEQ ID NO: 62: Modified antibody fragment
- SEQ ID NO: 63: Modified antibody fragment
- SEQ ID NO: 64: Modified antibody fragment
- SEQ ID NO: 65: Modified antibody fragment
- SEQ ID NO: 66: Modified antibody fragment
- SEQ ID NO: 67: Modified antibody fragment
- SEQ ID NO: 68: Modified antibody fragment
- SEQ ID NO: 69: Modified antibody fragment

EP 2 937 697 A1

SEQ ID NO: 70: Modified antibody fragment
SEQ ID NO: 71: Modified antibody fragment
SEQ ID NO: 72: Modified antibody fragment
SEQ ID NO: 73: Modified antibody fragment

5

[Sequence Listing]

[0184]

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

<110> CHUGAI SEIYAKU KABUSHIKI KAISHA
 <120> GPC3-targetted therapeutic agent to be administered to patients who
 is responsible to GPC3-targetted therapy

<130> PCG-9038WO

<150> JP2012-280304

<151> 2012-12-21

<160> 90

<170> PatentIn version 3.1

<210> 1

<211> 580

<212> PRT

<213> homo sapiens

<400> 1

```

Met Ala Gly Thr Val Arg Thr Ala Cys Leu Val Val Ala Met Leu Leu
1          5          10          15
Ser Leu Asp Phe Pro Gly Gln Ala Gln Pro Pro Pro Pro Pro Pro Asp
20
Ala Thr Cys His Gln Val Arg Ser Phe Phe Gln Arg Leu Gln Pro Gly
35          40          45
Leu Lys Trp Val Pro Glu Thr Pro Val Pro Gly Ser Asp Leu Gln Val
50          55          60
Cys Leu Pro Lys Gly Pro Thr Cys Cys Ser Arg Lys Met Glu Glu Lys
65          70          75          80
Tyr Gln Leu Thr Ala Arg Leu Asn Met Glu Gln Leu Leu Gln Ser Ala
85          90          95
Ser Met Glu Leu Lys Phe Leu Ile Ile Gln Asn Ala Ala Val Phe Gln
100          105          110
Glu Ala Phe Glu Ile Val Val Arg His Ala Lys Asn Tyr Thr Asn Ala
115          120          125
Met Phe Lys Asn Asn Tyr Pro Ser Leu Thr Pro Gln Ala Phe Glu Phe
130          135          140
Val Gly Glu Phe Phe Thr Asp Val Ser Leu Tyr Ile Leu Gly Ser Asp
145          150          155          160
Ile Asn Val Asp Asp Met Val Asn Glu Leu Phe Asp Ser Leu Phe Pro
165          170          175
Val Ile Tyr Thr Gln Leu Met Asn Pro Gly Leu Pro Asp Ser Ala Leu
180          185          190
Asp Ile Asn Glu Cys Leu Arg Gly Ala Arg Arg Asp Leu Lys Val Phe
195          200          205
Gly Asn Phe Pro Lys Leu Ile Met Thr Gln Val Ser Lys Ser Leu Gln
210          215          220
Val Thr Arg Ile Phe Leu Gln Ala Leu Asn Leu Gly Ile Glu Val Ile
225          230          235          240
Asn Thr Thr Asp His Leu Lys Phe Ser Lys Asp Cys Gly Arg Met Leu
245          250          255
Thr Arg Met Trp Tyr Cys Ser Tyr Cys Gln Gly Leu Met Met Val Lys
260          265          270
Pro Cys Gly Gly Tyr Cys Asn Val Val Met Gln Gly Cys Met Ala Gly
275          280          285
Val Val Glu Ile Asp Lys Tyr Trp Arg Glu Tyr Ile Leu Ser Leu Glu
290          295          300
Glu Leu Val Asn Gly Met Tyr Arg Ile Tyr Asp Met Glu Asn Val Leu
305          310          315          320
Leu Gly Leu Phe Ser Thr Ile His Asp Ser Ile Gln Tyr Val Gln Lys
325          330          335
Asn Ala Gly Lys Leu Thr Thr Thr Ile Gly Lys Leu Cys Ala His Ser
340          345          350
Gln Gln Arg Gln Tyr Arg Ser Ala Tyr Tyr Pro Glu Asp Leu Phe Ile
355          360          365
Asp Lys Lys Val Leu Lys Val Ala His Val Glu His Glu Glu Thr Leu
370          375          380
Ser Ser Arg Arg Arg Glu Leu Ile Gln Lys Leu Lys Ser Phe Ile Ser

```


EP 2 937 697 A1

<211> 16
 <212> PRT
 <213> Mus musculus
 <400> 7
 5 Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Phe Leu Asn
 1 5 10 15
 <210> 8
 <211> 7
 <212> PRT
 <213> Mus musculus
 10 <400> 8
 Leu Val Ser Arg Leu Asp Ser
 1 5
 <210> 9
 <211> 9
 <212> PRT
 15 <213> Mus musculus
 <400> 9
 Cys Gln Gly Thr His Phe Pro Arg Thr
 1 5
 <210> 10
 <211> 111
 <212> PRT
 <213> Mus musculus
 <400> 10
 20 Gln Ile Gln Leu Glu Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
 1 5 10 15
 25 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Arg Asp Tyr
 20 25 30
 Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
 35 35 40 45
 Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
 30 50 55 60
 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
 85 90 95
 35 Thr Ser Leu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 100 105 110
 <210> 11
 <211> 112
 <212> PRT
 <213> Mus musculus
 <400> 11
 40 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 45 Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Arg Leu Asp Ser Gly Val Pro
 50 50 60
 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 50 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Cys Gln Gly
 85 90 95
 Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys
 100 105 110
 <210> 12
 <211> 7
 <212> PRT
 <213> Mus musculus
 <400> 12
 55

EP 2 937 697 A1

Thr Tyr Gly Met Gly Val Gly
 1 5
 <210> 13
 <211> 16
 5 <212> PRT
 <213> Mus musculus
 <400> 13
 Asn Ile Trp Trp His Asp Asp Lys Tyr Tyr Asn Ser Ala Leu Lys Ser
 1 5 10 15
 <210> 14
 <211> 14
 10 <212> PRT
 <213> Mus musculus
 <400> 14
 Ile Ala Pro Arg Tyr Asn Lys Tyr Glu Gly Phe Phe Ala Phe
 1 5 10
 15 <210> 15
 <211> 16
 <212> PRT
 <213> Mus musculus
 <400> 15
 20 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu
 1 5 10 15
 <210> 16
 <211> 7
 <212> PRT
 <213> Mus musculus
 25 <400> 16
 Lys Val Ser Asn Arg Phe Ser
 1 5
 <210> 17
 <211> 9
 30 <212> PRT
 <213> Mus musculus
 <400> 17
 Phe Gln Gly Ser His Val Pro Trp Thr
 1 5
 35 <210> 18
 <211> 124
 <212> PRT
 <213> Mus musculus
 <400> 18
 Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
 1 5 10 15
 40 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Tyr
 20 25 30
 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
 35 40 45
 Trp Leu Ala Asn Ile Trp Trp His Asp Asp Lys Tyr Tyr Asn Ser Ala
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Ile Ser Asn Asn Gln Val
 65 70 75 80
 Phe Leu Lys Ile Ser Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 50 Cys Ala Gln Ile Ala Pro Arg Tyr Asn Lys Tyr Glu Gly Phe Phe Ala
 100 105 110
 Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 115 120
 <210> 19
 <211> 112
 55 <212> PRT
 <213> Mus musculus
 <400> 19

EP 2 937 697 A1

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
 1 5 10 15
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
 20 25 30
 5 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 10 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95
 Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110
 <210> 20
 <211> 5
 <212> PRT
 <213> Mus musculus
 <400> 20
 Asp Tyr Glu Met His
 1 5
 20 <210> 21
 <211> 17
 <212> PRT
 <213> Mus musculus
 <400> 21
 Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe Lys
 25 1 5 10 15
 Gly
 <210> 22
 <211> 6
 <212> PRT
 <213> Mus musculus
 <400> 22
 Phe Tyr Ser Tyr Thr Tyr
 1 5
 30 <210> 23
 <211> 16
 <212> PRT
 <213> Mus musculus
 <400> 23
 Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His
 40 1 5 10 15
 <210> 24
 <211> 7
 <212> PRT
 <213> Mus musculus
 <400> 24
 45 Lys Val Ser Asn Arg Phe Ser
 1 5
 <210> 25
 <211> 9
 <212> PRT
 <213> Mus musculus
 <400> 25
 50 Ser Gln Asn Thr His Val Pro Pro Thr
 1 5
 <210> 26
 <211> 115
 <212> PRT
 <213> Mus musculus
 <400> 26
 55

EP 2 937 697 A1

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 30
 5 Glu Met His Trp Val Lys Gln Thr Pro Val His Gly Leu Lys Trp Ile
 35 40 45
 Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 10 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ala
 15 115
 <210> 27
 <211> 112
 <212> PRT
 <213> Mus musculus
 <400> 27
 20 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
 1 5 10 15
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 25 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn
 85 90 95
 30 Thr His Val Pro Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110
 <210> 28
 <211> 5
 <212> PRT
 35 <213> Mus musculus
 <400> 28
 Ile Asn Ala Met Asn
 1 5
 <210> 29
 <211> 19
 40 <212> PRT
 <213> Mus musculus
 <400> 29
 Arg Ile Arg Ser Glu Ser Asn Asn Tyr Ala Thr Tyr Tyr Gly Asp Ser
 1 5 10 15
 45 Val Lys Asp
 <210> 30
 <211> 8
 <212> PRT
 <213> Mus musculus
 50 <400> 30
 Glu Val Thr Thr Ser Phe Ala Tyr
 1 5
 <210> 31
 <211> 16
 55 <212> PRT
 <213> Mus musculus
 <400> 31

EP 2 937 697 A1

Lys Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Asn
 1 5 10 15
 <210> 32
 <211> 7
 <212> PRT
 <213> Mus musculus
 <400> 32
 Trp Met Ser Asn Leu Ala Ser
 1 5
 <210> 33
 <211> 9
 <212> PRT
 <213> Mus musculus
 <400> 33
 Met Gln His Ile Glu Tyr Pro Phe Thr
 1 5
 <210> 34
 <211> 119
 <212> PRT
 <213> Mus musculus
 <400> 34
 Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Glu Gly
 1 5 10 15
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ile Asn
 20 25
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Arg Ile Arg Ser Glu Ser Asn Asn Tyr Ala Thr Tyr Tyr Gly Asp
 50 55 60
 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Asn Met
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Ile Tyr
 85 90 95
 Tyr Cys Val Arg Glu Val Thr Thr Ser Phe Ala Tyr Trp Gly Gln Gly
 100 105 110
 Thr Leu Val Thr Val Ser Ala
 115
 <210> 35
 <211> 112
 <212> PRT
 <213> Mus musculus
 <400> 35
 Asp Ile Val Met Thr Gln Ser Ala Pro Ser Val Pro Val Thr Pro Gly
 1 5 10 15
 Glu Ser Val Ser Ile Ser Cys Lys Ser Ser Lys Ser Leu Leu His Ser
 20 25 30
 Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Trp Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95
 Ile Glu Tyr Pro Phe Thr Phe Gly Thr Gly Thr Lys Leu Glu Ile Lys
 100 105 110
 <210> 36
 <211> 5
 <212> PRT
 <213> Mus musculus
 <400> 36
 Ala Ser Ala Met Asn
 1 5

EP 2 937 697 A1

<210> 37
 <211> 19
 <212> PRT
 <213> Mus musculus
 <400> 37
 5 Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Ile Tyr Tyr Ala Asp Ser
 1 5 10 15
 Val Lys Asp

 <210> 38
 <211> 12
 <212> PRT
 <213> Mus musculus
 <400> 38
 10 Asp Pro Gly Tyr Tyr Gly Asn Pro Trp Phe Ala Tyr
 1 5 10
 <210> 39
 <211> 16
 <212> PRT
 <213> Mus musculus
 <400> 39
 15 Arg Ser Ser Lys Ser Leu Leu His Ser Tyr Asp Ile Thr Tyr Leu Tyr
 1 5 10 15
 <210> 40
 <211> 7
 <212> PRT
 <213> Mus musculus
 <400> 40
 20 Gln Met Ser Asn Leu Ala Ser
 1 5
 <210> 41
 <211> 9
 <212> PRT
 <213> Mus musculus
 <400> 41
 25 Ala Gln Asn Leu Glu Leu Pro Pro Thr
 1 5
 <210> 42
 <211> 123
 <212> PRT
 <213> Mus musculus
 <400> 42
 30 Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Lys Gly
 1 5 10 15
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ala Ser
 20 25 30
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Ile Tyr Tyr Ala Asp
 50 55 60
 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr
 85 90 95
 Tyr Cys Val Arg Asp Pro Gly Tyr Tyr Gly Asn Pro Trp Phe Ala Tyr
 100 105 110
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 115 120
 <210> 43
 <211> 112
 <212> PRT
 <213> Mus musculus
 <400> 43
 55

EP 2 937 697 A1

Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly
 1 5 10 15
 Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 30
 Tyr Asp Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
 85 90 95
 Leu Glu Leu Pro Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110
 <210> 44
 <211> 115
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> modified antibody fragment
 <400> 44
 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ser
 115
 <210> 45
 <211> 115
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> modified antibody fragment
 <400> 45
 Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Leu Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ser
 115
 <210> 46
 <211> 115
 <212> PRT

EP 2 937 697 A1

```

<213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 46
5   Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
    1           5           10           15
    Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
      20           25           30
    Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35           40           45
10  Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
    50           55           60
    Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
    65           70           75           80
    Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
    85           90           95
15  Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
    100           105           110
    Val Ser Ser
      115
    <210> 47
    <211> 115
    <212> PRT
    <213> Artificial Sequence
    <220>
    <223> modified antibody fragment
    <400> 47
25  Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
    1           5           10           15
    Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
      20           25           30
    Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35           40           45
30  Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
    50           55           60
    Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
    65           70           75           80
    Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
    85           90           95
35  Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
    100           105           110
    Val Ser Ser
      115
    <210> 48
    <211> 115
    <212> PRT
    <213> Artificial Sequence
    <220>
    <223> modified antibody fragment
    <400> 48
45  Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
    1           5           10           15
    Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
      20           25           30
    Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35           40           45
50  Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
    50           55           60
    Lys Gly Arg Val Thr Leu Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
    65           70           75           80
    Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
    85           90           95
55  Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr

```


EP 2 937 697 A1

```

      50                               55                               60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
5  Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 58
<211> 112
<212> PRT
10 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 58
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
15 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Thr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
20 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
25 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 59
<211> 112
<212> PRT
30 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 59
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
35 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Gln Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
40 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
45 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 60
<211> 112
<212> PRT
50 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 60
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
55 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Ile Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

```

EP 2 937 697 A1

```

      50                               55                               60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
5  Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 61
<211> 112
<212> PRT
10 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 61
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
15 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Lys Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
20 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
25 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 62
<211> 112
<212> PRT
30 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 62
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
35 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Leu Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
40 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
45 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 63
<211> 112
<212> PRT
50 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 63
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
55 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Ser Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

```

EP 2 937 697 A1

```

      50                               55                               60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
5  Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 64
<211> 112
<212> PRT
10 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 64
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
15 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Trp Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
20 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
25 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 65
<211> 112
<212> PRT
30 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 65
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
35 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Tyr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
40 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
      85      90      95
45 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100      105      110
<210> 66
<211> 112
<212> PRT
50 <213> Artificial Sequence
<220>
<223> modified antibody fragment
<400> 66
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
55 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asn Arg Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

```


EP 2 937 697 A1

35 40 45
 Gly Ala Ile Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Ser Phe
 50 55 60
 Gln Asp Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 5 65 70 75 80
 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ser
 115
 <210> 70
 <211> 112
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> modified antibody fragment
 <400> 70
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Glu Ser Leu Val His Ser
 20 20 25 30
 Asn Arg Asn Thr Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
 25 65 70 75 80
 Ser Ser Leu Gln Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
 85 90 95
 Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105 110
 <210> 71
 <211> 115
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> modified antibody fragment
 <400> 71
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Thr Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 20 25 30
 Glu Met His Trp Ile Arg Gln Pro Pro Gly Glu Gly Leu Glu Trp Ile
 35 35 40 45
 Gly Ala Ile Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Glu Ser Phe
 50 55 60
 Gln Asp Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ser
 115
 <210> 72
 <211> 112
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> modified antibody fragment
 <400> 72
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

EP 2 937 697 A1

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220
 5 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 225 230 235
 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270
 10 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300
 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320
 15 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330
 <210> 75
 <211> 326
 <212> PRT
 20 <213> homo sapiens
 <400> 75
 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15
 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25
 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
 65 70 75 80
 30 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
 100 105 110
 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 115 120 125
 35 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 130 135 140
 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
 145 150 155 160
 40 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
 165 170 175
 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
 180 185 190
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 195 200 205
 45 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
 210 215 220
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 225 230 235 240
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 245 250 255
 50 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 260 265 270
 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 275 280 285
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 290 295 300
 55 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 305 310 315 320

EP 2 937 697 A1

Ser Leu Ser Pro Gly Lys
 325

<210> 76
 <211> 377
 <212> PRT
 <213> homo sapiens
 <400> 76

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375

<210> 77
 <211> 327
 <212> PRT
 <213> homo sapiens
 <400> 77

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375

EP 2 937 697 A1

Gln Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gln
 35 40 45
 Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gln Trp Phe His Asn Glu
 50 55 60
 5 Ser Leu Ile Ser Ser Gln Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr
 65 70 75 80
 Val Asp Asp Ser Gly Glu Tyr Arg Cys Gln Thr Asn Leu Ser Thr Leu
 85 90 95
 Ser Asp Pro Val Gln Leu Glu Val His Ile Gly Trp Leu Leu Leu Gln
 100 105 110
 10 Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys
 115 120 125
 His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gln Asn
 130 135 140
 Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr Ile Pro
 145 150 155 160
 15 Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Val
 165 170 175
 Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gln
 180 185 190
 Gly Leu Ser Val Ser Thr Ile Ser Ser Phe Phe Pro Pro Gly Tyr Gln
 195 200 205
 20 Val Ser Phe Cys Leu Val Met Val Leu Leu Phe Ala Val Asp Thr Gly
 210 215 220
 Leu Tyr Phe Ser Val Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp Trp
 225 230 235 240
 25 Lys Asp His Lys Phe Lys Trp Arg Lys Asp Pro Gln Asp Lys
 245 250
 <210> 82
 <211> 233
 <212> PRT
 <213> homo sapiens
 30 <400> 82
 Met Trp Gln Leu Leu Leu Pro Thr Ala Leu Leu Leu Leu Val Ser Ala
 1 5 10 15
 Gly Met Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro
 20 25 30
 35 Gln Trp Tyr Ser Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gln
 35 40 45
 Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gln Trp Phe His Asn Glu
 50 55 60
 Ser Leu Ile Ser Ser Gln Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr
 65 70 75 80
 40 Val Asn Asp Ser Gly Glu Tyr Arg Cys Gln Thr Asn Leu Ser Thr Leu
 85 90 95
 Ser Asp Pro Val Gln Leu Glu Val His Ile Gly Trp Leu Leu Leu Gln
 100 105 110
 Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys
 115 120 125
 45 His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gln Asn
 130 135 140
 Gly Lys Asp Arg Lys Tyr Phe His His Asn Ser Asp Phe His Ile Pro
 145 150 155 160
 Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Val
 165 170 175
 50 Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gln
 180 185 190
 Gly Leu Ala Val Ser Thr Ile Ser Ser Phe Ser Pro Pro Gly Tyr Gln
 195 200 205
 Val Ser Phe Cys Leu Val Met Val Leu Leu Phe Ala Val Asp Thr Gly
 210 215 220
 55 Leu Tyr Phe Ser Val Lys Thr Asn Ile
 225 230

EP 2 937 697 A1

<210> 83
 <211> 140
 <212> PRT
 <213> Mus musculus
 <400> 83
 5 Met Glu Trp Ile Trp Ile Phe Leu Phe Ile Leu Ser Gly Thr Ala Gly
 1 5 10 15
 Val Gln Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg
 20 25 30
 10 Pro Gly Ala Ser Val Lys Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe
 35 40 45
 Thr Ser Tyr Gly Ile Ser Trp Met Met Gln Arg Thr Gly Gln Gly Leu
 50 55 60
 Glu Trp Ile Gly Glu Ile Tyr Pro Arg Ser Gly Ile Thr Tyr Tyr Asn
 65 70 75 80
 15 Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95
 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110
 Tyr Phe Cys Ala Arg Asp Val Ser Asp Gly Tyr Leu Phe Pro Tyr Trp
 115 120 125
 20 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys
 130 135 140
 <210> 84
 <211> 129
 <212> PRT
 <213> Mus musculus
 <400> 84
 25 Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
 1 5 10 15
 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 20 25 30
 30 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn
 35 40 45
 Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 50 55 60
 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Pro Glu Gly Val Pro Ser
 65 70 75 80
 35 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
 85 90 95
 Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr
 100 105 110
 Gly Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 115 120 125
 40 Ala
 <210> 85
 <211> 139
 <212> PRT
 <213> Mus musculus
 <400> 86
 45 Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Ala Leu Ile Leu Lys Gly
 1 5 10 15
 Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Asp Val Val Arg
 20 25 30
 50 Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 35 40 45
 Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Leu Pro Asp Lys Arg Leu
 50 55 60
 Glu Trp Val Ala Ser Val Gly Asn Gly Gly Ser Tyr Arg Tyr Tyr Pro
 65 70 75 80
 55 Glu Asn Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn
 85 90 95

EP 2 937 697 A1

Thr Leu Tyr Leu Gln Ile Ser Gly Leu Lys Ser Glu Asp Thr Ala Ile
 100 105 110
 Tyr Tyr Cys Ala Arg Arg Gly Ala Phe Pro Tyr Phe Asp Val Trp Gly
 115 120 125
 5 Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys
 130 135
 <210> 86
 <211> 129
 <212> PRT
 <213> Mus musculus
 10 <400> 86
 Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
 1 5 10 15
 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
 20 25 30
 15 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn
 35 40 45
 Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
 50 55 60
 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Pro Glu Gly Val Pro Ser
 65 70 75 80
 20 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
 85 90 95
 Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr
 100 105 110
 25 Gly Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 115 120 125
 Ala
 <210> 87
 <211> 136
 <212> PRT
 <213> Mus musculus
 30 <400> 87
 Met Arg Val Leu Ile Leu Leu Trp Leu Phe Thr Ala Phe Pro Gly Ile
 1 5 10 15
 Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro
 20 25 30
 35 Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr
 35 40 45
 Ser Asp Ser Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu
 50 55 60
 Glu Trp Met Ala Tyr Ile Met Tyr Ser Gly Ile Thr Ser Tyr Asn Pro
 65 70 75 80
 40 Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ala Lys Asn Gln
 85 90 95
 Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr
 100 105 110
 45 Tyr Cys Ser Arg Gly Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr
 115 120 125
 Thr Val Thr Val Ser Ser Ala Lys
 130 135
 <210> 88
 <211> 129
 <212> PRT
 <213> Mus musculus
 50 <400> 88
 Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15
 Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
 20 25 30
 55 Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser
 35 40 45

EP 2 937 697 A1

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser
 50 55 60
 Pro Lys Leu Leu Ile Tyr Ser Thr Ser Ile Leu Ala Ser Gly Val Pro
 65 70 75 80
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile
 85 90 95
 Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys Leu Gln Trp
 100 105 110
 Ile Thr Tyr Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
 115 120 125
 Ala
 <210> 89
 <211> 138
 <212> PRT
 <213> Mus musculus
 <400> 89
 Met Cys Trp Ser Cys Ile Ile Leu Phe Leu Leu Ala Thr Ala Ala Arg
 1 5 10 15
 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Gly
 20 20 25 30
 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Phe Gly Tyr Thr Phe
 35 40 45
 Thr Asn His His Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
 50 55 60
 Asp Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Tyr Thr Asn Tyr Asn
 65 70 75 80
 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
 85 90 95
 Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110
 Tyr Tyr Cys Ala Arg Ser Asp Pro Ala Trp Phe Ala Tyr Trp Gly Gln
 115 120 125
 Gly Thr Leu Val Thr Val Ser Ala Ala Lys
 130 135
 <210> 90
 <211> 129
 <212> PRT
 <213> Mus musculus
 <400> 90
 Met Arg Pro Ser Ile Gln Phe Leu Gly Leu Leu Leu Phe Trp Leu His
 1 5 10 15
 Gly Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
 20 25 30
 Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp
 35 40 45
 Ile Asn Lys Asn Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro
 50 55 60
 Arg Leu Leu Ile Trp Tyr Thr Tyr Thr Leu Gln Pro Gly Ile Pro Ser
 65 70 75 80
 Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser
 85 90 95
 Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp
 100 105 110
 Asn Leu Pro Phe Thr Phe Gly Thr Gly Thr Lys Leu Glu Ile Lys Arg
 115 120 125
 Ala

Claims

1. A method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient or determining the continuation of GPC3-targeting drug therapy for a patient, comprising monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined.
2. The method according to claim 1, wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the patient.
3. The method according to claim 2, wherein the concentration of free GPC3 in the biological sample isolated from the patient is a concentration in the plasma sample or the serum sample.
4. The method according to any of claims 1 to 3, wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL.
5. The method according to any of claims 1 to 4, wherein the concentration of free GPC3 is measured using an immunological method.
6. The method according to any of claims 1 to 5, wherein the concentration of free GPC3 is larger than that in a biological sample isolated before the start of the GPC3-targeting drug therapy from the patient.
7. The method according to any of claims 1 to 6, wherein the patient shows high expression of GPC3 in an immunohistochemical staining score.
8. The method according to any of claims 1 to 7, wherein the cancer is liver cancer.
9. The method according to any of claims 1 to 8, wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient.
10. The method according to any of claims 1 to 9, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient.
11. The method according to claim 10, wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity.
12. The method according to claim 10 or 11, wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):
 - (1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;
 - (2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;
 - (3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;
 - (4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and
 - (5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively.
13. The method according to any of claims 10 to 12, wherein the anti-GPC3 antibody comprises any of the following

(1) to (6):

(1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

(3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

(5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73.

14. The method according to claim 10, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance.

15. A GPC3-targeting drug which is to be administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy.

16. A GPC3-targeting drug which is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy.

17. The drug according to claim 15 or 16, wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the cancer patient.

18. The drug according to claim 17, wherein the concentration of free GPC3 in the biological sample isolated from the cancer patient is a concentration in the plasma sample or the serum sample.

19. The drug according to any of claims 15 to 18, wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 60 ng/mL.

20. The drug according to any of claims 15 to 19, wherein the concentration of free GPC3 is measured using an immunological method.

21. The drug according to any of claims 15 to 20, wherein the concentration of free GPC3 has been increased as a result of receiving the GPC3-targeting drug therapy.

22. The drug according to any of claims 15 to 21, wherein the patient shows high expression of GPC3 in an immunohistochemical staining score.

23. The drug according to any of claims 15 to 22, wherein the cancer patient is a liver cancer patient.

24. The drug according to any of claims 15 to 23, wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient.

25. The drug according to any of claims 15 to 24, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient.

26. The drug according to claim 25, wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity.

27. The drug according to claim 25 or 26, wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):

(1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;

(2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;

(3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;

(4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and

(5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively.

28. The drug according to any of claims 25 to 27, wherein the anti-GPC3 antibody comprises any of the following (1) to (6):

(1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

(3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

(5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73.

29. The drug according to claim 25, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance.

30. A preparation for GPC3-targeting treatment, comprising an instruction stating that the preparation is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient before the start of GPC3-targeting drug therapy.

31. A preparation for GPC3-targeting treatment, comprising an instruction stating that the preparation is to be further administered to a cancer patient having a predetermined value of a concentration of free GPC3 in a biological sample isolated from the cancer patient after the start of GPC3-targeting drug therapy.

32. The preparation according to claim 30 or 31, wherein the concentration of free GPC3 is a concentration in a whole blood sample, a plasma sample, or a serum sample isolated from the cancer patient.

33. The preparation according to claim 32, wherein the concentration of free GPC3 in the biological sample isolated from the cancer patient is a concentration in the plasma sample or the serum sample.

34. The preparation according to any of claims 30 to 33, wherein the predetermined value of free GPC3 ranges from 0.1 ng/mL to 100 ng/mL.

35. The preparation according to any of claims 30 to 34, wherein the concentration of free GPC3 is measured using an immunological method.

36. The preparation according to any of claims 30 to 35, wherein the concentration of free GPC3 has been increased as a result of receiving the GPC3-targeting drug therapy.

37. The preparation according to any of claims 30 to 36, wherein the patient shows high expression of GPC3 in an immunohistochemical staining score.

38. The preparation according to any of claims 30 to 37, wherein the cancer patient is a liver cancer patient.

39. The preparation according to any of claims 30 to 38, wherein the GPC3-targeting drug is administered to achieve a blood trough level of 200 µg/ml or higher in the cancer patient.

40. The preparation according to any of claims 30 to 39, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody as an active ingredient.

41. The preparation according to claim 40, wherein the anti-GPC3 antibody has antibody-dependent cellular cytotoxicity (ADCC) activity and/or complement-dependent cytotoxicity (CDC) activity.

42. The preparation according to claim 40 or 41, wherein the anti-GPC3 antibody is an anti-GPC3 chimeric antibody or a humanized anti-GPC3 antibody comprising any of the following (1) to (5):

(1) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 4, 5, and 6, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 7, 8, and 9, respectively;

(2) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 12, 13, and 14, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 15, 16, and 17, respectively;

(3) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 23, 24, and 25, respectively;

(4) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 28, 29, and 30, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 31, 32, and 33, respectively; and

(5) heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 represented by SEQ ID NOs: 36, 37, and 38, respectively, and light chain CDR1, light chain CDR2, and light chain CDR3 represented by SEQ ID NOs: 39, 40, and 41, respectively.

43. The preparation according to any of claims 40 to 42, wherein the anti-GPC3 antibody comprises any of the following (1) to (6):

(1) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region represented by SEQ ID NO: 51;

(2) a heavy chain variable region selected from the group of heavy chain variable regions represented by SEQ ID NOs: 44, 45, 46, 47, 48, 49, and 50 and a light chain variable region selected from the group of light chain variable regions represented by SEQ ID NOs: 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, and 66;

(3) a heavy chain variable region represented by SEQ ID NO: 67 and a light chain variable region represented by SEQ ID NO: 68;

(4) a heavy chain variable region represented by SEQ ID NO: 69 and a light chain variable region represented by SEQ ID NO: 70;

(5) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 72; and

(6) a heavy chain variable region represented by SEQ ID NO: 71 and a light chain variable region represented by SEQ ID NO: 73.

44. The preparation according to claim 40, wherein the GPC3-targeting drug comprises an anti-GPC3 antibody conjugated with a cytotoxic substance.

FIG.1A




FIG.1B




FIG.2




FIG.3




FIG.4 A




FIG.4 B




FIG.5A




FIG.5B




FIG.6A




FIG.6B




FIG.7A




FIG.7B




FIG.7C




FIG.7D




FIG.7E




FIG.7F




FIG.8A




FIG.8B




FIG.8C




FIG.8D




FIG.8E





FIG.8F



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2013/007529

A. CLASSIFICATION OF SUBJECT MATTER		
G01N33/574(2006.01)i, A61K39/395(2006.01)i, A61K45/00(2006.01)i, A61P1/16(2006.01)i, A61P35/00(2006.01)i, G01N33/48(2006.01)i, G01N33/53(2006.01)i, C07K16/30(2006.01)n		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) G01N33/574, A61K39/395, A61K45/00, A61P1/16, A61P35/00, G01N33/48, G01N33/53, C07K16/30		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2014 Kokai Jitsuyo Shinan Koho 1971-2014 Toroku Jitsuyo Shinan Koho 1994-2014		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPlus/JMEDPlus/JST7580 (JDreamIII), PubMed		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/038420 A1 (Perseus Proteomics Inc.), 06 May 2004 (06.05.2004), page 25, line 13 to page 28, the last line	1-5, 8-11, 15-35, 38-41
Y	& US 2006/0014223 A1 & EP 1548442 A1	7, 12-14, 37, 42-44
A	& CA 2497418 A & HK 1079568 A & AU 2003261943 A & KR 10-2005-0057205 A & CN 1678911 A & AU 2002330482 A	6, 36
X	WO 2009/116659 A1 (University of Miyazaki), 24 September 2009 (24.09.2009), paragraphs [0034] to [0039]	15-29 7, 12-14, 37, 42-44
Y	& US 2011/0091907 A1 & EP 2270509 A1	1-6, 8-11, 30-36, 38-41
A	& AU 2009226423 A & CA 2718707 A & CN 102027372 A & MX 2010010136 A & IL 208167 D & KR 10-2011-0005812 A & TW 200949248 A	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 04 March, 2014 (04.03.14)	Date of mailing of the international search report 18 March, 2014 (18.03.14)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2013/007529

5
10
15
20
25
30
35
40
45
50
55

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	JP 2011-68682 A (Chugai Pharmaceutical Co., Ltd.), 07 April 2011 (07.04.2011), claims & US 2010/0239577 A1 & EP 2196541 A1 & WO 2009/041062 A1 & PE 16552009 A & AU 2008305851 A & CA 2700986 A & AR 71003 A & MX 2010003158 A & CN 101809162 A & AU 2009233301 A & CA 2720359 A & KR 10-2010-0132060 A	15-29 12-14, 42-44
A	WO 2005/106485 A1 (Perseus Proteomics Inc.), 10 November 2005 (10.11.2005), paragraphs [0006], [0010], [0015] & JP 4658926 B & US 2007/0286807 A1 & EP 1742061 A1	1-14, 30-44
A	Ho M, Kim H, Glypican-3: a new target for cancer immunotherapy, Eur J Cancer, 2011.02, 47(3), 333-338	1-44

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2013/007529

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The inventions in claims 1 to 14 relate to a method for determining the continuation of a therapy using a GPC3-targeting therapeutic agent, said method comprising monitoring the free GPC3 concentration in a biological sample isolated from a patient.

The inventions in claims 30 to 44 are inventions of a product relating to "a preparation for a GPC3-targeting therapy".
(Continued to extra sheet)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2013/007529

5

Continuation of Box No.III of continuation of first sheet(2)

10

Since the aforesaid preparation includes "an instruction that directs a user to administer to a cancer patient showing a definite free GPC3 concentration in a biological sample isolated from him/her", there are the same or corresponding special technical features between the inventions in claims 1 to 14 and the inventions in claims 30-44.

The inventions in claims 15 to 29 are inventions of a product relating to a GPC3-targeting therapeutic agent.

15

Since the free GPC3 concentration of a patient exerts no effect on the constitution of the aforesaid therapeutic agent, there are neither the same nor corresponding special technical features between the inventions in claims 1 to 14 and the inventions in claims 15 to 29.

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2003000883 A [0011]
- WO 2006006693 A [0011] [0065] [0152] [0154]
- WO 2006046751 A [0011] [0109]
- WO 2007047291 A [0011] [0099]
- WO 2009041062 A [0011] [0065] [0109]
- WO 2009122667 A [0011]
- WO 2004038420 A [0011]
- WO 2009116659 A [0011] [0058] [0154]
- JP 2012280304 A [0018]
- WO 2008046085 A [0063]
- WO 2007137170 A [0064] [0079]
- WO 2003100429 A [0064]
- WO 2009140242 A [0079]
- WO 2009086320 A [0093]
- WO 2008092117 A [0093] [0097]
- WO 2007041635 A [0093] [0097]
- WO 2006105338 A [0093] [0097]
- WO 2007024249 A [0097]
- WO 2007021841 A [0097]
- WO 2006031370 A [0097]
- WO 2000042072 A [0097]
- WO 2004029207 A [0097]
- WO 2004099249 A [0097]
- WO 2005070963 A [0097]
- WO 2006020114 A [0097]
- WO 2006116260 A [0097]
- WO 2006023403 A [0097]
- WO 1999054342 A [0109]
- WO 2000061739 A [0109] [0110]
- WO 2002031140 A [0109] [0110]
- WO 2006067913 A [0109] [0110]
- WO 2002079255 A [0111]
- WO 2004065540 A [0111]
- WO 2004022739 A [0162] [0173]

Non-patent literature cited in the description

- LLOVET JM ; BURROUGHS A ; BRUIX J. *Lancet*, 2003, vol. 362, 1907-17 [0012]
- BOSCH FX ; RIBES J ; CLERIES R. *Gastroenterology*, 2004, vol. 127, 5-16 [0012]
- TAKENAKA K ; KAWAHARA N ; YAMAMOTO K ; KAJIYAMA K ; MAEDA T ; ITASAKA H ; SHIRABE K ; NISHIZAKI T ; YANAGA K ; SUGIMACHI K. *Arch Surg*, 1996, vol. 131, 71-6 [0012]
- YEO W ; MOK TS ; ZEE B ; LEUNG TW ; LAI PB ; LAU WY ; KOH J ; MO FK ; YU SC ; CHAN AT. *J Natl Cancer Inst*, 2005, vol. 97, 1532-8 [0012]
- LLOVET J ; RICCI S ; MAZZAFERRO V ; HILGARD P ; GANE E et al. Sorafenib in advanced hepatocellular carcinoma. *New Eng. J. Med.*, 2008, vol. 359, 378-90 [0012]
- CHENG AL ; CHEN Z ; TSAO CJ ; QIN S ; KIM JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. *Lancet Oncol.*, 2009, vol. 10, 25-34 [0012]
- DE CAT B ; MUYLDERMANS S-Y ; COOMANS C ; DEGEEST G ; VANDERSCHUEREN B et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. *J. Cell. Biol.*, 2003, vol. 163, 625-635 [0012]
- TRAISTER A ; SHI W ; FILMUS J. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. *Biochem. J.*, 2008, vol. 410, 503-511 [0012]
- KUNKEL et al. *Proc. Natl. Acad. Sci. USA*, 1985, vol. 82, 488-492 [0022] [0095]
- *Annu. Rev. Biophys. Biomol. Struct.*, 2006, vol. 35, 225-249 [0022]
- *Proc. Natl. Acad. Sci. U.S.A.*, 2003, vol. 100 (11), 6353-6357 [0022] [0095]
- Sequences of Proteins of Immunological Interest. National Institute of Health, 1987 [0024]
- *J. Cell. Biol.*, 2003, vol. 163 (3), 625-635 [0028]
- KS. MCCARTY JR. et al. Use of a monoclonal anti-Estrogen receptor antibody in the immunohistochemical evaluation of human tumors. *Cancer Res.*, 1986, vol. 46, 4244s-4248s [0059]
- *Cancer Res.*, 2005, vol. 65, 6245-6254 [0062]
- *Carcinogenesis*, 2008, vol. 29 (7), 1319-1326 [0062]
- *Int. J. Cancer*, 2003, vol. 103 (4), 455-465 [0062]
- *Clin. Cancer Res.*, 2006, vol. 12 (9), 2689-2697 [0063]
- ALLEY et al. *Curr. Opin. Chem. Biol.*, 2010, vol. 14, 529-537 [0079]
- LANGONE et al. *Methods in Enzymology*, 1983, vol. 93, 307-308 [0082]
- *Nature Medicine*, 1996, vol. 2, 350-353 [0082]

EP 2 937 697 A1

- **FULTON et al.** *J. Biol. Chem.*, 1986, vol. 261, 5314-5319 [0082]
- **SIVAM et al.** *Cancer Res.*, 1987, vol. 47, 3169-3173 [0082]
- **CUMBER et al.** *J. Immunol. Methods*, 1990, vol. 135, 15-24 [0082]
- **WAWRZYNCZAK et al.** *Cancer Res.*, 1990, vol. 50, 7519-7562 [0082]
- **GHEEITE et al.** *J. Immunol. Methods*, 1991, vol. 142, 223-230 [0082]
- **THORPE et al.** *Cancer Res.*, 1987, vol. 47, 5924-5931 [0082]
- **WAWRZYNCZAK et al.** *Br. J. Cancer*, 1992, vol. 66, 361-366 [0082]
- **BOLOGNESI et al.** *Clin. exp. Immunol.*, 1992, vol. 89, 341-346 [0082]
- **BOLOGNESI et al.** *Clin. exp. Immunol.*, 1992, vol. 89, 341-346 [0082]
- **STIRPE F. ; BARBIERI L.** *FEBS letter*, 1986, vol. 195, 1-8 [0082]
- **CASELLAS et al.** *Eur. J. Biochem.*, 1988, vol. 176, 581-588 [0082]
- *Proc. Natl. Acad. Sci. U.S.A.*, 2006, vol. 103 (11), 4005-4010 [0085] [0088]
- **LAZOR et al.** *Proc. Natl. Acad. Sci. U.S.A.*, 2006, vol. 103 (11), 4005-4010 [0091]
- *Curr. Opin. Biotechnol.*, 2009, vol. 20 (6), 685-91 [0093]
- *Curr. Opin. Immunol.*, 2008, vol. 20 (4), 460-470 [0093]
- *Protein Eng. Des. Sel.*, 2010, vol. 23 (4), 195-202 [0093]
- *Annu. Rev. Biophys. Biomol. Struct.*, 2006, vol. 35, 225-249 [0095]
- **VAUPEL et al.** *Cancer Res.*, 1989, vol. 49, 6449-6665 [0100]
- **WEITZHANDLER et al.** *J. Pharma. Sciences*, 1994, vol. 83 (12), 1670-1675 [0102]
- **SCHENK et al.** *J. Clin. Investigation*, 2001, vol. 108 (11), 1687-1695 [0102]
- **BIGGE et al.** *Anal. Biochem.*, 1995, vol. 230 (2), 229-238 [0102]
- **SATO et al.** *Expert Opin. Biol. Ther.*, 2006, vol. 6 (11), 1161-1173 [0109]
- **HIPPO et al.** *Cancer Res.*, 2004, vol. 64, 2418-2423 [0163]

专利名称(译)	GPC3靶向治疗剂，用于对GPC3靶向治疗剂治疗有效的患者给药		
公开(公告)号	EP2937697A1	公开(公告)日	2015-10-28
申请号	EP2013864465	申请日	2013-12-24
申请(专利权)人(译)	中外SEIYAKU株式会社		
当前申请(专利权)人(译)	中外SEIYAKU株式会社		
[标]发明人	OHTOMO TOSHIHIKO AMANO JUN NAKAMURA MIKIKO		
发明人	OHTOMO, TOSHIHIKO AMANO, JUN NAKAMURA, MIKIKO		
IPC分类号	G01N33/574 A61K39/395 A61K45/00 A61P1/16 A61P35/00 G01N33/48 G01N33/53 C07K16/30		
CPC分类号	A61K2039/505 C07K16/303 G01N33/57438 G01N2400/00 A61K2039/54 A61K2039/545 A61P1/16 A61P35/00 C07K2317/73 G01N2800/52 A61K39/395 G01N33/574 C07K16/28 C07K2317/34 G01N2333/4722		
代理机构(译)	POWER, DAVID		
优先权	2012280304 2012-12-21 JP		
其他公开文献	EP2937697A4 EP2937697B1		
外部链接	Espacenet		

摘要(译)

本发明公开了一种用于在GPC3靶向药物治疗或患者开始之前确定患者中癌症的GPC3靶向药物疗法功效或确定患者继续GPC3靶向药物治疗的方法，包括监测a在GPC3靶向药物治疗开始前和/或用GPC3靶向药物治疗的患者开始的患者中分离的生物样品中游离GPC3的浓度，其中当游离GPC3的浓度是预定值时，效力确定GPC3靶向药物疗法或确定GPC3靶向药物疗法的继续。本发明还公开了GPC3靶向药物或制剂，其将进一步给予患者，其已经确定了GPC3靶向药物疗法功效或已经确定了GPC3靶向药物疗法的继续。

[Expression 1]

$$IHC\ total = PR + SI-Cp + SI-Cm + Sp-Cm$$